Spirocyclic aminoquinolones as GSK-3 inhibitors

ABSTRACT

Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases. In Formula (I): X 1  is O or NR 8 ; A is bond or substituted or unsubstituted C 1 -C 2  alkylene, wherein the substituents when present are selected from one to four Q 2  groups; where Q 2  is alkyl or haloalkyl; p is 0 or 1; and q is an integer of 0 to 2.

PRIORITY CLAIM

This application is the national phase entry pursuant to 35 U.S.C. §371of International Application No. PCT/US2008/010700, filed Sep. 12, 2008,which claims priority to U.S. provisional application Ser. No.60/993,545 filed Sep. 12, 2007 to Cociorva et al. The disclosures of theabove referenced applications are incorporated by reference in theirentireties.

FIELD

Compounds, compositions and methods for treating GSK-3 mediated diseasesare provided. The compounds provided herein are spirocyclicaminoquinolones that are GSK-3 inhibitors.

BACKGROUND

Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinasehaving α and β isoforms that are each encoded by distinct genes [Coghlanet al., Chemistry & Biology, 7, 793-803 (2000); and Kim and Kimmel,Curr. Opinion Genetics Dev., 10, 508-514 (2000)]. GSK-3 has beenimplicated in various diseases including diabetes, Alzheimer's disease,CNS disorders such as manic depressive disorder and neurodegenerativediseases, and cardiomyocete hypertrophy [see, e.g., WO 99/65897; WO00/38675; and Haq et al., J. Cell Biol. (2000) 151, 117]. These diseasesmay be caused by, or may result in, the abnormal operation of certaincell signaling pathways in which GSK-3 plays a role.

GSK-3 has been found to phosphorylate and modulate the activity of anumber of regulatory proteins. These include glycogen synthase, which isthe rate-limiting enzyme required for glycogen synthesis, themicrotubule-associated protein Tau, the gene transcription factorβ-catenin, the translation initiation factor e1F-2B, as well as ATPcitrate lyase, axin, heat shock factor-1, c-Jun, c-myc, c-myb, CREB, andCEPB α. These diverse targets implicate GSK-3 in many aspects ofcellular metabolism, proliferation, differentiation and development.

Small molecule inhibitors of GSK-3 have recently been reported [WO99/65897 (Chiron) and WO 00/38675 (SmithKline Beecham)], however, thereis a continued need to find more effective therapeutic agents to treatGSK-3 mediated diseases.

SUMMARY

Provided herein are compounds represented by the Formula (1):

or a pharmaceutically acceptable derivative thereof, wherein

R² is hydrogen or lower alkyl;

R³ is hydrogen, CN, C(O)R^(3a), C(NH)NHOH or 5-tetrazolyl;

R^(3a) is OH, alkoxy or NHR^(3b);

R^(3b) is hydrogen, NH₂, OH or lower alkyl;

R^(5a) and R^(5b) are each independently hydrogen, lower alkyl oraralkyl which is optionally substituted with one to three substituents,each independently selected from Q⁰ groups;

wherein Q⁰ is halo, cyano, nitro, NH₂, alkyl or alkoxy;

R⁶ is halo;

in each instance, independently, R^(a) and X³ are selected from (i) or(ii) as follows:

-   -   (i) R^(a) is hydrogen or lower alkyl; and        -   X³ is substituted or unsubstituted C₁-C₃ alkylene,            substituted or unsubstituted 3-6 membered cycloalkylene or            substituted or unsubstituted 3-6 membered heterocyclylene,            wherein the substituents when present are selected from one            to four Q² groups; or    -   (ii) R^(a) and X³ together with the nitrogen atom to which they        are bonded, may form a 5 to 7 membered saturated or unsaturated        ring optionally containing one or more O or S atoms, or one or        more additional N atoms, in the ring;

R^(b) is —(CHR^(7a))_(n)R⁷, —NR^(7b)R⁷, —OR⁷, —S(O), R⁷, —NR^(7b)COY¹R⁷or —Y²CONR^(7b)R⁷;

Y¹ is bond, O or NR^(7b);

Y² is bond or O;

n is 0 or 1;

r is an integer of 0 to 2;

R⁷ is alkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, fusedheterocyclylaryl, or fused arylheterocyclyl, where R⁷ is optionallysubstituted with one to five substituents, each independently selectedfrom Q¹ groups;

R^(7a) is hydrogen alkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl,fused heterocyclylaryl, or fused arylheterocyclyl, where R^(7a) isoptionally substituted with one to five substituents, each independentlyselected from Q¹ groups;

R^(7b) is hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, orfused heterocyclylaryl, where R^(7b) is optionally substituted with oneto five substituents, each independently selected from Q¹ groups;

where Q¹ is halo, hydroxy, oxo, thioxo, cyano, nitro, azido, mercapto,formyl, hydroxycarbonyl, hydroxycarbonylalkyl, alkyl, haloalkyl,alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl,heteroaralkyl, alkoxy, haloalkoxy, cycloalkoxy, heterocyclyloxy,aryloxy, heteroaryloxy, aralkyloxy, heretoaralkyloxy, alkylcarbonyl,arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl,aralkyloxycarbonyl, unsubstituted or substituted aminocarbonyl,alkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy,alkoxycarbonyloxy, aryloxycarbonyloxy, aralkyloxycarbonyloxy,unsubstituted or substituted aminocarbonyloxy, unsubstituted orsubstituted amino, alkylthio, cycloalkylthio, arylthio, heteroarylthio,aralkylthio, heteroaralkylthio, alkylsulfinyl, cycloalkylsulfinyl,arylsulfinyl, heteroarylsulfinyl, aralkylsulfinyl,heteroaralkylsulfinyl, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl,heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfony,alkoxysulfonyl, aryloxysulfonyl, unsubstituted or substitutedaminosulfonyl or hydroxysulfonyl;

X¹ is O or NR⁸;

R⁸ is hydrogen or lower alkyl;

X² is CH₂, O, NR¹ or S;

R¹ is hydrogen or lower alkyl;

A is bond or substituted or unsubstituted C₁-C₂ alkylene, wherein thesubstituents when present are selected from one to four Q² groups;

wherein Q² is alkyl or haloalkyl;

p is 0 or 1;

q is an integer of 0 to 2.

Also provided herein are pharmaceutical compositions containing acompound of Formula (1) and a pharmaceutically acceptable carrier.

Also provided herein are methods for treating, preventing, orameliorating one or more symptoms of GSK-3 mediated diseases byadministering the compounds and compositions provided herein.

DETAILED DESCRIPTION OF EMBODIMENTS A. Definitions

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as is commonly understood by one of ordinary skillin the art. All patents, applications, published applications and otherpublications are incorporated by reference in their entirety. In theevent that there are a plurality of definitions for a term herein, thosein this section prevail unless stated otherwise.

As used herein, the nomenclature alkyl, alkoxy, carbonyl, etc. is usedas is generally understood by those of skill in this art.

As used herein, alkyl carbon chains, if not specified, contain from 1 to20 carbons, 1 to 16 carbons or 1 to 6 carbons and are straight orbranched. In certain embodiments, alkyl carbon chains contain from 1 to6 carbons. Exemplary alkyl groups herein include, but are not limitedto, methyl, ethyl, propyl, isopropyl, isobutyl, n-butyl, sec-butyl,tert-butyl, isopentyl, neopentyl, tert-pentyl, isohexyl. As used herein,lower alkyl refers to carbon chains having from about 1 carbons up toabout 6 carbons.

As used herein, alkenyl carbon chains, if not specified, contain from 2to 20 carbons, 2 to 16 carbons or 2 to 6 carbons and are straight orbranched. In certain embodiments, alkenyl carbon chains contain from 2to 6 carbons. Alkenyl carbon chains of from 2 to 20 carbons, in certainembodiments, contain 1 to 8 double bonds, and the alkenyl carbon chainsof 2 to 16 carbons, in certain embodiments, contain 1 to 5 double bonds.The alkenyl carbon chains of 2 to 6 carbons, in certain embodiments,contain 1 to 2 double bonds. Exemplary alkenyl groups herein include,but are not limited to, vinyl, 1-propenyl, 2-propenyl, isopropenyl,1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl. As used herein, loweralkenyl refer to carbon chains having from about 2 carbons up to about 6carbons.

As used herein, alkynyl carbon chains, if not specified, contain from 2to 20 carbons, 2 to 16 carbons or 2 to 6 carbons and are straight orbranched. In certain embodiments, alkynyl carbon chains contain from 2to 6 carbons. Alkynyl carbon chains of from 2 to 20 carbons, in certainembodiments, contain 1 to 8 triple bonds, and the alkynyl carbon chainsof 2 to 16 carbons, in certain embodiments, contain 1 to 5 triple bonds.Alkynyl carbon chains of from 2 to 6 carbons, in certain embodiments,contain 1 to 2 triple bonds. Exemplary alkynyl groups herein include,but are not limited to, ethynyl, 1-propynyl and 2-propynyl. As usedherein, lower alkynyl refer to carbon chains having from about 2 carbonsup to about 6 carbons.

As used herein, “alkoxy” contain from 1 to 20 carbons, 1 to 16 carbonsor 1 to 6 carbons and are straight or branched. In certain embodiments,alkoxy carbon chains contain from 1 to 6 carbons. Exemplary alkoxygroups herein include, but are not limited to, methoxy, ethoxy, propoxy,isopropoxy, isobutoxy, n-butoxy, sec-butoxy, tert-butoxy, isopentoxy,neopentoxy, tert-pentoxy and isohexyloxy.

As used herein, “aralkyl” refers to an alkyl group in which one of thehydrogen atoms of the alkyl is replaced by an aryl.

As used herein, “halo”, “halogen” or “halide” refers to F, Cl, Br or I.

As used herein, “aryl” refers to aromatic monocyclic or multicyclicgroups containing from 6 to 19 carbon atoms. Aryl groups include, butare not limited to groups such as fluorenyl, substituted fluorenyl,phenyl, substituted phenyl, naphthyl and substituted naphthyl.

As used herein, “cycloalkyl” refers to a saturated mono- or multicyclicring system, in certain embodiments of 3 to 10 carbon atoms, in otherembodiments of 3 to 6 carbon atoms; cycloalkenyl and cycloalkynyl referto mono- or multicyclic ring systems that respectively include at leastone double bond and at least one triple bond. Cycloalkenyl andcycloalkynyl groups may, in certain embodiments, contain 3 to 10 carbonatoms, with cycloalkenyl groups, in further embodiments, containing 4 to7 carbon atoms and cycloalkynyl groups, in further embodiments,containing 8 to 10 carbon atoms. The ring systems of the cycloalkyl,cycloalkenyl and cycloalkynyl groups may be composed of one ring or twoor more rings which may be joined together in a fused, bridged orspiro-connected fashion.

As used herein, “heterocyclyl” refers to a monocyclic or multicyclicnon-aromatic ring system, in one embodiment of 3 to 10 members, inanother embodiment of 4 to 7 members, in a further embodiment of 5 to 6members, where one or more, in certain embodiments, 1 to 3, of the atomsin the ring system is a heteroatom, that is, an element other thancarbon, including but not limited to, nitrogen, oxygen or sulfur. Inembodiments where the heteroatom(s) is(are) nitrogen, the nitrogen isoptionally substituted with alkyl, alkenyl, alkynyl, aryl, heteroaryl,aralkyl, heteroaralkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl,heterocyclylalkyl, acyl, aminocarbonyl, alkoxycarbonyl, guanidino, orthe nitrogen may be quaternized to form an ammonium group where thesubstituents are selected as above.

As used herein, “heteroaryl” refers to a monocyclic or multicyclicaromatic ring system, in certain embodiments, of about 5 to about 15members where one or more, in one embodiment 1 to 3, of the atoms in thering system is a heteroatom, that is, an element other than carbon,including but not limited to, nitrogen, oxygen or sulfur. The heteroarylgroup may be optionally fused to a benzene ring. Heteroaryl groupsinclude, but are not limited to, furyl, imidazolyl, pyrimidinyl,tetrazolyl, thienyl, pyridyl, pyrrolyl, N-methylpyrrolyl, quinolinyl andisoquinolinyl.

As used herein, “fused heterocyclylaryl” refers to aryl which was fusedwith a heterocyclyl group. In one embodiment, fused heterocyclylarylsare those wherein heterocyclyl contains about 5 to about 6 ring atomsand the aryl thereof is phenyl. A fused heterocyclylaryl may be bondedthrough any atom of the ring system. Representative fusedheterocyclylaryl groups include 1,3-benzodioxolan-4-yl,1,3-benzodioxolan-5-yl, 1,3-benzodioxolan-6-yl, 1,3-benzodioxolan-7-yl,4-indolinyl, 5-indolinyl, 6-indolinyl and 7-indolinyl.

As used herein, “fused arylheterocyclyl” refers to fused heterocyclylwhich was fused to an aryl group. In one embodiment, fusedarylheterocyclyls are those wherein the aryl thereof is phenyl and theheterocyclyl contains about 5 to about 6 ring atoms. A fusedarylheterocyclyl may be bonded through any atom of the ring system.Representative fused arylheterocyclyl groups include 1-indolinyl,2-indolinyl, 3-indolinyl, 1,2,3,4-tetrahydroqunolin-1-yl,1,2,3,4-tetrahydroqunolin-2-yl, 1,2,3,4-tetrahydroqunolin-3-yl and1,2,3,4-tetrahydroqunolin-4-yl.

As used herein, “haloalkyl” refers to an alkyl group in which one ormore of the hydrogen atoms are replaced by halogen. “Lower haloalkyl”refers to a lower alkyl group in which one or more of the hydrogen atomsare replaced by halogen. Such groups include, but are not limited to,chloromethyl, trifluoromethyl and 1-chloro-2-fluoroethyl.

As used herein, “heteroaralkyl” refers to an alkyl group in which one ofthe hydrogen atoms are replaced by heteroaryl.

As used herein, “haloalkoxy” refers to RO— in which R is a haloalkylgroup.

As used herein, “cycloalkoxy” refers to RO— in which R is a cycloalkylgroup.

As used herein, “aryloxy” refers to RO— in which R is an aryl.

As used herein, “heteroaryloxy” refers to RO— in which R is aheteroaryl.

As used herein, “heterocyclyloxy” refers to RO— in which R is aheterocyclyl.

As used herein, “aralkyloxy” refers to RO— in which R is an aralkyl.

As used herein, “heteroaralkyloxy” refers to RO— in which R is aheteroaralkyl.

As used herein, “alkylcarbonyl” refers to RCO— in which R is an alkylgroup.

As used herein, “arylcarbonyl” refers to RCO— in which R is an aryl.

As used herein, “heteroarylcarbonyl” refers to RCO— in which R is aheteroaryl.

As used herein, “alkoxycarbonyl” refers to RCO— in which R is an alkoxygroup.

As used herein, “aryloxycarbonyl” refers to RCO— in which R is anaryloxy.

As used herein, “aralkyloxycarbonyl” refers to RCO— in which R is anaralkyloxy.

As used herein, “unsubstituted or substituted aminocarbonyl” refers to—C(O)NR′R in which R′ and R are independently hydrogen, alkyl aryl,heteroaryl, aralkyl or heteroaralkyl.

As used herein, “alkylcarbonyloxy” refers to —OC(O)R in which R isalkyl.

As used herein, “arylcarbonyloxy” refers to —OC(O)R in which R is aryl.

As used herein, “aralkylcarbonyloxy” refers to —OC(O)R in which R isaralkyl.

As used herein, “alkoxycarbonyloxy” refers to —OC(O)O R in which R isalkyl.

As used herein, “aryloxycarbonyloxy” refers to —OC(O)O R in which R isaryl.

As used herein, “aralkyloxycarbonyloxy” refers to —OC(O)O R in which Ris aralkyl.

As used herein, “unsubstituted or substituted aminocarbonyloxy” refersto —OC(O)NR′R in which R and R are independently hydrogen, alkyl aryl,heteroaryl, aralkyl or heteroaralkyl.

As used herein, “unsubstituted or substituted amino” refers to —NR′R inwhich R′ and R are independently hydrogen, alkyl, aryl, heteroaryl,aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl,alkoxycarbonyl, aryloxycarbonyl, aralkyloxycarbonyl, unsubstituted orsubstituted aminocarbonyl, alkylsulfonyl, cycloalkylsulfonyl,arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, orheteroaralkylsulfonyl.

As used herein, “alkylthio” refers to —SR in which R is alkyl.

As used herein, “cycloalkylthio” refers to —SR in which R is cycloalkyl.

As used herein, “arylthio” refers to —SR in which R is aryl.

As used herein, “heteroarylthio” refers to —SR in which R is heteroaryl.

As used herein, “aralkylthio” refers to —SR in which R is aralkyl.

As used herein, “heteroaralkylthio” refers to —SR in which R isheteroaralkyl.

As used herein, “alkylsulfinyl” refers to —S(O)R in which R is alkyl.

As used herein, “cycloalkylsulfinyl” refers to —S(O)R in which R iscycloalkyl.

As used herein, “arylsulfinyl” refers to —S(O)R in which R is aryl.

As used herein, “heteroarylsulfinyl” refers to —S(O)R in which R isheteroaryl.

As used herein, “aralkylsulfinyl” refers to —S(O)R in which R isaralkyl.

As used herein, “heteroaralkylsulfinyl” refers to —S(O)R in which R isheteroaralkyl.

As used herein, “alkylsulfonyl” refers to —S(O)₂R in which R is alkyl.

As used herein, “cycloalkylsulfonyl” refers to —S(O)₂R in which R iscycloalkyl.

As used herein, “arylsulfonyl” refers to —S(O)₂R in which R is aryl.

As used herein, “heteroarylsulfonyl” refers to —S(O)₂R in which R isheteroaryl.

As used herein, “aralkylsulfonyl” refers to —S(O)₂R in which R isaralkyl.

As used herein, “heteroaralkylsulfonyl” refers to —S(O)₂R in which R isheteroaralkyl.

As used herein, “alkoxysulfonyl” refers to —S(O)₂R in which R is alkoxy.

As used herein, “unsubstituted or substituted aminosulfonyl” refers to—S(O)₂N R′R in which R′ and R are independently hydrogen, alkyl aryl,heteroaryl, aralkyl or heteroaralkyl.

As used herein, pharmaceutically acceptable derivatives of a compoundinclude salts, esters, enol ethers, enol esters, acetals, ketals,orthoesters, hemiacetals, hemiketals, acids, bases, solvates, hydratesor prodrugs thereof. Such derivatives may be readily prepared by thoseof skill in this art using known methods for such derivatization. Thecompounds produced may be administered to animals or humans withoutsubstantial toxic effects and either are pharmaceutically active or areprodrugs. Pharmaceutically acceptable salts include, but are not limitedto, amine salts, such as but not limited toN,N′-dibenzylethylenediamine, chloroprocaine, choline, ammonia,diethanolamine and other hydroxyalkylamines, ethylenediamine,N-methylglucamine, procaine, N-benzylphenethylamine,1-para-chlorobenzyl-2-pyrrolidin-1′-ylmethylbenzimidazole, diethylamineand other alkylamines, piperazine and tris(hydroxymethyl)aminomethane;alkali metal salts, such as but not limited to lithium, potassium andsodium; alkali earth metal salts, such as but not limited to barium,calcium and magnesium; transition metal salts, such as but not limitedto zinc; and inorganic salts, such as but not limited to, sodiumhydrogen phosphate and disodium phosphate; and also including, but notlimited to, salts of mineral acids, such as but not limited tohydrochlorides and sulfates; and salts of organic acids, such as but notlimited to acetates, lactates, malates, tartrates, citrates, ascorbates,succinates, butyrates, valerates, mesylates, and fumarates.Pharmaceutically acceptable esters include, but are not limited to,alkyl, alkenyl, alkynyl, aryl, aralkyl, and cycloalkyl esters of acidicgroups, including, but not limited to, carboxylic acids, phosphoricacids, phosphinic acids, sulfonic acids, sulfinic acids and boronicacids. Pharmaceutically acceptable enol ethers include, but are notlimited to, derivatives of formula C═C(OR) where R is hydrogen, alkyl,alkenyl, alkynyl, aryl, aralkyl and cycloalkyl. Pharmaceuticallyacceptable enol esters include, but are not limited to, derivatives offormula C═C(OC(O)R) where R is hydrogen, alkyl, alkenyl, alkynyl, aryl,aralkyl and cycloalkyl. Pharmaceutically acceptable solvates andhydrates are complexes of a compound with one or more solvent or watermolecules, or 1 to about 100, or 1 to about 10, or one to about 2, 3 or4, solvent or water molecules.

It is to be understood that the compounds provided herein may containchiral centers. Such chiral centers may be of either the (R) or (S)configuration, or may be a mixture thereof. Thus, the compounds providedherein may be enantiomerically pure, or be stereoisomeric ordiastereomeric mixtures.

As used herein, substantially pure means sufficiently homogeneous toappear free of readily detectable impurities as determined by standardmethods of analysis, such as thin layer chromatography (TLC), gelelectrophoresis, high performance liquid chromatography (HPLC), nuclearmagnetic resonance (NMR), and mass spectrometry (MS), used by those ofskill in the art to assess such purity, or sufficiently pure such thatfurther purification would not detectably alter the physical andchemical properties, such as enzymatic and biological activities, of thesubstance. Methods for purification of the compounds to producesubstantially chemically pure compounds are known to those of skill inthe art. A substantially chemically pure compound may, however, be amixture of stereoisomers. In such instances, further purification mightincrease the specific activity of the compound. The instant disclosureis meant to include all such possible isomers, as well as, their racemicand optically pure forms. Optically active (+) and (−), (R)- and (S)-,or (D)- and (L)-isomers may be prepared using chiral synthons or chiralreagents, or resolved using conventional techniques, such as reversephase HPLC. When the compounds described herein contain olefinic doublebonds or other centers of geometric asymmetry, and unless specifiedotherwise, it is intended that the compounds include both E and Zgeometric isomers. Likewise, all tautomeric forms are also intended tobe included.

As used herein, the IC₅₀ refers to an amount, concentration or dosage ofa particular test compound that achieves a 50% inhibition of a maximalresponse in an assay that measures such response.

As used herein, EC₅₀ refers to a dosage, concentration or amount of aparticular test compound that elicits a dose-dependent response at 50%of maximal expression of a particular response that is induced, provokedor potentiated by the particular test compound.

As used herein, treatment means any manner in which one or more of thesymptoms of a disease or disorder are ameliorated or otherwisebeneficially altered. Treatment also encompasses any pharmaceutical useof the compositions herein, such as use for treating diabetes.

As used herein, amelioration of the symptoms of a particular disorder byadministration of a particular compound or pharmaceutical compositionrefers to any lessening, whether permanent or temporary, lasting ortransient that can be attributed to or associated with administration ofthe composition.

As used herein, the terms “preventing” means guard against therecurrence of the specified disease or disorder in a patient who hasalready suffered from the disease or disorder, and/or lengthening thetime that a patient who has suffered from the disease or disorderremains in remission.

The terms “GSK-3 mediated disease, or “GSK-3 mediated condition”, asused herein, mean any disease or other deleterious condition or state inwhich GSK-3 is known to play a role. Such diseases or conditionsinclude, without limitation, diabetes, conditions associated withdiabetes, chronic neurodegenerative conditions including dementias suchas Alzheimer's disease, Parkinson's disease, progressive supranuclearpalsy, subacute sclerosing panencephalitis parkinsonism,postencephalitic parkinsonism, pugilistic encephalitis, guamparkinsonism-dementia complex, Pick's disease, corticobasaldegeneration, frontotemporal dementia, Huntington's Disease, AIDSassociated dementia, amyotrophic lateral sclerosis, multiple sclerosis,neurotraumatic diseases such as acute stroke, epilepsy, mood disorderssuch as depression, schizophrenia and bipolar disorders, rheumatoidarthritis, inflammatory bowel disease, ulceractive colitis, Crohn'sdisease, sepsis, pancreatic cancer, ovarian cancer and osteoporosis.

B. Compounds

Provided herein are compounds of Formula (1):

or a pharmaceutically acceptable derivative thereof, wherein

R² is hydrogen or lower alkyl;

R³ is hydrogen, CN, C(O)R^(3a), C(NH)NHOH or 5-tetrazolyl;

R^(3a) is OH, alkoxy or NHR^(3b);

R^(3b) is hydrogen, NH₂, OH or lower alkyl;

R^(5a) and R^(5b) are each independently hydrogen, lower alkyl oraralkyl which is optionally substituted with one to three substituents,each independently selected from Q⁰ groups;

wherein Q⁰ is halo, cyano, nitro, NH₂, alkyl or alkoxy;

R⁶ is halo;

in each instance, independently, R^(a) and X³ are selected from (i) or(ii) as follows:

-   -   (i) R^(a) is hydrogen or lower alkyl; and        -   X³ is substituted or unsubstituted C₁-C₃ alkylene,            substituted or unsubstituted 3-6 membered cycloalkylene or            substituted or unsubstituted 3-6 membered heterocyclylene,            wherein the substituents when present are selected from one            to four Q² groups; or    -   (ii) R^(a) and X³ together with the nitrogen atom to which they        are bonded, may form a 5 to 7 membered saturated or unsaturated        ring optionally containing one or more O or S atoms, or one or        more additional N atoms, in the ring;

R^(b) is —(CHR^(7a))_(n)R⁷, —NR^(7b)R⁷, —OR⁷, —S(O)_(l)R⁷,—NR^(7b)COY¹R⁷ or —Y²CONR^(7b)R⁷;

Y¹ is bond, O or NR^(7b);

Y² is bond or O;

n is 0 or 1;

l is an integer of 0 to 2;

R⁷ is alkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, fusedheterocyclylaryl, or fused arylheterocyclyl, where R⁷ is optionallysubstituted with one to five substituents, each independently selectedfrom Q¹ groups;

R^(7a) is hydrogen alkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl,fused heterocyclylaryl, or fused arylheterocyclyl, where R^(7a) isoptionally substituted with one to five substituents, each independentlyselected from Q¹ groups;

R^(7b) is hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, orfused heterocyclylaryl, where R^(7b) is optionally substituted with oneto five substituents, each independently selected from Q¹ groups;

wherein Q¹ is halo, hydroxy, oxo, thioxo, cyano, nitro, azido, mercapto,formyl, hydroxycarbonyl, hydroxycarbonylalkyl, alkyl, haloalkyl,alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl,heteroaralkyl, alkoxy, haloalkoxy, cycloalkoxy, heterocyclyloxy,aryloxy, heteroaryloxy, aralkyloxy, heretoaralkyloxy, alkylcarbonyl,arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl,aralkyloxycarbonyl, unsubstituted or substituted aminocarbonyl,alkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy,alkoxycarbonyloxy, aryloxycarbonyloxy, aralkyloxycarbonyloxy,unsubstituted or substituted aminocarbonyloxy, unsubstituted orsubstituted amino, alkylthio, cycloalkylthio, arylthio, heteroarylthio,aralkylthio, heteroaralkylthio, alkylsulfinyl, cycloalkylsulfinyl,arylsulfinyl, heteroarylsulfinyl, aralkylsulfinyl,heteroaralkylsulfinyl, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl,heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl,alkoxysulfonyl, aryloxysulfonyl, unsubstituted or substitutedaminosulfonyl or hydroxysulfonyl;

X¹ is O or NR⁸;

R⁸ is hydrogen or lower alkyl;

X² is CH₂, O, NR¹ or S;

R¹ is hydrogen or lower alkyl;

A is bond or substituted or unsubstituted C₁-C₂ alkylene, wherein thesubstituents when present are selected from one to four Q² groups;

wherein Q² is alkyl or haloalkyl;

p is 0 or 1; and

q is an integer of 0 to 2.

In one embodiment, R^(5a) and R^(5b) are each hydrogen.

In one embodiment, R² is hydrogen.

In another embodiment, X¹ is O.

In another embodiment, Y¹ is bond.

In another embodiment, R³ is CN.

In another embodiment, R³ is C(O)R^(3a).

In another embodiment, R³ is C(NH)NHOH.

In another embodiment, R³ is 5-tetrazolyl.

In one embodiment, R^(3a) is OH.

In one embodiment, X¹ is O and R² is hydrogen.

In another embodiment, R^(a) is hydrogen.

In one embodiment, X³ is substituted or unsubstituted C₁-C₃ alkylene,wherein the substituents when present are selected from one to four Q²groups, where Q² is alkyl or haloalkyl.

In another embodiment, A is substituted or unsubstituted C₁-C₂ alkylene.

In another embodiment, A is substituted with from one to four Q² groups,wherein Q² is alkyl or haloalkyl; and p is 0.

In one embodiment, X² is CH₂.

In another embodiment, X² is O.

In another embodiment, A is CH₂; p is 0 and q is 2.

In another embodiment, X¹ is O.

In certain embodiments, R⁶ is F.

In certain embodiments, the compounds are of Formula (Ia):

or a pharmaceutically acceptable derivative thereof, wherein

R³ is hydrogen, CN, C(O)R^(3a), C(NH)NHOH or 5-tetrazolyl;

R^(a) is OH, alkoxy or NHR^(3b);

R^(3b) is hydrogen, NH₂, OH or lower alkyl;

R^(5a) and R^(5b) are each independently hydrogen or lower alkyl;

R⁶ is halo;

in each instance, independently, R^(a) and X³ are selected from (i) or(ii) as follows:

-   -   (i) R^(a) is hydrogen or lower alkyl; and        -   X³ is substituted or unsubstituted C₁-C₃ alkylene,            substituted or unsubstituted 3-6 membered cycloalkylene or            substituted or unsubstituted 3-6 membered heterocyclylene,            wherein the substituents when present are selected from one            to four Q² groups; or    -   (ii) R^(a) and X³ together with the nitrogen atom to which they        are bonded, may form a 5 to 7 membered saturated or unsaturated        ring optionally containing one or more O or S atoms, or one or        more additional N atoms, in the ring;

R^(b) is —(CHR^(7a))_(n)R⁷, —NR^(7b)R⁷, —OR⁷, —S(O)_(n)R⁷,—NR^(7b)COY¹R⁷ or —Y²CONR^(7b)R⁷;

Y¹ is bond, O or NR^(7b);

Y² is bond or O;

n is 0 or 1;

r is an integer of 0 to 2;

R⁷ is alkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, fusedheterocyclylaryl, or fused arylheterocyclyl, where R⁷ is optionallysubstituted with one to five substituents, each independently selectedfrom Q¹ groups;

R^(7a) is hydrogen alkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl,fused heterocyclylaryl, or fused arylheterocyclyl, where R^(7a) isoptionally substituted with one to five substituents, each independentlyselected from Q¹ groups;

R^(7b) is hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, orfused heterocyclylaryl, where R^(7b) is optionally substituted with oneto five substituents, each independently selected from Q¹ groups;

wherein Q¹ is halo, hydroxy, oxo, thioxo, cyano, nitro, azido, mercapto,formyl, hydroxycarbonyl, hydroxycarbonylalkyl, alkyl, haloalkyl,alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl,heteroaralkyl, alkoxy, haloalkoxy, cycloalkoxy, heterocyclyloxy,aryloxy, heteroaryloxy, aralkyloxy, heretoaralkyloxy, alkylcarbonyl,arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl,aralkyloxycarbonyl, unsubstituted or substituted aminocarbonyl,alkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy,alkoxycarbonyloxy, aryloxycarbonyloxy, aralkyloxycarbonyloxy,unsubstituted or substituted aminocarbonyloxy, unsubstituted orsubstituted amino, alkylthio, cycloalkylthio, arylthio, heteroarylthio,aralkylthio, heteroaralkylthio, alkylsulfinyl, cycloalkylsulfinyl,arylsulfinyl, heteroarylsulfinyl, aralkylsulfinyl,heteroaralkylsulfinyl, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl,heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl,alkoxysulfonyl, aryloxysulfonyl, unsubstituted or substitutedaminosulfonyl or hydroxysulfonyl; and

Q² is alkyl or haloalkyl.

In one embodiment, the compounds are of Formula (Ia), wherein R^(5a) andR^(5b) are hydrogen.

In one embodiment, the compounds are of Formula (Ia), wherein R³ is CN.

In one embodiment, the compounds are of Formula (Ia), wherein R³ isC(O)R^(3a).

In one embodiment, the compounds are of Formula (Ia), wherein R³ isC(NH)NHOH.

In one embodiment, the compounds are of Formula (Ia), wherein R³ is5-tetrazolyl.

In one embodiment, the compounds are of Formula (Ia), wherein R^(3a) isOH.

In one embodiment, the compounds are of Formula (Ia), wherein R^(a) ishydrogen.

In certain embodiments, the compounds are of Formula (Ib):

or a pharmaceutically acceptable derivative thereof, wherein R⁶ is halo;n is 1-3; X³ is substituted or unsubstituted C₁-C₃ alkylene, wherein thesubstituents when present are selected from one to four Q² groups; Q² isalkyl or haloalkyl; and other variables are as disclosed elsewhereherein.

In certain embodiments, the compounds are of Formula (Ic):

or a pharmaceutically acceptable derivative thereof, wherein n is 1-3;X³ is substituted or unsubstituted C₁-C₃ alkylene, wherein thesubstituents when present are selected from one to four Q² groups; Q² isalkyl or haloalkyl; and other variables are as disclosed elsewhereherein.

In certain embodiments, the compounds are of Formula (Id):

or a pharmaceutically acceptable derivative thereof, wherein X³ issubstituted or unsubstituted C₁-C₃ alkylene, wherein the substituentswhen present are selected from one to four Q² groups; Q² is alkyl orhaloalkyl; R³ is CN, C(O)OH, C(O)NH₂, C(NH)NHOH or 5-tetrazolyl; andother variables are as disclosed elsewhere herein.

In certain embodiments, compounds provided herein exhibit an IC₅₀ withrespect to GSK3 of no more than about 20 μM, in one embodiment, no morethan about 10 μM, no more than about 5 μM, or no more than 1 μM, asmeasured in the cell-free GSK3 kinase assay. In certain embodiments,compounds provided herein exhibit inhibitory activity that is selectivewith respect to GSK3, as compared to at least one other type of kinase.

In certain embodiments, GSK3 inhibitors provided herein aresubstantially free of antibacterial activity or having very lowantibacterial activity. The antibacterial activity can be measured bymethods known in the art by estimating a minimum inhibitoryconcentration (MIC) for test compounds (e.g. E. Coli and/or S. aureus,Clinical and Laboratory Standards Institute. Methods for DilutionAntimicrobial Susceptibility Tests for Bacteria That Grow Aerobically;Approved Standard-Sixth Edition: CLSI document M7-A4. CLSI, Wayne, Pa.(2003))

C. Preparation of the Compounds

The compounds provided herein can be prepared by methods known to one ofskill in the art as showed below and following procedures similar tothose described in the Examples section herein and routine modificationsthereof.

-   Kyorin Pharmaceutical Co., Ltd., Japanese Unexamined Patent    Publication S62-252772,-   Ube Industries, Ltd., Japanese Unexamined Patent Publication    S63-264439,-   Bayer AG Japanese Unexamined Patent Publication H1-268679,-   Ihara Chemical Industry Co., Ltd., Japanese Unexamined Patent    Publication H10-70584,-   Daiichi Seiyaku Co., Ltd., Japanese Unexamined Patent Publication    S59-1489,-   Tokyo Tanabe Co., Ltd., Japanese Unexamined Patent Publication    S62-53987,-   F. Hoffmann-La Roche Ltd., Japanese Unexamined Patent Publication    S63-132891,-   H. Koga et al., J. Med. Chem., 1980, 23, 1358,-   Y. Yoshida et al., Synlett, 2003, 2139,-   I. Hayakawa et al., Chem. Pharm. Bull., 1984, 32, 4907,-   S. Atarashi et al., Chem. Pharm. Bull., 1987, 35, 1986,-   S. Atarashi et al., J. Heterocyclic Chem., 1991, 28, 329,-   H. Egawa et al., Chem. Pharm. Bull., 1986, 34, 4098,-   L. A. Mitscher et al., J. Med. Chem., 1987, 30, 2283,-   G B. Mullen et al., J. Med. Chem., 1988, 31, 1694,-   J. S. Kiely et al., J. Med. Chem., 1988, 31, 2004,-   H. Ishikawa et al., Chem. Pharm. Bull., 1989, 37, 2103,-   V. D. Parikh et al., J. Heterocyclic Chem., 1988, 25, 1567,-   H. Ishikawa et al., Chem. Pharm. Bull., 1990, 38, 2459,-   P. Remuzon et al., J. Med. Chem., 1991, 34, 29,-   D. J. Augeri et al., J. Heterocyclic Chem., 1990, 27, 1509,-   T. Okada et al., J. Heterocyclic Chem., 1991, 28, 1067,-   D. T. W. Chu et al., J. Heterocyclic Chem., 1987, 24, 453, and-   S. L. Dax et al., J. Org. Chem., 1992, 57, 744.-   J. S. Kiely et al., J. Heterocyclic Chem., 1989, 26, 1675.-   M. Fujita et al., Chem. Pharm. Bull., 1996, 44, 987.

The compounds represented by the general formula (1) according to thepresent invention can be produced by Synthesis 1 or a combination ofconventional methods.

wherein X^(1a) is X¹ or N-PG¹ (PG¹ is a protective group), and A, R²,R³, Rya, R^(5b), R⁶, R^(a), R^(b), X¹, X², X³, p and q are as describedabove.

The protective group PG¹ represents acyl groups (such as acetyl group),lower alkoxycarbonyl groups (such as tert-butoxycarbonyl group),aryloxycarbonyl groups (such as benzyloxycarbonyl groups optionally withsubstitutents), aralkyl groups (such as benzyl group and p-methoxybenzylgroup) or silyl groups (such as trimethylsilyl group andtert-butyldimethylsilyl group).

When X^(1a) in the general formula (2) represents X¹, the conversionfrom the general formula (2) and the general formula (3) to the generalformula (1) (i.e., Process 1-A) is carried out at room temperature to180° C. for 1-48 hours by using a base (such as triethylamine, pyridine,isopropylethylamine, and 1,8-diazabicycloundecyne) in a suitable solvent(such as N,N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone,toluene, acetonitrile, tetrahydrofran, methanol, ethanol or a mixturethereof) or solvent-free.

When X^(1a) in the general formula (2) represents N-PG¹, the conversionfrom the general formula (2) and the general formula (3) to the generalformula (1) (i.e., Process 1-A) can be carried out by using a generaldeprotection method (such as the method described in Protecting Groupsin Organic Synthesis (John Wily and Sons (1999)) after theabove-mentioned process.

Among the compounds represented by the general formula (1) according tothe present invention, the compounds represented by the general formula(1b) or (1c) can be produced by Synthesis 2 as well.

wherein A, R^(a), R^(b), R², R^(3b), R^(5a), R^(5b), R⁶, X¹, X², X³, pand q are as described above.

The conversion from the general formula (Ia) to the general formula (Ib)(i.e., Process 2-A) can be carries out at room temperature to 180° C.for 1-72 hours by using a cyanide salt (such as potassium cyanide andsodium cyanide) in a suitable solvent (such as N,N-dimethylformamide anddimethylsulfoxide).

Alternatively, the conversion can be carried out at room temperature to250° C. for 1-72 hours in a suitable solvent (such as diphenylether,mesitylene, N,N-dimethylformamide, dimethylsulfoxide, toluene,acetonitrile, tetrahydrofuran, methanol, ethanol, acetic acid or amixture thereof). The reaction can be carried out in the absence or inpresence of acid (such as hydrochloric acid) or copper salt (such ascopper chloride).

The conversion from the general formula (Ia) to the general formula (Ic)(i.e., Process 2-B) can be carried out as follows: the general formula(Ia) is first reacted with thionyl chloride, thionyl bromide, aceticanhydride, ethyl chlorocarbonate, methyl chlorocarbonate, or the like)in a suitable solvent (such as N,N-dimethylformamide, dichloromethane,chloroform, tetrahydrofuran or a mixture thereof) at −15° C. to roomtemperature for 5 min to 3 hours. This converts the carboxyl group to areactive derivatizing group. The reaction can be carried out in theabsence or in the presence of base (such as pyridine and triethylamine).Subsequently, the reaction product is reacted with the general formula(4) in the presence of base (such as pyridine and triethylamine) in asuitable solvent (such as N,N-dimethylformamide, dichloromethane,chloroform, tetrahydrofuran or a mixture thereof) at a temperature from0° C. to 100° C. for 30 min to 24 hours.

Alternatively, the conversion can be performed as follows: the generalformula (Ia) is reacted with the general formula (4) by using acondensation reagent (such as dicyclohexylcarbodiimide,3-(3-dimethylaminopropyl)-1-ethylcarbodiimide chloride, diethylcyanophosphonate, diphenylphosphoryl azide and carbonyldiimidazol) in asuitable solvent (such as N,N-dimethylformamide, dichloromethane,chloroform, tetrahydrofuran or a mixture thereof) at 0° C. to 50° C. for1-24 hours. The reaction can be carried out in the absence or in thepresence of base (such as pyridine, triethylamine, N-methylmorphorine).

Among the compounds represented by the general formula (1) according tothe present invention, the compounds represented by the general formula(1d), (1e) or (1f) can be produced by Synthesis 3 as well.

wherein A, R^(a), R^(b), R², R^(5a), R^(5b), R⁶, X¹, X², X³, p and q areas described above.

The conversion from the general formula (1 ca) to the general formula(Id) (i.e., Process 3-A) can be carried out as follows: the generalformula (1ca) is reacted with a dehydroxylation reagent (such astrifluoroacetic anhydride and phosphorus oxychloride) in the presence ofbase (pyridine and triethylamine) in a suitable solvent (such asdichloromethane, chloroform, tetrahydrofuran or a mixture thereof) at 0°C. to 50° C. for 1-24 hours. After the reaction, the reaction productcan be treated with base (such as potassium carbonate, sodium hydroxideand NH silicagel) as need.

The conversion from the general formula (1d) to the general formula (1e)(i.e., Process 3-B) can be carried out at room temperature to 50° C. for1-24 hours by using an azide compound (such as sodium azide andtrimethylsilily azide) in a suitable solvent (such as 2-propanol, wateror a mixture thereof) in the presence of zinc salts (such as zincchloride and zinc bromide).

The conversion from the general formula (1d) to the general formula (1f)(i.e., Process 3-C) can be carried out at 0° C. to reflux temperaturefor 1-24 hours by using hydroxylamine in a suitable solvent (such asethanol, methanol, N,N-dimethylformamide, tetrahydrofuran or a mixturethereof). The reaction can be carried out in the absence or in thepresence of base (such as potassium bicarbonate, sodium carbonate,pyridine and triethylamone).

In Synthesis 1, the compounds represented by the general formula (2) canbe produced by Synthesis 4.

wherein A, R², R³, R^(5a), R^(5b), R⁶, X^(1a), X², p and q are asdescribed above.

The conversions from the general formula (5) and the general formula (6)to the general formula (7) (i.e., Process 4-A) can be performed asfollows: the general formula (5) is reacted with a mixture of aceticanhydride and ortho-acid ester (such as ortho-formic acid ethyl esterand ortho-acetic ethyl ester) at 100° C. to 150° C. for 1-8 hours, andthen the reaction product is reacted with the general formula (6) in asuitable solvent (such as toluene, tetrahydrofuran, methanol, ethanol,t-butanol, or a mixture thereof) at room temperature for 1-24 hours. Thereaction can be carried out in the absence or in the presence of a base(potassium carbonate, sodium carbonate, t-BuOK, t-BuONa, triethylamineand pyridine).

The conversion from the general formula (7) to the general formula (8)(i.e., Process 4-B) can be carried out at 0° C. to 150° C. for 1-24hours by using a base (such as potassium hydride, sodium hydride,potassium carbonate, sodium carbonate, t-BuOK and t-BuONa) or fluoridesalt (such as potassium fluoride and sodium fluoride) in a suitablesolvent (such as N,N-dimethylformamide, dimethylsulfoxide,tetrahydrofuran, or a mixture thereof).

The conversion from the general formula (8) to the general formula (2)(i.e., Process 4-C) can be carried out at room temperature to 180° C.for 1-24 hours in the presence of a base (such as triethylamine,pyridine, isopropylethylamine, and 1,8-diazabicycloundecyne) in asuitable solvent (such as N,N-dimethylformamide, dimethylsulfoxide,toluene, acetonitrile, tetrahydrofran, methanol, ethanol or a mixturethereof) in the presence of base (such as triethylamine, pyridine,isopropylethylamine, and 1,8-diazabicycloundecyne) or solvent-free.

Among the compounds represented by the general formula (2), thecompounds represented by the general formula (2a) can be produced bySynthesis 5 as well.

wherein A, R², R³, R⁶, X^(1a), X², p and q are as described above.

The conversion from the general formula (10) and the general formula (6)to the general formula (11) (i.e., Process 5-A) can be conducted by amethod similar to Process 4-A.

The conversion from the general formula (11) to the general formula (12)(i.e., Process 5-B) can be performed by a method similar to Process 4-B.

The conversion from the general formula (12) to the general formula (13)(i.e., Process 5-C) can be conducted by general nitration, for instance,a reaction in concentrated sulfuric acid using a nitrosating reagent(such as potassium nitrate, sodium nitrate and nitric acid). Thereaction can be carried out at 0° C. to 50° C. for 1-8 hours.

The conversion from the general formula (13) to the general formula (2a)(i.e., Process 5-D) can be carried out at room temperature to 120° C.for 1-48 hours by using a metal (such as reduced iron, tin and zinc) inthe presence of acid (such as hydrochloric acid and acetic acid) in asuitable solvent (such as tetrahydrofuran, methanol, ethanol, water or amixture thereof) or solvent-free.

Alternatively, the conversion can be performed by hydrogenation usingmetal catalyst (such as palladium on activated carbon, platinum onactivated carbon, oxidized platinum and Raney nickel) in a suitablesolvent (such as methanol, ethanol, ethyl acetate, tetrahydrofuran,N,N-dimethylformamide, acetic acid or a mixture thereof) at roomtemperature to 80° C. for 1-24 hours. The reaction can be carried out ata pressure from normal pressure to 0.5 MPa in hydrogen atmosphere.

Furthermore, the conversion can be performed by reduction using sodiumhydrosulfite in a suitable solvent (such as water, methanol, ethanol,tetrahydrofuran or a mixture thereof) at room temperature to 100° C. for1-24 hours.

In Synthesis 4 or Synthesis 5, a compound of the general formula (15),(16), (17) and (18) can be produced by Synthesis 6 as well.

wherein R⁵ is hydrogen, NO₂ or R^(5a)R^(5b)N—, and A, R^(a), R^(b), R²,R⁶, X^(1a), X², p and q are as described above.

The conversion from the general formula (14) to the general formula (15)(i.e., Process 6-A) can be performed by a method similar to Process 2-B.

The conversion from the general formula (15) to the general formula (16)(i.e., Process 6-B) can be performed by a method similar to Process 3-A.

The conversion from the general formula (16) to the general formula (17)(i.e., Process 6-C) can be performed by a method similar to Process 3-B.

The conversion from the general formula (16) to the general formula (18)(i.e., Process 6-D) can be performed by a method similar to Process 3-C.

Among compounds represented by the general formula (13) in Synthesis 5,the compound represented by the general formula (13b) can be produced bySynthesis 7 as well.

wherein R^(3aa) is alkoxy, X is halogens, and A, R², R⁵, R⁶, X^(1a), X²,p and q are as described above.

The conversion from the general formula (13a) and the general formula(19) to the general formula (20) (i.e., Process 7-A) can be carried at atemperature from −78° C. to 0° C. for 1-24 hours in a suitable solvent(such as tetrahydrofuran, diethylether or a mixture thereof). Theconversion can be carried out in the absence or in the presence of acopper salt (such as copper iodide and copper chloride).

The conversion from the general formula (20) to the general formula(13b) (i.e., Process 7-B) can be conducted at room temperature to 130°C. for 1-120 hours by using manganese dioxide in a suitable solvent(such as dichloromethane, chloroform, toluene, ethanol or a mixturethereof).

Alternatively, the conversion can be carried out at room temperature to130° C. for 1-24 hour by using a quinone compound (such asdichlorodicyano-p-benzoquinone and chloranil).

Among the compounds represented by the general formula (13) in Synthesis5, the compound represented by the general formula (13d) can be producedby Synthesis 8.

wherein A, R², R³, X^(1a), X², p, and q are as described above.

The conversion from the general formula (13c) to the general formula(21) (i.e., Process 8-A) can be carried out at room temperature to −78°C. for 1 to 72 hours by using ammonium carbonate in a suitable solvent(such as N,N-dimethylformamide, dimethylsulfoxide, ethanol, methanol,water or a mixture thereof).

The conversion from the general formula (21) to the general formula(13d) (i.e., Process 8-B) can be carried out at 0° C. to 100° C. for1-48 hours by using a nitrite ester (such as t-butyl nitrite, amylnitrite, iso-amyl nitrite) in the presence of a copper salt (such ascopper chloride and copper bromide) in a suitable solvent such asacetonitrile).

Alternatively, the conversion can be performed as follows: the generalformula (21) is reacted with a nitrite salt (such as potassium nitriteand sodium nitrite) in the presence of an acid (such as hydrochloricacid, sulfuric acid, and acetic acid) in a suitable solvent (forexample, tetrahydrofuran, 1,4-dioxane, H₂O or a mixture thereof) at atemperature from 0° C. to room temperature for 5 min. to 1 hr, and then,the reaction product is treated with a copper salt (such as copperchloride and copper bromide) in a suitable solvent (for example,tetrahydrofuran, 1,4-dioxane, H₂O or a mixture thereof) at 0° C.-100° C.for 1-48 hours.

In Synthesis 1-8, the compounds with substituent X^(1a) representingN-PG¹ can be converted to compounds with X^(1a) representing NH by aconventional method such as the method described in Protecting Groups inOrganic Synthesis (John Wily and Sons (1999)).

In Synthesis 1-8, the compounds with substituent R^(5a) and/or R^(5b)representing aralkyl group which optionally with substituents can beconverted to compounds with substituent R^(5a) and/or R^(5b)representing H by a conventional method, for example, by catalyticreduction using acid (such as hydrochloric acid and trifluoroaceticacid), inorganic base (such as potassium carbonate and sodiumhydroxide), organic base (such as hydrazine), quaternary ammonium salt(such as tetrabutylammonium fluoride) and metal (such as palladium oncarbon).

In Synthesis 1-8, the compounds with substituent R³ representingalkoxycarbonyl group can be converted to compounds with substituent R³is COOH by a conventional method, for example, a solvent-free reactionor a reaction in a suitable solvent (such as methanol, ethanol,tetrahydrofuran, water or a mixture thereof) in the presence of eitherbase (such as potassium hydroxide, sodium hydroxide, potassium carbonateand sodium carbonate) or acid (such as sulfuric acid, hydrochloric acidand acetic acid) at a temperature from room temperature to 120° C. for1-48 hours.

Optical isomers of the compounds represented by the general formula (1)can be produced by using the aforementioned Syntheses 1-8 or acombination of the conventional methods, using optically active startingmaterials.

Alternatively, these optical isomers can be prepared from racemetes ofrepresented by the general formula (1) by fractional crystallizationusing optically active acid or base, or chromatography using ciralsupport.

Certain exemplary reaction schemes for the preparation of compounds areshown below:

In one embodiment, the product of Synthesis 9 is8-amino-9-fluoro-7-oxo-10-(2-(pyridin-2-ylamino)ethylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-]quinoline-3,1′-cyclopentane]-6-carboxylicacid (8), as illustrated in Synthesis 11.

D. Pharmaceutical Compositions

The pharmaceutical compositions provided herein contain therapeuticallyeffective amounts of one or more of compounds provided herein that areuseful in the prevention, treatment, or amelioration of one or more ofthe symptoms of GSK-3 mediated diseases.

Pharmaceutical compositions of the compounds provided herein may beadministered systemically or locally, or orally or parentelly such asrectally, subcutaneously, intramuscularly, intravenously orpercutaneusly.

The compositions contain one or more compounds provided herein. Thecompounds can be formulated into suitable pharmaceutical preparationssuch as solutions, suspensions, tablets, dispersible tablets, pills,capsules, granules, powders, fine powders, injections, sustained releaseformulations or elixirs, for oral administration or in sterile solutionsor suspensions for parenteral administration, as well as transdermalpatch preparation and dry powder inhalers. In certain embodiments, thecompositions provided herein can be produced by adding convenientexcipients, fillers, binders, disintegrators, coating agents, sugarcoating agents, pH modulators, solublizing agents, or aqueous ornon-aqueous solvents according to the conventional pharmaceuticalpreparation techniques. Typically, the compounds described above areformulated into pharmaceutical compositions using techniques andprocedures well known in the art (see, e.g., Ansel Introduction toPharmaceutical Dosage Forms, Seventh Edition 1999).

In the compositions, effective concentrations of one or more compoundsor pharmaceutically acceptable derivatives is (are) mixed with asuitable pharmaceutical carrier or vehicle. The compounds may bederivatized as the corresponding salts, esters, enol ethers or esters,acids, bases, solvates, hydrates or prodrugs prior to formulation, asdescribed above. The concentrations of the compounds in the compositionsare effective for delivery of an amount, upon administration, thattreats, prevents, or ameliorates one or more of the symptoms of GSK-3mediated diseases.

Typically, the compositions are formulated for single dosageadministration. To formulate a composition, the weight fraction ofcompound is dissolved, suspended, dispersed or otherwise mixed in aselected vehicle at an effective concentration such that the treatedcondition is relieved or ameliorated. Pharmaceutical carriers orvehicles suitable for administration of the compounds provided hereininclude any such carriers known to those skilled in the art to besuitable for the particular mode of administration.

In addition, the compounds may be formulated as the solepharmaceutically active ingredient in the composition or may be combinedwith other active ingredients. Liposomal suspensions, includingtissue-targeted liposomes, such as tumor-targeted liposomes, may also besuitable as pharmaceutically acceptable carriers. These may be preparedaccording to methods known to those skilled in the art. For example,liposome formulations may be prepared as known in the art. Briefly,liposomes such as multilamellar vesicles (MLV's) may be formed by dryingdown egg phosphatidyl choline and brain phosphatidyl serine (7:3 molarratio) on the inside of a flask. A solution of a compound providedherein in phosphate buffered saline lacking divalent cations (PBS) isadded and the flask shaken until the lipid film is dispersed. Theresulting vesicles are washed to remove unencapsulated compound,pelleted by centrifugation, and then resuspended in PBS.

The active compound is included in the pharmaceutically acceptablecarrier in an amount sufficient to exert a therapeutically useful effectin the absence of undesirable side effects on the patient treated. Thetherapeutically effective concentration may be determined empirically bytesting the compounds in in vitro and in vivo systems described hereinand then extrapolated therefrom for dosages for humans.

The concentration of active compound in the pharmaceutical compositionwill depend on absorption, inactivation and excretion rates of theactive compound, the physicochemical characteristics of the compound,the dosage schedule, and amount administered as well as other factorsknown to those of skill in the art. For example, the amount that isdelivered is sufficient to ameliorate one or more of the symptoms ofGSK-3 mediated diseases.

In certain embodiments, a therapeutically effective dosage shouldproduce a serum concentration of active ingredient of from about 0.1ng/ml to about 50-100 μg/ml. In one embodiment, the pharmaceuticalcompositions provide a dosage of from about 0.001 mg to about 2000 mg ofcompound per kilogram of body weight per day. Pharmaceutical dosage unitforms are prepared to provide from about 1 mg to about 1000 mg and incertain embodiments, from about 10 to about 500 mg of the essentialactive ingredient or a combination of essential ingredients per dosageunit form.

The active ingredient may be administered at once, or may be dividedinto a number of smaller doses to be administered at intervals of time.It is understood that the precise dosage and duration of treatment is afunction of the disease being treated and may be determined empiricallyusing known testing protocols or by extrapolation from in vivo or invitro test data. It is to be noted that concentrations and dosage valuesmay also vary with the severity of the condition to be alleviated. It isto be further understood that for any particular subject, specificdosage regimens should be adjusted over time according to the individualneed and the professional judgment of the person administering orsupervising the administration of the compositions, and that theconcentration ranges set forth herein are exemplary only and are notintended to limit the scope or practice of the claimed compositions.

Pharmaceutically acceptable derivatives include acids, bases, enolethers and esters, salts, esters, hydrates, solvates and prodrug forms.The derivative is selected such that its pharmacokinetic properties aresuperior to the corresponding neutral compound.

Thus, effective concentrations or amounts of one or more of thecompounds described herein or pharmaceutically acceptable derivativesthereof are mixed with a suitable pharmaceutical carrier or vehicle forsystemic, topical or local administration to form pharmaceuticalcompositions. Compounds are included in an amount effective forameliorating one or more symptoms of, or for treating or preventingkinase-mediated, including, but not limited to, GSK-3-mediated diseases.The concentration of active compound in the composition will depend onabsorption, inactivation, excretion rates of the active compound, thedosage schedule, amount administered, particular formulation as well asother factors known to those of skill in the art.

The compositions are intended to be administered by a suitable route,including orally, parenterally, rectally, topically and locally. Fororal administration, capsules and tablets can be formulated. Thecompositions are in liquid, semi-liquid or solid form and are formulatedin a manner suitable for each route of administration.

Solutions or suspensions used for parenteral, intradermal, subcutaneous,or topical application can include any of the following components: asterile diluent, such as water for injection, saline solution, fixedoil, polyethylene glycol, glycerine, propylene glycol, dimethylacetamide or other synthetic solvent; antimicrobial agents, such asbenzyl alcohol and methyl parabens; antioxidants, such as ascorbic acidand sodium bisulfite; chelating agents, such asethylenediaminetetraacetic acid (EDTA); buffers, such as acetates,citrates and phosphates; and agents for the adjustment of tonicity suchas sodium chloride or dextrose. Parenteral preparations can be enclosedin ampules, disposable syringes or single or multiple dose vials made ofglass, plastic or other suitable material.

In instances in which the compounds exhibit insufficient solubility,methods for solubilizing compounds may be used. Such methods are knownto those of skill in this art, and include, but are not limited to,using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants,such as TWEEN®, or dissolution in aqueous sodium bicarbonate.

Upon mixing or addition of the compound(s), the resulting mixture may bea solution, suspension, emulsion or the like. The form of the resultingmixture depends upon a number of factors, including the intended mode ofadministration and the solubility of the compound in the selectedcarrier or vehicle. The effective concentration is sufficient forameliorating the symptoms of the disease, disorder or condition treatedand may be empirically determined.

The pharmaceutical compositions are provided for administration tohumans and animals in unit dosage forms, such as tablets, capsules,pills, powders, granules, sterile parenteral solutions or suspensions,and oral solutions or suspensions, and oil water emulsions containingsuitable quantities of the compounds or pharmaceutically acceptablederivatives thereof. The pharmaceutically therapeutically activecompounds and derivatives thereof are formulated and administered inunit dosage forms or multiple dosage forms. Unit dose forms as usedherein refer to physically discrete units suitable for human and animalsubjects and packaged individually as is known in the art. Each unitdose contains a predetermined quantity of the therapeutically activecompound sufficient to produce the desired therapeutic effect, inassociation with the required pharmaceutical carrier, vehicle ordiluent. Examples of unit dose forms include ampules and syringes andindividually packaged tablets or capsules. Unit dose forms may beadministered in fractions or multiples thereof. A multiple dose form isa plurality of identical unit dosage forms packaged in a singlecontainer to be administered in segregated unit dose form. Examples ofmultiple dose forms include vials, bottles of tablets or capsules orbottles of pints or gallons. Hence, multiple dose form is a multiple ofunit doses which are not segregated in packaging.

Sustained-release preparations can also be prepared. Suitable examplesof sustained-release preparations include semipermeable matrices ofsolid hydrophobic polymers containing the compound provided herein,which matrices are in the form of shaped articles, e.g., films, ormicrocapsule. Examples of sustained-release matrices include polyesters,hydrogels (for example, poly(2-hydroxyethyl-methacrylate), orpoly(vinylalcohol)), polylactides, copolymers of L-glutamic acid andethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradablelactic acid-glycolic acid copolymers such as the LUPRON DEPOT™(injectable microspheres composed of lactic acid-glycolic acid copolymerand leuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid. Whilepolymers such as ethylene-vinyl acetate and lactic acid-glycolic acidenable release of molecules for over 100 days, certain hydrogels releaseproteins for shorter time periods. When encapsulated compound remain inthe body for a long time, they may denature or aggregate as a result ofexposure to moisture at 37° C., resulting in a loss of biologicalactivity and possible changes in their structure. Rational strategiescan be devised for stabilization depending on the mechanism of actioninvolved. For example, if the aggregation mechanism is discovered to beintermolecular S—S bond formation through thio-disulfide interchange,stabilization may be achieved by modifying sulfhydryl residues,lyophilizing from acidic solutions, controlling moisture content, usingappropriate additives, and developing specific polymer matrixcompositions.

Dosage forms or compositions containing active ingredient in the rangeof 0.005% to 100% with the balance made up from non toxic carrier may beprepared. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by the incorporation of any of the normallyemployed excipients, such as, for example pharmaceutical grades ofmannitol, lactose, starch, magnesium stearate, talcum or talc, cellulosederivatives, gelatin, agar, pectin, arabic gum, olive oil, sesame oil,cacao butter, ethylene glycol, sodium crosscarmellose, glucose, sucrose,magnesium carbonate or sodium saccharin. Such compositions includesolutions, suspensions, tablets, capsules, powders and sustained releaseformulations, such as, but not limited to, implants andmicroencapsulated delivery systems, and biodegradable, biocompatiblepolymers, such as collagen, ethylene vinyl acetate, polyanhydrides,polyglycolic acid, polyorthoesters, polylactic acid and others. Methodsfor preparation of these compositions are known to those skilled in theart. The contemplated compositions may contain about 0.001-100% activeingredient, in certain embodiments, about 0.1-85% or about 75-95%.

The active compounds or pharmaceutically acceptable derivatives may beprepared with carriers that protect the compound against rapidelimination from the body, such as time release formulations orcoatings.

The compositions may include other active compounds to obtain desiredcombinations of properties. The compounds provided herein, orpharmaceutically acceptable derivatives thereof as described herein, mayalso be advantageously administered for therapeutic or prophylacticpurposes together with another pharmacological agent known in thegeneral art to be of value in treating one or more of the diseases ormedical conditions referred to hereinabove, such as GSK-3 mediateddiseases. It is to be understood that such combination therapyconstitutes a further aspect of the compositions and methods oftreatment provided herein.

Lactose-free compositions provided herein can contain excipients thatare well known in the art and are listed, for example, in the U.S.Pharmocopia (USP) SP (XXI)/NF (XVI). In general, lactose-freecompositions contain an active ingredient, a binder/filler, and alubricant in pharmaceutically compatible and pharmaceutically acceptableamounts. Exemplary lactose-free dosage forms contain an activeingredient, microcrystalline cellulose, pre-gelatinized starch andmagnesium stearate.

Further encompassed are anhydrous pharmaceutical compositions and dosageforms containing a compound provided herein. For example, the additionof water (e.g., 5%) is widely accepted in the pharmaceutical arts as ameans of simulating long-term storage in order to determinecharacteristics such as shelf-life or the stability of formulations overtime. See, e.g., Jens T. Carstensen, Drug Stability: Principles &Practice, 2d. Ed., Marcel Dekker, NY, N.Y., 1995, pp. 379-80. In effect,water and heat accelerate the decomposition of some compounds. Thus, theeffect of water on a formulation can be of great significance sincemoisture and/or humidity are commonly encountered during manufacture,handling, packaging, storage, shipment and use of formulations.

Anhydrous pharmaceutical compositions and dosage forms as describedherein can be prepared using anhydrous or low moisture containingingredients and low moisture or low humidity conditions. Pharmaceuticalcompositions and dosage forms that comprise lactose and at least oneactive ingredient that comprises a primary or secondary amine may be, incertain embodiments, anhydrous if substantial contact with moistureand/or humidity during manufacturing, packaging, and/or storage isexpected.

An anhydrous pharmaceutical composition should be prepared and storedsuch that its anhydrous nature is maintained. Accordingly, anhydrouscompositions are, in certain embodiments, packaged using materials knownto prevent exposure to water such that they can be included in suitableformulary kits. Examples of suitable packaging include, but are notlimited to, hermetically sealed foils, plastics, unit dose containers(e.g., vials), blister packs and strip packs.

Oral Dosage Forms

Oral pharmaceutical dosage forms are either solid, gel or liquid. Thesolid dosage forms are tablets, capsules, granules, and bulk powders.Types of oral tablets include compressed, chewable lozenges and tabletswhich may be enteric coated, sugar coated or film coated. Capsules maybe hard or soft gelatin capsules, while granules and powders may beprovided in non effervescent or effervescent form with the combinationof other ingredients known to those skilled in the art.

In certain embodiments, the formulations are solid dosage forms, such ascapsules or tablets: The tablets, pills, capsules, troches and the likecan contain any of the following ingredients, or compounds of a similarnature: a binder; a diluent; a disintegrating agent; a lubricant; aglidant; a sweetening agent; and a flavoring agent.

Examples of binders include microcrystalline cellulose, gum tragacanth,glucose solution, acacia mucilage, gelatin solution, sucrose and starchpaste. Lubricants include talc, starch, magnesium or calcium stearate,lycopodium and stearic acid. Diluents include, for example, lactose,sucrose, starch, kaolin, salt, mannitol and dicalcium phosphate.Glidants include, but are not limited to, colloidal silicon dioxide.Disintegrating agents include crosscarmellose sodium, sodium starchglycolate, alginic acid, corn starch, potato starch, bentonite,methylcellulose, agar and carboxymethylcellulose. Coloring agentsinclude, for example, any of the approved certified water soluble FD andC dyes, mixtures thereof; and water insoluble FD and C dyes suspended onalumina hydrate. Sweetening agents include sucrose, lactose, mannitoland artificial sweetening agents such as saccharin, and any number ofspray dried flavors. Flavoring agents include natural flavors extractedfrom plants such as fruits and synthetic blends of compounds whichproduce a pleasant sensation, such as, but not limited to peppermint andmethyl salicylate. Wetting agents include propylene glycol monostearate,sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylenelaural ether. Emetic coatings include fatty acids, fats, waxes, shellac,ammoniated shellac and cellulose acetate phthalates. Film coatingsinclude hydroxyethylcellulose, sodium carboxymethylcellulose,polyethylene glycol 4000 and cellulose acetate phthalate.

If oral administration is desired, the compound could be provided in acomposition that protects it from the acidic environment of the stomach.For example, the composition can be formulated in an enteric coatingthat maintains its integrity in the stomach and releases the activecompound in the intestine. The composition may also be formulated incombination with an antacid or other such ingredient.

When the dosage unit form is a capsule, it can contain, in addition tomaterial of the above type, a liquid carrier such as a fatty oil. Inaddition, dosage unit forms can contain various other materials whichmodify the physical form of the dosage unit, for example, coatings ofsugar and other enteric agents. The compounds can also be administeredas a component of an elixir, suspension, syrup, wafer, sprinkle, chewinggum or the like. A syrup may contain, in addition to the activecompounds, sucrose as a sweetening agent and certain preservatives, dyesand colorings and flavors.

The active materials can also be mixed with other active materials whichdo not impair the desired action, or with materials that supplement thedesired action, such as antacids, H2 blockers, and diuretics. The activeingredient is a compound or pharmaceutically acceptable derivativethereof as described herein. Higher concentrations, up to about 98% byweight of the active ingredient may be included.

Pharmaceutically acceptable carriers included in tablets are binders,lubricants, diluents, disintegrating agents, coloring agents, flavoringagents, and wetting agents. Enteric coated tablets, because of theenteric coating, resist the action of stomach acid and dissolve ordisintegrate in the neutral or alkaline intestines. Sugar coated tabletsare compressed tablets to which different layers of pharmaceuticallyacceptable substances are applied. Film coated tablets are compressedtablets which have been coated with a polymer or other suitable coating.Multiple compressed tablets are compressed tablets made by more than onecompression cycle utilizing the pharmaceutically acceptable substancespreviously mentioned. Coloring agents may also be used in the abovedosage forms. Flavoring and sweetening agents are used in compressedtablets, sugar coated, multiple compressed and chewable tablets.Flavoring and sweetening agents are especially useful in the formationof chewable tablets and lozenges.

Liquid oral dosage forms include aqueous solutions, emulsions,suspensions, solutions and/or suspensions reconstituted from noneffervescent granules and effervescent preparations reconstituted fromeffervescent granules. Aqueous solutions include, for example, elixirsand syrups. Emulsions are either oil in-water or water in oil.

Elixirs are clear, sweetened, hydroalcoholic preparations.Pharmaceutically acceptable carriers used in elixirs include solvents.Syrups are concentrated aqueous solutions of a sugar, for example,sucrose, and may contain a preservative. An emulsion is a two phasesystem in which one liquid is dispersed in the form of small globulesthroughout another liquid. Pharmaceutically acceptable carriers used inemulsions are non aqueous liquids, emulsifying agents and preservatives.Suspensions use pharmaceutically acceptable suspending agents andpreservatives. Pharmaceutically acceptable substances used in noneffervescent granules, to be reconstituted into a liquid oral dosageform, include diluents, sweeteners and wetting agents. Pharmaceuticallyacceptable substances used in effervescent granules, to be reconstitutedinto a liquid oral dosage form, include organic acids and a source ofcarbon dioxide. Coloring and flavoring agents are used in all of theabove dosage forms.

Solvents include glycerin, sorbitol, ethyl alcohol and syrup. Examplesof preservatives include glycerin, methyl and propylparaben, benzoicadd, sodium benzoate and alcohol. Examples of non aqueous liquidsutilized in emulsions include mineral oil and cottonseed oil. Examplesof emulsifying agents include gelatin, acacia, tragacanth, bentonite,and surfactants such as polyoxyethylene sorbitan monooleate. Suspendingagents include sodium carboxymethylcellulose, pectin, tragacanth, Veegumand acacia. Diluents include lactose and sucrose. Sweetening agentsinclude sucrose, syrups, glycerin and artificial sweetening agents suchas saccharin. Wetting agents include propylene glycol monostearate,sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylenelauryl ether. Organic adds include citric and tartaric acid. Sources ofcarbon dioxide include sodium bicarbonate and sodium carbonate. Coloringagents include any of the approved certified water soluble FD and Cdyes, and mixtures thereof. Flavoring agents include natural flavorsextracted from plants such as fruits, and synthetic blends of compoundswhich produce a pleasant taste sensation.

For a solid dosage form, the solution or suspension, in for examplepropylene carbonate, vegetable oils or triglycerides, is encapsulated ina gelatin capsule. Such solutions, and the preparation and encapsulationthereof, are disclosed in U.S. Pat. Nos. 4,328,245; 4,409,239; and4,410,545. For a liquid dosage form, the solution, e.g., for example, ina polyethylene glycol, may be diluted with a sufficient quantity of apharmaceutically acceptable liquid carrier, e.g., water, to be easilymeasured for administration.

Alternatively, liquid or semi solid oral formulations may be prepared bydissolving or dispersing the active compound or salt in vegetable oils,glycols, triglycerides, propylene glycol esters (e.g., propylenecarbonate) and other such carriers, and encapsulating these solutions orsuspensions in hard or soft gelatin capsule shells. Other usefulformulations include, but are not limited to, those containing acompound provided herein, a dialkylated mono- or poly-alkylene glycol,including, but not limited to, 1,2-dimethoxymethane, diglyme, triglyme,tetraglyme, polyethylene glycol-350-dimethyl ether, polyethyleneglycol-550-dimethyl ether, polyethylene glycol-750-dimethyl etherwherein 350, 550 and 750 refer to the approximate average molecularweight of the polyethylene glycol, and one or more antioxidants, such asbutylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propylgallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine,lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoricacid, thiodipropionic acid and its esters, and dithiocarbamates.

Other formulations include, but are not limited to, aqueous alcoholicsolutions including a pharmaceutically acceptable acetal. Alcohols usedin these formulations are any pharmaceutically acceptable water-misciblesolvents having one or more hydroxyl groups, including, but not limitedto, propylene glycol and ethanol. Acetals include, but are not limitedto, di(lower alkyl)acetals of lower alkyl aldehydes such as acetaldehydediethyl acetal.

In all embodiments, tablets and capsules formulations may be coated asknown by those of skill in the art in order to modify or sustaindissolution of the active ingredient. Thus, for example, they may becoated with a conventional enterically digestible coating, such asphenylsalicylate, waxes and cellulose acetate phthalate.

Injectables, Solutions and Emulsions

Parenteral administration, generally characterized by injection, eithersubcutaneously, intramuscularly or intravenously is also contemplatedherein. Injectables can be prepared in conventional forms, either asliquid solutions or suspensions, solid forms suitable for solution orsuspension in liquid prior to injection, or as emulsions. Suitableexcipients are, for example, water, saline, dextrose, glycerol orethanol. In addition, if desired, the pharmaceutical compositions to beadministered may also contain minor amounts of non toxic auxiliarysubstances such as wetting or emulsifying agents, pH buffering agents,stabilizers, solubility enhancers, and other such agents, such as forexample, sodium acetate, sorbitan monolaurate, triethanolamine oleateand cyclodextrins. Implantation of a slow release or sustained releasesystem, such that a constant level of dosage is maintained is alsocontemplated herein. Briefly, a compound provided herein is dispersed ina solid inner matrix, e.g., polymethylmethacrylate,polybutylmethacrylate, plasticized or unplasticized polyvinylchloride,plasticized nylon, plasticized polyethyleneterephthalate, naturalrubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene,ethylene-vinylacetate copolymers, silicone rubbers,polydimethylsiloxanes, silicone carbonate copolymers, hydrophilicpolymers such as hydrogels of esters of acrylic and methacrylic acid,collagen, cross-linked polyvinylalcohol and cross-linked partiallyhydrolyzed polyvinyl acetate, that is surrounded by an outer polymericmembrane, e.g., polyethylene, polypropylene, ethylene/propylenecopolymers, ethylene/ethyl acrylate copolymers, ethylene/vinylacetatecopolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber,chlorinated polyethylene, polyvinylchloride, vinylchloride copolymerswith vinyl acetate, vinylidene chloride, ethylene and propylene, ionomerpolyethylene terephthalate, butyl rubber epichlorohydrin rubbers,ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcoholterpolymer, and ethylene/vinyloxyethanol copolymer, that is insoluble inbody fluids. The compound diffuses through the outer polymeric membranein a release rate controlling step. The percentage of active compoundcontained in such parenteral compositions is highly dependent on thespecific nature thereof, as well as the activity of the compound and theneeds of the subject.

Parenteral administration of the compositions includes intravenous,subcutaneous and intramuscular administrations. Preparations forparenteral administration include sterile solutions ready for injection,sterile dry soluble products, such as lyophilized powders, ready to becombined with a solvent just prior to use, including hypodermic tablets,sterile suspensions ready for injection, sterile dry insoluble productsready to be combined with a vehicle just prior to use and sterileemulsions. The solutions may be either aqueous or nonaqueous.

If administered intravenously, suitable carriers include physiologicalsaline or phosphate buffered saline (PBS), and solutions containingthickening and solubilizing agents, such as glucose, polyethyleneglycol, and polypropylene glycol and mixtures thereof.

Pharmaceutically acceptable carriers used in parenteral preparationsinclude aqueous vehicles, nonaqueous vehicles, antimicrobial agents,isotonic agents, buffers, antioxidants, local anesthetics, suspendingand dispersing agents, emulsifying agents, sequestering or chelatingagents and other pharmaceutically acceptable substances.

Examples of aqueous vehicles include Sodium Chloride Injection, RingersInjection, Isotonic Dextrose Injection, Sterile Water Injection,Dextrose and Lactated Ringers Injection. Nonaqueous parenteral vehiclesinclude fixed oils of vegetable origin, cottonseed oil, corn oil, sesameoil and peanut oil. Antimicrobial agents in bacteriostatic orfungistatic concentrations must be added to parenteral preparationspackaged in multiple dose containers which include phenols or cresols,mercurials, benzyl alcohol, chlorobutanol, methyl and propyl phydroxybenzoic acid esters, thimerosal, benzalkonium chloride andbenzethonium chloride. Isotonic agents include sodium chloride anddextrose. Buffers include phosphate and citrate. Antioxidants includesodium bisulfate. Local anesthetics include procaine hydrochloride.Suspending and dispersing agents include sodium carboxymethylcelluose,hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifyingagents include Polysorbate 80 (TWEEN® 80). A sequestering or chelatingagent of metal ions include EDTA. Pharmaceutical carriers also includeethyl alcohol, polyethylene glycol and propylene glycol for watermiscible vehicles and sodium hydroxide, hydrochloric acid, citric acidor lactic acid for pH adjustment.

The concentration of the pharmaceutically active compound is adjusted sothat an injection provides an effective amount to produce the desiredpharmacological effect. The exact dose depends on the age, weight andcondition of the patient or animal as is known in the art.

The unit dose parenteral preparations are packaged in an ampule, a vialor a syringe with a needle. All preparations for parenteraladministration must be sterile, as is known and practiced in the art.

Illustratively, intravenous or intraarterial infusion of a sterileaqueous solution containing an active compound is an effective mode ofadministration. Another embodiment is a sterile aqueous or oily solutionor suspension containing an active material injected as necessary toproduce the desired pharmacological effect.

Injectables are designed for local and systemic administration.Typically a therapeutically effective dosage is formulated to contain aconcentration of at least about 0.1% w/w up to about 90% w/w or more,such as more than 1% w/w of the active compound to the treatedtissue(s). The active ingredient may be administered at once, or may bedivided into a number of smaller doses to be administered at intervalsof time. It is understood that the precise dosage and duration oftreatment is a function of the tissue being treated and may bedetermined empirically using known testing protocols or by extrapolationfrom in vivo or in vitro test data. It is to be noted thatconcentrations and dosage values may also vary with the age of theindividual treated. It is to be further understood that for anyparticular subject, specific dosage regimens should be adjusted overtime according to the individual need and the professional judgment ofthe person administering or supervising the administration of theformulations, and that the concentration ranges set forth herein areexemplary only and are not intended to limit the scope or practice ofthe claimed formulations.

The compound may be suspended in micronized or other suitable form ormay be derivatized to produce a more soluble active product or toproduce a prodrug. The form of the resulting mixture depends upon anumber of factors, including the intended mode of administration and thesolubility of the compound in the selected carrier or vehicle. Theeffective concentration is sufficient for ameliorating the symptoms ofthe condition and may be empirically determined.

Lyophilized Powders

Of interest herein are also lyophilized powders, which can bereconstituted for administration as solutions, emulsions and othermixtures. They may also be reconstituted and formulated as solids orgels.

The sterile, lyophilized powder is prepared by dissolving a compoundprovided herein, or a pharmaceutically acceptable derivative thereof, ina suitable solvent. The solvent may contain an excipient which improvesthe stability or other pharmacological component of the powder orreconstituted solution, prepared from the powder. Excipients that may beused include, but are not limited to, dextrose, sorbital, fructose, cornsyrup, xylitol, glycerin, glucose, sucrose or other suitable agent. Thesolvent may also contain a buffer, such as citrate, sodium or potassiumphosphate or other such buffer known to those of skill in the art at, inone embodiment, about neutral pH. Subsequent sterile filtration of thesolution followed by lyophilization under standard conditions known tothose of skill in the art provides the desired formulation. Generally,the resulting solution will be apportioned into vials forlyophilization. Each vial will contain a single dosage (i.e., 10-1000 mgor 100-500 mg) or multiple dosages of the compound. The lyophilizedpowder can be stored under appropriate conditions, such as at about 4°C. to room temperature.

Reconstitution of this lyophilized powder with water for injectionprovides a formulation for use in parenteral administration. Forreconstitution, about 1-50 mg, about 5-35 mg, or about 9-30 mg oflyophilized powder, is added per mL of sterile water or other suitablecarrier. The precise amount depends upon the selected compound. Suchamount can be empirically determined.

Topical Administration

Topical mixtures are prepared as described for the local and systemicadministration. The resulting mixture may be a solution, suspension,emulsions or the like and are formulated as creams, gels, ointments,emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes,foams, aerosols, irrigations, sprays, suppositories, bandages, dermalpatches or any other formulations suitable for topical administration.

The compounds or pharmaceutically acceptable derivatives thereof may beformulated as aerosols for topical application, such as by inhalation(see, e.g., U.S. Pat. Nos. 4,044,126, 4,414,209, and 4,364,923 whichdescribe aerosols for delivery of a steroid useful for treatment ofinflammatory diseases, particularly asthma). These formulations foradministration to the respiratory tract can be in the form of an aerosolor solution for a nebulizer, or as a microfine powder for insufflation,alone or in combination with an inert carrier such as lactose. In such acase, the particles of the formulation will have diameters of less than50 microns or less than 10 microns.

The compounds may be formulated for local or topical application, suchas for topical application to the skin and mucous membranes, such as inthe eye, in the form of gels, creams, and lotions and for application tothe eye or for intracisternal or intraspinal application. Topicaladministration is contemplated for transdermal delivery and also foradministration to the eyes or mucosa, or for inhalation therapies. Nasalsolutions of the active compound alone or in combination with otherpharmaceutically acceptable excipients can also be administered.

These solutions, particularly those intended for ophthalmic use, may beformulated as 0.01%-10% isotonic solutions, pH about 5-7, withappropriate salts.

Compositions for Other Routes of Administration

Other routes of administration, such as topical application, transdermalpatches, and rectal administration are also contemplated herein.

For example, pharmaceutical dosage forms for rectal administration arerectal suppositories, capsules and tablets for systemic effect. Rectalsuppositories are used herein mean solid bodies for insertion into therectum which melt or soften at body temperature releasing one or morepharmacologically or therapeutically active ingredients.Pharmaceutically acceptable substances utilized in rectal suppositoriesare bases or vehicles and agents to raise the melting point. Examples ofbases include cocoa butter (theobroma oil), glycerin gelatin, carbowax(polyoxyethylene glycol) and appropriate mixtures of mono, di andtriglycerides of fatty acids. Combinations of the various bases may beused. Agents to raise the melting point of suppositories includespermaceti and wax. Rectal suppositories may be prepared either by thecompressed method or by molding. An exemplary weight of a rectalsuppository is about 2 to 3 μm.

Tablets and capsules for rectal administration are manufactured usingthe same pharmaceutically acceptable substance and by the same methodsas for formulations for oral administration.

Sustained Release Compositions

Active ingredients provided herein can be administered by controlledrelease means or by delivery devices that are well known to those ofordinary skill in the art. Examples include, but are not limited to,those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809;3,598,123; and 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548,5,073,543, 5,639,476, 5,354,556, 5,639,480, 5,733,566, 5,739,108,5,891,474, 5,922,356, 5,972,891, 5,980,945, 5,993,855, 6,045,830,6,087,324, 6,113,943, 6,197,350, 6,248,363, 6,264,970, 6,267,981,6,376,461, 6,419,961, 6,589,548, 6,613,358, 6,699,500 and 6,740,634,each of which is incorporated herein by reference. Such dosage forms canbe used to provide slow or controlled-release of one or more activeingredients using, for example, hydropropylmethyl cellulose, otherpolymer matrices, gels, permeable membranes, osmotic systems, multilayercoatings, microparticles, liposomes, microspheres, or a combinationthereof to provide the desired release profile in varying proportions.Suitable controlled-release formulations known to those of ordinaryskill in the art, including those described herein, can be readilyselected for use with the active ingredients provided herein.

All controlled-release pharmaceutical products have a common goal ofimproving drug therapy over that achieved by their non-controlledcounterparts. In one embodiment, the use of an optimally designedcontrolled-release preparation in medical treatment is characterized bya minimum of drug substance being employed to cure or control thecondition in a minimum amount of time. In certain embodiments,advantages of controlled-release formulations include extended activityof the drug, reduced dosage frequency, and increased patient compliance.In addition, controlled-release formulations can be used to affect thetime of onset of action or other characteristics, such as blood levelsof the drug, and can thus affect the occurrence of side (e.g., adverse)effects.

Most controlled-release formulations are designed to initially releasean amount of drug (active ingredient) that promptly produces the desiredtherapeutic effect, and gradually and continually release of otheramounts of drug to maintain this level of therapeutic or prophylacticeffect over an extended period of time. In order to maintain thisconstant level of drug in the body, the drug must be released from thedosage form at a rate that will replace the amount of drug beingmetabolized and excreted from the body. Controlled-release of an activeingredient can be stimulated by various conditions including, but notlimited to, pH, temperature, enzymes, water, or other physiologicalconditions or compounds.

In certain embodiments, the agent may be administered using intravenousinfusion, an implantable osmotic pump, a transdermal patch, liposomes,or other modes of administration. In one embodiment, a pump may be used(see, Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald etal., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574(1989). In another embodiment, polymeric materials can be used. In yetanother embodiment, a controlled release system can be placed inproximity of the therapeutic target, i.e., thus requiring only afraction of the systemic dose (see, e.g., Goodson, Medical Applicationsof Controlled Release, vol. 2, pp. 115-138 (1984).

In some embodiments, a controlled release device is introduced into asubject in proximity of the site of inappropriate immune activation or atumor. Other controlled release systems are discussed in the review byLanger (Science 249:1527-1533 (1990). The active ingredient can bedispersed in a solid inner matrix, e.g., polymethylmethacrylate,polybutylmethacrylate, plasticized or unplasticized polyvinylchloride,plasticized nylon, plasticized polyethyleneterephthalate, naturalrubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene,ethylene-vinylacetate copolymers, silicone rubbers,polydimethylsiloxanes, silicone carbonate copolymers, hydrophilicpolymers such as hydrogels of esters of acrylic and methacrylic acid,collagen, cross-linked polyvinylalcohol and cross-linked partiallyhydrolyzed polyvinyl acetate, that is surrounded by an outer polymericmembrane, e.g., polyethylene, polypropylene, ethylene/propylenecopolymers, ethylene/ethyl acrylate copolymers, ethylene/vinylacetatecopolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber,chlorinated polyethylene, polyvinylchloride, vinylchloride copolymerswith vinyl acetate, vinylidene chloride, ethylene and propylene, ionomerpolyethylene terephthalate, butyl rubber epichlorohydrin rubbers,ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcoholterpolymer, and ethylene/vinyloxyethanol copolymer, that is insoluble inbody fluids. The active ingredient then diffuses through the outerpolymeric membrane in a release rate controlling step. The percentage ofactive ingredient contained in such parenteral compositions is highlydependent on the specific nature thereof, as well as the needs of thesubject.

Targeted Formulations

The compounds provided herein, or pharmaceutically acceptablederivatives thereof, may also be formulated to be targeted to aparticular tissue, receptor, or other area of the body of the subject tobe treated. Many such targeting methods are well known to those of skillin the art. All such targeting methods are contemplated herein for usein the instant compositions. For non-limiting examples of targetingmethods, see, e.g., U.S. Pat. Nos. 6,316,652, 6,274,552, 6,271,359,6,253,872, 6,139,865, 6,131,570, 6,120,751, 6,071,495, 6,060,082,6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252,5,840,674, 5,759,542 and 5,709,874.

In one embodiment, liposomal suspensions, including tissue-targetedliposomes, such as tumor-targeted liposomes, may also be suitable aspharmaceutically acceptable carriers. These may be prepared according tomethods known to those skilled in the art. For example, liposomeformulations may be prepared as described in U.S. Pat. No. 4,522,811.Briefly, liposomes such as multilamellar vesicles (MLV's) may be formedby drying down egg phosphatidyl choline and brain phosphatidyl serine(7:3 molar ratio) on the inside of a flask. A solution of a compoundprovided herein in phosphate buffered saline lacking divalent cations(PBS) is added and the flask shaken until the lipid film is dispersed.The resulting vesicles are washed to remove unencapsulated compound,pelleted by centrifugation, and then resuspended in PBS.

Articles of Manufacture

The compounds or pharmaceutically acceptable derivatives can be packagedas articles of manufacture containing packaging material, a compound orpharmaceutically acceptable derivative thereof provided herein, which isused for treatment, prevention or amelioration of one or more symptomsassociated with kinase activity, including, but not limited to, GSK-3activity, and a label that indicates that the compound orpharmaceutically acceptable derivative thereof is used for treatment,prevention or amelioration of one or more symptoms of kinase-mediated,including, but not limited to, GSK-3-mediated diseases.

The articles of manufacture provided herein contain packaging materials.Packaging materials for use in packaging pharmaceutical products arewell known to those of skill in the art. See, e.g., U.S. Pat. Nos.5,323,907, 5,052,558 and 5,033,252. Examples of pharmaceutical packagingmaterials include, but are not limited to, blister packs, bottles,tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, andany packaging material suitable for a selected formulation and intendedmode of administration and treatment. A wide array of formulations ofthe compounds and compositions provided herein are contemplated.

E. Methods of Treatment

Methods of use of the compounds and compositions are also provided. Themethods involve both in vitro and in vivo uses of the compounds andcompositions.

In certain embodiments, provided herein are methods for inhibiting theaction of GSK-3 by administering compounds and compositions providedherein. In one embodiment, the methods involve contacting GSK-3 with acompound provided herein.

F. Evaluation of Compound Activity

GSK3 inhibitory activity of the compounds provided herein can be readilydetected using the assays described herein, as well as assays generallyknown to those of ordinary skill in the art.

Exemplary methods for identifying specific inhibitors of GSK3 includeboth cell-free and cell-based GSK3 kinase assays. A cell-free GSK3kinase assay detects inhibitors that act by direct interaction with thepolypeptide GSK3, while a cell-based GSK3 kinase assay may identifyinhibitors that function either by direct interaction with GSK3 itself,or by interference with GSK3 expression or with post-translationalprocessing required to produce mature active GSK3. U.S. Application No.20050054663 describes exemplary cell-free and cell-based GSK3 kinaseassays. Exemplary assays used herein are discussed briefly below:

10-25 ng of recombinant full-length human GSK3β (Upstate) is incubatedin the presence or absence of compound at varying concentrations for 1hour at 30 degrees Celsius in 20 mM MOPS, pH 7.0, 10 mM magnesiumacetate, 0.2 mM EDTA, 2 mM EGTA, 30 mM magnesium chloride, 62.5 μMphospho-glycogen synthase peptide-2, 5 μM ATP, 10 mM β-glycerolphosphate, 1 mM sodium orthovanadate and 1 mM dithiothreitol. Proceed toKinaseGlo luciferase reaction.

Following the completion of the kinase reaction an equal volume ofKinaseGlo luciferase reagent (Promega) is added and the luminescenceread using a luminescence plate reader within 5-10 minutes. Compoundactivity is expressed as % inhibition relative to maximal inhibitionobserved at the maximal dose and 1050 values then calculated using curvefitting software (GraphPad Prizm).

EXAMPLES Example 18′-amino-9′-fluoro-7′-oxo-10′-[2-(2-pyridylamino)ethylamino]spiro[cyclopentane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine-1-6′-carboxylicAcid 1A) Preparation of ethyl3-[1-(hydroxymethyl)cyclopentylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate

A stirred solution of ethyl3-oxo-3-(2,3,4,5-tetrafluorophenyl)propionate (3.17 g, 12 mmol), aceticanhydride (3.34 mL, 3.6 g, 30 mmol) and triethyl orthoformate (3.00 mL,2.6 g, 18 mmol) was heated at 130° C. for 1.5 h. The mixture wasconcentrated in vacuo and dried under high vacuum for 3 hours. The crudeproduct was dissolved in EtOH (15 mL) and cooled to 0° C. and then1-amino-1-cyclopentanemethanol (1.01 g, 8.8 mmol) was added very slowly.After 1.5 h, the solvent was removed by evaporation to yield the titlecompound as yellow oil (3.1 g crude) that was used in the next stepwithout further purification.

1B) Preparation of Ethyl-9′,10′-difluoro-7′-oxospiro[cyclopentane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate

To a solution of3-[1-(hydroxymethyl)cyclopentylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate(570 mg, 1.46 mmol) in THF (10 mL), crushed pellets of KOH (164 mg, 2.93mmol) were added under ice-cooling. After 1.5 h more KOH was added (80mg, 1.42 mmol) and the reaction mixture was warmed up to roomtemperature and stirred overnight. The reaction mixture was acidifiedwith 0.5 N HCl to pH 2. The white precipitate was collected byfiltration to give the title compound which was used crude in the nextstep (454 mg, 1.3 mmol, 89%).

1C) Preparation of 9′,10′-difluoro-7′-oxospiro[cyclopentane-1,3′(2′H)-[4H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicacid

A solution ofethyl-9′,10′-difluoro-7′-oxospiro[cyclopentane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate(13.2 g, 38 mmol) in a mixture of acetic acid/water/H₂SO₄ (8:6:1 v/v, 75mL) was heated under reflux for 2 h. The reaction mixture was pouredinto ice water. A precipitate formed and was collected by filtration,washed with water and then dried to give the title compound (10.5 g,32.7 mmol, 86%) as a light yellow solid.

1D) Preparation of 9′,10′-difluoro-8′-nitro-7′-oxospiro[cyclopentane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6-carboxylicacid

A solution of9′,10′-difluoro-7′-oxospiro[cyclopentane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicacid (1.8 g, 5.6 mmol) in concentrated H₂SO₄ (10 mL) was treatedportionwise at 0° C. with solid KNO₃ (736 mg, 7.29 mmol). After stirringat 0° C. for 1 h, the reaction mixture was poured into 500 mL ofice-water and the resulting precipitate was removed by filtration andwashed with ice-cold water. The resulting solid was dried to yield thetitle compound as a pale yellow solid (1.8 g, 88%).

1E) Preparation of 8′-amino-9′,10′-difluoro-7′-oxospiro[cyclopentane-1,3′(2H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylic acid

A solution of 9′,10′-difluoro-8′-nitro-7′-oxospiro[cyclopentane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylic acid (3.9 g,0.01 mmol) in ethanol/acetic acid (1:1, v/v, 100 mL) was hydrogenatedunder atmospheric pressure over 10% Pd/C (390 mg) at 80° C. for 18 h.Then 200 mL of DMF were added and the reaction mixture was heated untilit became clear. The catalyst was removed by filtration over Celite,which was washed two times with hot DMF and the combined filtrates wereconcentrated in vacuo to dryness to yield the title compound (2.85 g,73%) which was used crude in the next step.

1F) Preparation of8′-amino-9′-fluoro-7′-oxo-10′-[2-(2-pyridylamino)ethylamino]spiro[cyclopentane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicAcid

A solution of 8′-amino-9′10′-difluoro-7′-oxospiro[cyclopentane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylic acid (500 mg,1.37 mmol) and N-(2-pyridyl)-1,2-ethanediamine (226 mg, 1.64 mmol) and19 μL triethylamine in DMSO (5 mL) was stirred at 90° C. for 24 h. Thereaction mixture was poured into water and the precipitate that formedwas collected by filtration. The crude product was passed through asilica gel column (CH₂Cl₂/CH₃OH 10:1 v/v) and then re-crystallized fromdiethyl ether to yield the title compound (284 mg, 42%) as a yellowsolid. MS (EP) m/z: 454 (M⁺+1). (Calcd. for C₂₃H₂₄FN₅O₄, 453.18).

Example 28-amino-9-fluoro-10-(2-(4-methylquinolin-2-ylamino)-ethylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylic Acid

A solution of8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid (13 mg, 0.04 mmol) and N1-(4-methylquinolin-2-yl)ethane-1,2-diamine(10 mg, 0.05 mmol) and 11 μL triethylamine in DMSO (0.3 mL) was stirredat 90° C. for 72 h. The reaction mixture was cooled and freeze-driedovernight. The crude product was taken up in CH₂Cl₂ and purified bypreparative TLC to yield8-amino-9-fluoro-10-(2-(4-methylquinolin-2-ylamino)ethylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid (0.8 mg, 4%) as a yellow solid. MS (EP) m/z: 518 (M⁺+1). (Calcd.for C₂₈H₂₈FN₅O₄, 517.21).

Example 310-(3-(1H-1,2,4-triazol-1-yl)propylamino)-8-amino-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

A solution of8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid (13 mg, 0.04 mmol) and 3-(1H-1,2,4-triazol-1-yl)propan-1-amine (5mg, 0.04 mmol) and 5.5 μL triethylamine in DMSO (0.3 mL) was stirred at90° C. for 24 h. The reaction mixture was cooled and freeze-driedovernight. The crude product was taken up in ACN and purified by prepHPLC to yield10-(3-(1H-1,2,4-triazol-1-yl)propylamino)-8-amino-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid (3.2 mg, 18%) as a yellow solid. MS (EP) m/z: 443 (M⁺+1). (Calcd.For C₂₁H₂₃FN₆O₄, 442.18).

Example 48-amino-9-fluoro-10-(3-(4-fluorophenyl)propylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid

8-amino-9-fluoro-10-(3-(4-fluorophenyl)propylamino)-7-oxo-2,7-dihydrospiro-[[1,4]oxazino[2,3,4-j]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 470 (M⁺+1). (Calcd. For C₂₅H₂₅F₂N₃O₄,469.18).

Example 58-amino-10-(3-(3,4-dihydroquinolin-1(2H)-yl)-propylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-10-(3-(3,4-dihydroquinolin-1(2H)-yl)propylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylic acidwas prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 507 (M⁺+1). (Calcd. For C₂₈H₃₁FN₄O₄,506.23).

Example 68-amino-10-(4-(4-chlorophenyl)butan-2-ylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-10-(4-(4-chlorophenyl)butan-2-ylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 500 (M⁺+1). (Calcd. For C₂₆H₂₇ClFN₃O₄,499.17).

Example 78-amino-9-fluoro-10-(3-(furan-2-carboxamido)-propylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-9-fluoro-10-(3-(furan-2-carboxamido)propylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 485 (M⁺+1). (Calcd. For C₂₄H₂₅FN₄O₆,484.18).

Example 88-amino-10-(3-(adamantanecarboxamido)propylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]6-carboxylicAcid

8-amino-10-(3-(adamantanecarboxamido)propylamino)-9-fluoro-7-oxo-2,7-dihydrospio[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 553 (M⁺+1). (Calcd. For C₃₀H₃₇FN₄O₅,552.27).

Example 98-amino-9-fluoro-10-(2-(4-fluorophenoxy)ethylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-9-fluoro-10-(2-(4-fluorophenoxy)ethylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 472 (M⁺+1). (Calcd. For C₂₄H₂₃F₂N₃O₅,471.16).

Example 108-amino-10-(2-(4-chloro-3-methylphenoxy)ethylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-10-(2-(4-chloro-3-methylphenoxy)ethylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 502 (M⁺+1). (Calcd. For C₂₅H₂₅ClFN₃O₅,501.15).

Example 1110-(2-(1H-indol-3-ylthio)ethylamino)-8-amino-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

10-(2-(1H-indol-3-ylthio)ethylamino)-8-amino-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3Y-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 509 (M⁺+1). (Calcd. For C₂₆H₂₅FN₄O₄S,508.16).

Example 128-amino-10-(2-(4-chlorophenoxy)ethylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-10-(2-(4-chlorophenoxy)ethylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 487.9 (M⁺+1). (Calcd. For C₂₄H₂₃ClFN₃O₅,487.13).

Example 138-amino-10-(2-(2,4-dichlorophenoxy)ethylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-10-(2-(2,4-dichlorophenoxy)ethylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 521.9 (M⁺+1). (Calcd. For C₂₄H₂₂Cl₂FN₃O₅,521.09).

Example 148-amino-10-(3-(3,4-dimethoxyphenyl)propylamino)-9-fluoro-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-10-(3-(3,4-dimethoxyphenyl)propylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 512 (M⁺+1). (Calcd. For C₂₇H₃₀FN₃O₆,511.21).

Example 158-amino-10-(2-(2,6-dimethylquinolin-4-ylamino)-ethylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-10-(2-(2,6-dimethylquinolin-4-ylamino)ethylamino)-9-fluoro-7-oxo-2,7-dihydrospiroa-1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 532 (M⁺+1). (Calcd. For C₂₉H₃₀FN₅O₄,531.23).

Example 168-amino-9-fluoro-10-(2-(3-methyl-1H-1,2,4-triazol-5-ylthio)ethylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-9-fluoro-10-(2-(3-methyl-1H-1,2,4-triazol-5-ylthio)ethylamino)-7-oxo-2,7-diydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 474.9 (M⁺+1). (Calcd. For C₂₁H₂₃FN₆O₄S,474.15).

Example 178-amino-10-(2-(4-cyclohexylphenoxy)ethylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-10-(2-(4-cyclohexylphenoxy)ethylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 536 (M⁺+1). (Calcd. For C₃₀H₃₄FN₃O₅,535.25).

Example 188-amino-9-fluoro-10-(2-(1-methyl-1H-imidazol-2-ylthio)-ethylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-9-fluoro-10-(2-(1-methyl-1H-imidazol-2-ylthio)ethylamino)-7-oxo-2,7-dihydospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 474 (M⁺+1). (Calcd. For C₂₂H₂₄FN₅O₄S,473.15).

Example 198-amino-9-fluoro-7-oxo-10-(2-(piperidin-1-ylsulfonyl)-ethylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylic Acid

8-amino-9-fluoro-7-oxo-10-(2-(piperidin-1-ylsulfonyl)ethylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylic acid wasprepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 509 (M⁺+1). (Calcd. For C₂₃H₂₉FN₄O₆S,508.18).

Example 208-amino-10-(2-(1,1-dioxo-1H-1λ-6-benzo[d]isothiazol-3-ylamino)ethylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-10-(2-(1,1-dioxo-1H-1λ-6-benzo[d]isothiazol-3-ylamino)ethylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]-oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 541.9 (M⁺+1). (Calcd. For C₂₅H₂₄FN₅O₆S,541.14).

Example 218-amino-9-fluoro-7-oxo-10-(2-(1-phenyl-1H-tetrazol-5-ylthio)ethylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-9-fluoro-7-oxo-10-(2-(1-phenyl-1H-tetrazol-5-ylthio)ethylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 538 (M⁺+1). (Calcd. For C₂₅H₂₄FN₇O₄S,537.16).

Example 2210-(3-(1H-benzo[d]imidazol-1-yl)-2-hydroxypropylamino)-8-amino-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

10-(3-(1H-benzo[d]imidazol-1-yl)-2-hydroxypropylamino)-8-amino-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro-[[1,4]oxazino-[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 508.0 (M⁺+1). (Calcd. for C₂₆H₂₆FN₅O₅,507.19).

Example 238-amino-10-(3-(ethyl(phenyl)amino)propylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-10-(3-(ethyl(phenyl)amino)propylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 495 (M⁺+1). (Calcd. For C₂₇H₃₁FN₄O₄,494.23).

Example 248-amino-9-fluoro-10-(2-(indolin-1-yl)ethylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-9-fluoro-10-(2-(indolin-1-yl)ethylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ef]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 479 (M⁺+1). (Calcd. For C₂₆H₂₇FN₄O₄,478.20).

Example 258-amino-9-fluoro-7-oxo-10-(2-(p-tolyloxy)ethylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-9-fluoro-7-oxo-10-(2-(p-tolyloxy)ethylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 468 (M⁺+1). (Calcd. For C₂₅H₂₆FN₃O₅,467.19).

Example 268-amino-9-fluoro-7-oxo-10-(3-(pyridin-2-yl)propylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-9-fluoro-7-oxo-10-(3-(pyridin-2-yl)propylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylic acid was preparedfrom8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 453 (M⁺+1). (Calcd. For C₂₄H₂₅FN₄O₄,452.19).

Example 278-amino-10-(3-(2-chlorophenyl)propylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-#]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-10-(3-(2-chlorophenyl)propylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylic acidwas prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 486 (M⁺+1). (Calcd. For C₂₅H₂₅ClFN₃O₄,485.15).

Example 288-amino-9-fluoro-10-(3-(4-methoxyphenyl)propylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-9-fluoro-10-(3-(4-methoxyphenyl)propylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 482 (M⁺+1). (Calcd. For C₂₆H₂₈FN₃O₅,481.20).

Example 298-amino-10-(3-(3,4-diethoxyphenyl)propylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-10-(3-(3,4-diethoxyphenyl)propylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 540 (M⁺+1). (Calcd. For C₂₉H₃₄FN₃O₆,539.24).

Example 308-amino-9-fluoro-10-(2-(2-methylquinolin-4-ylamino)-ethylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-9-fluoro-10-(2-(2-methylquinolin-4-ylamino)ethylamino)-7-oxo-2,7-dihydrosiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 518 (M⁺+1). (Calcd. For C₂₈H₂₈FN₅O₄,517.21).

Example 318-amino-10-(4-(2-chlorophenyl)butan-2-ylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-10-(4-(2-chlorophenyl)butan-2-ylamino)-9-fluoro-7-oxo-2,7-dihydrospiro-[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 500 (M⁺+1). (Calcd. For C₂₆H₂₇ClFN₃O₄,499.17).

Example 328-amino-9-fluoro-7-oxo-10-(3-(1,3,5-trimethyl-1H-pyrazol-4-yl)propylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-1H]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-9-fluoro-7-oxo-10-(3-(1,3,5-trimethyl-1H-pyrazol-4-yl)propylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 484 (M⁺+1). (Calcd. For C₂₅H₃₀FN₅O₄,483.23).

Example 338-amino-9-fluoro-10-(3-(3-methoxyphenyl)propylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-9-fluoro-10-(3-(3-methoxyphenyl)propylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 482 (M⁺+1). (Calcd. For C₂₆H₂₈FN₃O₅,481.20).

Example 348-amino-9-fluoro-10-(2-(4-methoxyphenoxy)ethylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

8-amino-9-fluoro-10-(2-(4-methoxyphenoxy)ethylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above. MS (EP) m/z: 484 (M⁺+1). (Calcd. For C₂₅H₂₆FN₃O₆,483.18).

Example 358-amino-9-fluoro-10-(3-(pyridin-2-yl)propylamino)-6-1H-tetrazol-5-yl)spiro-[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentan]-7(2H)-onehydrochloride 35A) Preparation of9,10-difluoro-8-nitro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxamide

9,10-difluoro-8-nitro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicacid (3 g, 8.2 mmol) was suspended in SOCl₂ (25 ml) and refluxed for 3 huntil a clear solution was obtained. Upon completion of the reaction,SOCl₂ was removed under vacuo. The remaining solid was diluted withdioxane and cooled in an ice bath. A solution of concentrated NH₄OH wasadded carefully under vigorous stirring. A precipitate formed that wascollected by filtration and washed with water. The solid was dried undervacuo to give 2.2 g (75% yield) of the title compound. This compound wasused in the next step without further purification

35B) Preparation of8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxamide

To a suspension of9,10-difluoro-8-nitro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxamide(1 g, 2.7 mmol) in a mixture of water/methanol (1:1 v/v, 30 mL) wasadded sodium hydrosulfite (Na₂S₂O₄, 3.75 g, 22 mmol). The suspension wasrefluxed for 5 h until all starting material had disappeared. Uponcompletion, the reaction mixture was cooled to room temperature and 50ml of water were added. After 20 minutes, a light yellow solid wascollected by filtration and washed with water. The solid was dried undervacuo to give 660 mg (73% yield) of the title compound that was usedwithout further purification in the next step.

35C) Preparation of8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carbonitrile

To a cooled solution of8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxamide (1 g, 2.9 mmol) andtriethylamine (2 mL, 10 mmol.) in DCM (20 ml) was added POCl₃ (780 μl,8.7 mmol.) dropwise and stirred at 0° C. for an additional 5 h. A darkcolored mixture formed. Upon completion of the reaction, DCM was removedunder vacuo and the residue was washed several times with water. Thesolid was dried under vacuum to give 540 mg (58.7% yield) of the titlecompound. This product is not very soluble except in DMF or DMSO and isused in the next step without further purification.

35D) Preparation of8-amino-9,10-difluoro-6-(1H-tetrazol-5-yl)spiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentan]-7(2H)-one

To a mixture of nitrile8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carbonitrile(180 mg, 0.56 mmol) in isopropanol and water (1:1 v/v, 15 ml) were added80 mg of sodium azide (1.14 mmole) and 170 mg of zinc chloride (1.14mmole). The mixture was heated to 110° C. for 18 h. The precipitateswere collected by filtration and washed with water. The solid was driedunder vacuum to give 135 mg (67% yield) of the title compound. Thiscompound was used without further purification in the next step.

35E) Preparation of8-amino-9-fluoro-10-(3-(pyridin-2-yl)-propylamino)-6-1H-tetrazol-5-yl)spiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentan]-7(2H)-oneHydrochloride

MS (EP) m/z: 477.5 (M+1). (Calcd. for C₂₄H₂₅FN₈O₂, 476.51).

Compounds 36-42 may be prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carbonitrileor8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid using synthetic procedures similar to those described in theexamples above.

Example 368-amino-9-fluoro-7-oxo-10-(3-(pyridin-2-yl)propylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-#]quinoline-3,1′-cyclopentane]-6-carbonitrileHydrochloride

MS (EP) m/z: 434.4 (M+1). (Calcd. for C₂₄H₂₄FN₅O₂, 433.48).

Example 37 Preparation of10-(3-(1H-imidazol-1-yl)propylamino)-8-amino-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carbonitrileHydrochloride

MS (EP) m/z: 423.4 (M+1). (Calcd. for C₂₂H₂₃FN₆O₂, 422.46).

Example 388-amino-9-fluoro-7-oxo-10-(3-(1,3,5-trimethyl-1H-pyrazol-4-yl)propylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carbonitrileHydrochloride

MS (EP) m/z: 465.5 (M+1). (Calcd. for C₂₅H₂₉FN₆O₂, 464.54).

Example 398-amino-9-fluoro-10-(3-(4-fluorophenyl)-3-(4-methoxyphenyl)propylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylic Acid

MS (EP) m/z: 576.6 (M+1). (Calcd. for C₃₂H₃₁F₂N₃O₅, 575.6).

Example 408-amino-10-(3-(4-chlorophenyl)propylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

MS (EP) m/z: 486.9 (M+1). (Calcd. for C₂₅H₂₅ClFN₃O₄, 485.94).

Example 418-amino-10-(3-(3,5-dimethyl-1H-pyrazol-1-yl)propylamino)-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

MS (EP) m/z: 470.5 (M+1). (Calcd. for C₂₄H₂₈FN₅O₄, 469.51).

Example 428-amino-9-fluoro-10-(3-(5-methyl-1H-pyrazol-4-yl)propylamino)-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

MS (EP) m/z: 456 (M+1). (Calcd. for C₂₃H₂₆FN₅O₄, 455.48).

Example 438′-amino-9′-fluoro-7′-oxo-10′-[3-(1-imidazolyl)propyl]spiro[cyclopentane-1,3′-(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboximidamide43A) Preparation of8′-amino-9′,10′-difluoro-7′-oxospiro-[cyclopentane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboximidamide

To a solution of8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[1,4]oxazino-[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carbonitrile(400 mg, 1.26 mmol) in 5 ml of ethonal/dimethylformamade (50:50, v:v)was added ammonium hydroxide (260 mg, 3.78 mmol) and potassium carbonate(521 mg, 3.78 mmol). The reaction mixture was heated to reflux for 3 hand then cooled down to room temperature. Undissolved inorganic materialwas filtered off and the filtrate was concentrated under vacuo to yielda solid material that was resuspended in methanol (50 mL), filtered,washed with methanol and dried under vacuum to give the title compoundas a yellow solid (200 mg, 45% yield). MS (EP) m/z: 351 (M+1). (Calcd.for C₁₆H₁₆F₂N₄O₃, 350.12).

43B) Preparation of8′-amino-9′-fluoro-7′-oxo-10′-[3-(1-imidazolyl)-propyl]spiro[cyclopentane-1,3′(2′H)-(7H]pyrido[1,2,3-de]11,41-benzoxazine]-6′-carboximidamide

The title compound was prepared from8′-amino-9′,10′-difluoro-7′-oxospiro-[cyclopentane-1,3′(2′H)-[7H]-pyrido[1,2,3-de][1,4]benzoxazine]-6%carboximidamide according to the procedures above. MS (EP) m/z: 426.4(M+1). (Calcd. for C₁₉H₂₀FN₉O₂, 425.42).

Example 448′-amino-9′-fluoro-7′-oxo-10′-[2-(pyridin-2-ylamino)ethylamino]spiro[cyclobutane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicAcid 44A) Preparation of Ethyl3-[1-(hydroxymethyl)cyclobutylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate

A stirred solution of ethyl3-oxo-3-(2,3,4,5-tetrafluorophenyl)propionate (2.00 g, 7.57 mmol), Ac₂O(4.29 mL, 45.4 mmol) and triethyl iorthoformate (2.51 mL, 15.1 mmol) washeated at 120° C. for 3 hours. The mixture was concentrated in vacuo anddried under high vacuum. The crude product was dissolved in toluene (30mL) and a suspension of (1-aminocyclobutyl)methanol (1.04 g, 7.57 mmol)in toluene (5 mL), triethylamine (1.06 mL, 7.57 mmol) were added underice-cooling. The mixture was stirred for 18 h at room temperature andconcentrated in vacuo to yield the crude product. The crude product waspurified by column chromatography (Hexane: EtOAc 10:1→1:1) to yield thetitle compound (1.57 g, 55%) as a white solid. ¹H-NMR (400 MHz, CDCl₃) δ0.95-1.11 (3H, m), 1.85-1.90 (1H, m), 1.91-2.07 (2H, m), 2.17-2.26 (2H,m), 2.27-2.36 (2H, m), 3.80-3.83 (2H, m), 4.00-4.10 (2H, m), 6.95-7.13(1H, m), 8.17-8.22 (1H, m), 9.87-11.36 (1H, m). ESIMS (+): 376 [M+H]⁺.

44B) Preparation of Ethyl9′,10′-difluoro-7′-oxospiro[cyclobutane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate

A solution of ethyl3-[1-(hydroxymethyl)cyclobutylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate(1.52 g, 4.05 mmol) in DMF (10 mL) was added to an ice-cooled suspensionof 60% NaH in oil (356 mg, 8.91 mmol) in DMF (10 mL), under argonatmosphere. The reaction mixture was stirred for 4 hours and poured intoice-water. The product was extracted with AcOEt, dried over MgSO₄ andthe crude product was purified by column chromatography (Hexane: EtOAc2:1→AcOEt) to yield the title compound (604 mg, 44%) as a white solid.Mp 255-256° C. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.29 (3H, t, J=7.3 Hz),1.91-2.07 (2H, m), 2.16-2.22 (2H, m), 2.65-2.76 (2H, m), 4.24 (2H, q,J=7.3 Hz), 4.62 (2H, s), 7.62 (1H, dd, J=10.4, 7.9 Hz), 8.80 (1H, s).ESIMS (+): 336 [M+H]⁺.

44C) Preparation of Ethyl9′,10′-difluoro-8′-nitro-7′-oxospiro-[cyclobutane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate

A solution of ethyl9′,10′-difluoro-7′-oxospiro[cyclobutane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate(580 mg, 1.73 mmol) in concentrated H₂SO₄ (7 mL) was treated portionwise at 0° C. with solid KNO₃ (245 mg, 2.42 mmol). The reaction mixturewas stirred for 1 hour at 0° C. and poured into ice-water. The resultingprecipitate was collected by filtration, washed with water and dried toyield the title compound (600 mg, 91%) as a pale yellow solid. ¹H-NMR(400 MHz, DMSO-d₆) δ 1.30 (3H, t, J=7.3 Hz), 1.93-2.09 (2H, m),2.16-2.25 (2H, m), 2.73-2.80 (2H, m), 4.26 (2H, q, J=7.3 Hz), 4.69 (2H,s), 8.87 (1H, s). ESIMS (+): 381 [M+H]⁺.

44D) Preparation of Ethyl8′-amino-9′,10′-difluoro-7′-oxospiro-[cyclobutane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate

A solution of ethyl9′,10′-difluoro-8′-nitro-7′-oxospiro[cyclobutane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate(580 mg, 1.53 mmol) in DMF (30 mL) was treated with hydrogen underatmospheric pressure over 10% Pd/C (60 mg) at 50° C. for 3 hours. Thecatalyst was removed by filtration with Celite and the filtrate waspoured into ice-water. The resulting precipitate was stirred for 1 hourand collected by filtration, washed with water and dried to yield thetitle compound (468 mg, 88%) as a pale yellow solid. ¹H-NMR (400 MHz,DMSO-d₆) δ 1.29 (3H, t, J=7.3 Hz), 1.92-2.02 (2H, m), 2.10-2.19 (2H, m),2.61-2.69 (2H, m), 4.23 (2H, q, J=7.3 Hz), 4.39 (2H, s), 7.38 (2H, brs),8.65 (1H, brs). ESIMS (+): 351 [M+H]⁺.

44E) Preparation of8′-amino-9′,10′-difluoro-7′-oxospiro-[cyclobutane-1,3′(2H)-[7]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicAcid

A solution of ethyl8′-amino-9′,10′-difluoro-7′-oxospiro[cyclobutane-1,3′(2′H)-[7H]-1]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate (440 mg,1.26 mmol) in a mixture of AcOH—H₂O—H₂SO₄ (2:1:0.3 v/v, 9.9 mL) washeated at 100° C. for 3 hours. The reaction mixture was poured intoice-water and stirred. After 30 minutes, the resulting precipitate wascollected by filtration, washed with water and dried to yield the titlecompound (384 mg, 94%) as a yellow solid ¹H-NMR (400 MHz, DMSO-d₆) δ1.94-2.03 (2H, m), 2.14-2.20 (2H, m), 2.69-2.77 (2H, m), 4.44 (2H, s),7.32 (2H, brs), 8.91 (1H, s), 14.67 (1H, s). ESIMS (+): 323 [M+H]⁺.

44F) Preparation of8′-amino-9′-fluoro-7′-oxo-10′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicAcid

A solution of8′-amino-9′,10′-difluoro-7′-oxospiro[cyclobutane-1,3′(2H)-[7]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicacid (360 mg, 1.12 mmol), N-2-pyridinyl-1,2-ethanediamine (230 mg, 1.68mmol) and triethylamine (0.234 mL, 1.68 mmol) in DMSO (5 mL) was stirredfor 3 hours at 100° C. The reaction mixture was poured into ice-waterand stirred for 30 minutes. The resulting precipitate was collected byfiltration, washed with water, suspended in EtOH (10 mL) and stirred atreflux for 1 hour. The suspension was cooled to room temperature, andthe resulting precipitate was collected by filtration and dried to yieldthe title compound (459 mg, 93%) as a yellow solid. ¹H-NMR (400 MHz,DMSO-d₆) δ 1.91-2.03 (2H, m), 2.08-2.17 (2H, m), 2.61-2.69 (2H, m),3.44-3.48 (2H, m), 3.58-3.66 (2H, m), 6.35-6.40 (1H, m), 6.45-6.49 (2H,m), 6.71 (1H, t, J=5.5 Hz), 6.88 (2H, brs), 7.35 (1H, td, J=6.7, 1.8Hz), 7.97 (1H, dd, J=4.9, 1.2 Hz), 8.71 (1H, s), 15.30 (1H, s). HRESIMS(+): 440.17267 (−0.74 mmu).

Example 458′-amino-9′-fluoro-7′-oxo-10′-[2-(2-pyridylamino)ethylamino)spiro[cyclobutane-1,2′(3′H)-[7H]pyrido[1,2,3-de]benzoxazepine]-6%carboxylic acid 45A) Preparation of Ethyl3-[[1-(hydroxymethyl)cyclopentyl]-methylamino]-2-(3,4,5,6-tetrafluorobenzoyl)acrylate

A solution of ethyl 3-oxo-3-(2,3,4,5-tetrafluorophenyl)propionate (7.93g, 30.0 mmol), Ac₂O (17.0 mL, 180 mmol) and triethyl orthoformate (10.0mL, 60.1 mmol) was heated at 120° C. for 3 hours. The mixture wasconcentrated in vacuo and dried under high vacuum. The crude product wasdissolved in anhydrous toluene (120 mL) and[1-(aminomethyl)-cyclopropyl]]methanol (3.04 g, 30.1 mmol) was addedvery slowly at 0° C. The ration mixture was stirred at room temperaturefor 3 hours, and the solvent was removed by evaporation. The crudeproduct was purified by column chromatography (Hexane: EtOAc 1:1) toyield the title compound (10.5 g, 94%) as a pale yellow solid. ¹H NMR(400 MHz, CDCl₃) δ 0.50-0.70 (4H, m), 0.97, 1.10 (each t, J=7.3 Hz,total 3H), 1.66 (1H, t, J=4.9 Hz), 3.47 (2H, d, J=6.1 Hz), 3.56 (2H, d,J=4.9 Hz), 4.01-4.09 (2H m), 6.96-7.13 (1H, m), 8.06-8.12 (1H, m), 9.71,11.1 (each br, total 1H). ESIMS (+): 375 [M+H].

45B) Preparation of Ethyl10′,11′-difluoro-8′-oxospiro[cyclopropane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

A solution of NaH (2.29 g, 57.3 mmol, 60%; in oil) in DMF (110 mL) wascooled to 0° C. and treated dropwise with Ethyl3-[[1-(hydroxymethyl)cyclopentyl]methylamino]-2-(3,4,5,6-tetrafluorobenzoyl)aminoacrylate(9.76 g, 26.0 mmol) in DMF (15 mL). The reaction mixture was stirred atroom temperature for 1 hour, and then stirred for 85° C. for 1 hour. Thereaction mixture was poured into ice water and the resulting precipitatewas removed by filtration and washed with water. The resulting solid wasdissolved in 100 mL of EtOH—CH₂Cl₂ (2:1) and filtered. The filtrate wasconcentrated to 70 mL and the resulting precipitate was removed byfiltration, washed with EtOH and dried to yield the title compound (6.73g, 77%) as a pale yellow solid. ¹H-NMR (400 MHz CDCl₃) δ 0.65 (2H, t,J=6.1 Hz), 0.82 (2H, t, J=6.1 Hz), 1.41 (3H, t, J=7.3 Hz), 4.21 (2H, s),4.35 (2H, s), 4.39 (2H, q, J=7.3 Hz), 8.05 (1H, dd, J=10.4, 8.6 Hz),8.25 (1H, s). ESIMS (+): 335 [M+H]⁺.

45C) Preparation of Ethyl9′,10′-difluoro-8′-nitro-7′-oxospiro-[cyclobutane-1,2′(3′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate

Ethyl10′,11′-difluoro-8′-oxospiro[cyclobutane-1,2′(3′H)-[7H]pyrido[1,2,3-ef]-benzoxazepine]-7′-carboxylatewas prepared by routine modification of the procedures shown elsewhereherein. A solution of ethyl10′,11′-difluoro-8′-oxospiro[cyclobutane-1,2′(3′H)-[7H]pyrido[1,2,3,-ef]benzoxazepine]-7′-carboxylate(1.50 g, 4.47 mmol) in concentrated H₂SO₄ (15 mL) was treatedportionwise at 0° C. with solid KNO₃ (633 mg, 6.26 mmol). After stirringat 0° C. for 2 hours, the reaction mixture was poured into 100 mL ofice-water and the resulting precipitate was removed by filtration. Theresulting solid was recrystallized by DMF, and washed with EtOH anddried to yield the title compound as a pale yellow solid (651 mg, 38%).¹H-NMR (400 MHz, DMSO-d₆) δ 1.27 (3H, t, J=7.3 Hz), 1.76-2.00 (2H, m),2.15-2.25 (2H, m), 2.27-2.40 (2H, m), 4.23 (2H, q, J=7.3 Hz), 4.53 (2H,s), 8.69 (1H, s). ESIMS (+): 381 [M+H]⁺.

45D) Preparation of Ethyl8′-amino-9′,10′-difluoro-7′-oxospiro-[cyclobutane-1,2′(3′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate

A solution of ethyl9′,10′-difluoro-8′-nitro-7′-oxo-spiro[cyclobutane-1,2′(3′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate(450 mg, 1.15 mmol) and 10% Pd/C (40.5 mg) in DMF (20 mL) was stirredunder hydrogen atmosphere(0.3 MPa) at 50° C. for 3 hours. The catalystwas removed by filtration over Celite and the filtrate was concentratedin vacuo. The resulting solid was dissolved in EtOH—CH₂Cl₂ (1:5) andfiltered. CH₂Cl₂ was removed, and the resulting precipitate was removedby filtration, washed with EtOH and dried to yield the title compound(270 mg, 67%) as a pale yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.27(3H, t, J=7.3 Hz), 1.74-1.96 (2H, m), 2.02-2.13 (2H, m), 2.14-2.25 (2H,m), 4.20 (2H, q, J=7.3 Hz), 4.33 (2H, s), 7.33 (2H, brs), 8.43 (1H, s).ESIMS (+): 350[M+H]⁺.

45E) Preparation of8′-amino-9′,10′-difluoro-7′-oxospiro-[cyclobutane-1,2′(3′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicAcid

A solution of ethyl8′-amino-9′,10′-difluoro-7′-oxospiro[cyclobutane-1,2′(3′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate(247 mg, 0.705 mmol) and 1M NaOH aq. (3.5 mL) in EtOH (3.5 mL) wasstirred at room 50° C. for 1.5 hours. The solvent was removed and theresidue was dissolved in water. The solution was acidified to pH 7 with2M HCl and the resulting precipitate was removed by filtration, washedwith water and dried to yield the title compound (216 mg, 95%) as ayellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.73-1.97 (2H, m), 2.04-2.27(4H, m), 4.50 (2H, s), 7.25 (2H, brs), 8.76 (1H, s), 14.67 (1H, s).ESIMS (+): 322[M+H]⁺.

45F) Preparation of8′-amino-9′-fluoro-7′-oxo-10′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,2′(3′11)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicAcid

A solution of8′-amino-9′,10′-difluoro-7′-oxospiro[cyclobutane-1,2′(3′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicacid (200 mg, 0.621 mmol), triethylamine (0.130 mL, 0.933 mmol) andN-2-pyridyl-1,2-ethanediamine (128 mg, 0.933 mmol) in DMSO (4 mL) wasstirred at 100° C. for 3 hours. The reaction mixture was poured into icewater and the resulting precipitate was removed by filtration, washedwith ethanol, and then dried to yield the title compound (223 mg, 82%)as a yellow solid.

¹H-NMR (400 MHz, DMSO-d₆) δ 1.30-1.50 (2H, m), 1.53-1.73 (1H, m),3.01-3.12 (2H, m), 3.19-3.30 (2H, m), 3.94 (2H, s), 5.65 (1H, brs),6.01-6.12 (2H, m), 6.29 (1H, t, J=5.5 Hz), 6.43 (2H, brs), 6.90-7.01(1H, m), 7.52-7.60 (1H, m), 8.13 (1H, s), 14.90 (1H, s). HRESIMS(+):440.17258 (Calcd for C₂₂H₂₃FN₅O₄, 440.17341).

Example 469′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclopropane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicAcid 46A) Preparation of Ethyl3-[1-(2-hydroxyethyl)cyclopropylamino]-2-(2,3,4,5,-tetrafluorobenzoyl)acrylate

A solution of ethyl 3-oxo-3-(2,3,4,5-tetrafluoropnenyl)propionate (3.09g, 11.7 mmol), Ac₂O (6.7 mL, 70.9 mmol) and triethyl orthoformate (3.90mL, 23.5 mmol) was heated at 120° C. for 3 hours. The mixture wasconcentrated in vacuo and dried under high vacuum. The crude product wasdissolved in anhydrous tolene (40 mL) and (1-amino-cyclopropyl)-ethanol(1.82 g, 11.7 mmol) was added very slowly at 0° C. The ration mixturewas stirred at room temperature for 5 hours and diluted with toluene.The organic layer was washed with water, brine, and then dried. Thesolvent was removed by evaporation and the crude product was purified bycolumn chromatography (Hexane: EtOAc 2:1→1:1) to yield the titlecompound (2.99 g, 68%) as a yellow oil. ¹H-NMR (400 MHz, CDCl₃) δ0.85-0.92 (2H, m), 0.94-1.11 (5H, m), 1.85-1.91 (2H, m), 3.85-3.89 (2H,m), 3.99-4.09 (2H, m), 6.95-7.13 (1H, m), 8.19 (1H, d, J=14.1 Hz), 9.84,11.2 (each d, J=13.4 Hz, total 1H). EIMS (+) 375 [M]⁺.

46B) Preparation of Ethyl10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro-[cyclopropane-1,4′-[4H,8H]pyrido[1,2,3-d][1,4]-benzoxazepine]-7′-Carboxylate

A solution of NaH (617 mg, 15.4 mmol, 60% in oil) in DMF (30 mL) wascooled to 0° C. and treated dropwise with ethyl3-[1-(2-hydroxyethyl)cyclopropylamino]-2-(2,3,4,5,-tetrafluorobenzoyl)propylaminoacrylate (2.63 g, 7.01 mmol) in DMF (4 mL). The reactionmixture was stirred at room temperature for 1 hour, and one additionalhour at 80° C. The reaction mixture was poured into ice water and theresulting precipitate was removed by filtration and washed with water.The resulting solid was dissolved in 100 mL of EtOH and filtered. Thefiltrate was concentrated to 50 mL and the resulting precipitate wasremoved by filtration, washed with EtOH and then dried to yield thetitle compound (1.43 g, 61%) as a pale brown solid. ¹H-NMR (400 MHz,DMSO-d₆) δ 1.03 (2H, br), 1.18 (2H, br), 1.26 (3H, t, J=7.3 Hz),2.03-2.73 (2H, br), 4.21 (2H, q, J=7.3 Hz), 7.66 (1H, dd, J=10.4, 7.9Hz), 8.51 (1H, s). EIMS (+) 335 [M]⁺.

46C) Preparation of Ethyl10′,11′-difluoro-2′,3′-dihydro-9′-nitro-8′-oxospiro[cyclopropane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

A solution of ethyl10′,11′-trifluoro-2′,3′-dihydro-8′-oxospiro[cyclopropane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(1.2 g, 3.58 mmol) in concentrated H₂SO₄ (15 mL) was treated portionwiseat 0° C. with solid KNO₃ (510 mg, 5.04 mmol). After stirring at 0° C.for 2 hours, the reaction mixture was poured into ice-water and theresulting precipitate was removed by filtration. The resulting solid waswashed with EtOH and dried to yield the title compound (554 mg, 41%) asa brown solid.

¹H-NMR (400 MHz, DMSO-d₆) δ 1.02 (2H, br), 1.10-1.27 (5H, m), 1.91-2.86(2H, br), 4.21 (2H, q, J=7.3 Hz), 4.61 (2H, br), 4.52 (2H, br), 8.58(1H, s). EIMS (+) 380 [M]⁺. HREIMS (+) 380.0856 (Calcd for C₁₇H₁₄F₂N₂O₆,380.0820).

46D) Preparation of Ethyl9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclopropane-1,4′-[4H,8H]pyrido[1,2,3-ej][1,4]benzoxazepine]-7′-carboxylate

A solution of ethyl10′,11′-difluoro2′,3′-dihydro-9′-nitro-8′-oxospiro-[cyclopropane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate (500 mg, 1.31mmol) and 10% Pd/C (100 mg) in DMF (30 mL) was stirred under hydrogenatmosphere at 50° C. for 1.5 hours. The catalyst was removed byfiltration over Celite and the filtrate was concentrated in vacuo. Theresulting solid was dissolved in CH₂Cl₂ and EtOH (3:1, 65 mL), andfiltered. After removal of CH₂Cl₂ the resulting precipitate was isolatedby filtration, washed with EtOH and dried to yield the title compound(355 mg, 77%) as a brown solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 0.99 (2H,br), 1.13 (2H, br), 1.25 (3H, t, J=7.3 Hz), 1.64-2.91 (2H, br), 4.18(2H, q, J=7.3 Hz), 4.35 (2H, br), 7.46 (2H, br), 8.35 (1H, s). EIMS (+)350 [M]⁺.

46E) Preparation of9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclopropane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicAcid

A solution of ethyl9′-Amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclopropane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(320 mg, 0.913 mmol) in mixture of AcOH—H₂O—H₂SO₄ (6:4:1 v/v, 5.3 mL)was heated at reflux for 1 h. The reaction mixture was poured into icewater and a precipitate was collected by filtration, washed with waterand then to give the title compound ¹H-NMR (400 MHz DMSO₄) δ 0.63-1.55(4H, br), 1.90-3.11 (2H, br), 3.78-4.96 (2H, br), 7.40 (2H, s), 8.64(1H, s), 14.5 (1H, s). EIMS (+) 322 [M]⁺.

46F) Preparation of9′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclopropane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicAcid

A solution of9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxo-spiro[cyclopropane-1,4′-[4H,8]pyrido[1,2,3,-ef][1,4]benzoxazepine]-7′-carboxylicacid (150 mg, 0.465 mmol), triethylamine (0.100 mL, 0.717 mmol) andN-2-(pyridinyl)-1,2-ethanediamine (95.5 mg, 0.696 mmol) in DMSO (2 mL)was stirred at 100° C. for 3 hours. The reaction mixture was poured intoice water and the resulting precipitate was removed by filtration andwashed with ethanol. The resulting solid was dissolved in DMF andfiltered. The filtrate was poured into water and the resultingprecipitate was removed by filtration, washed with water and dried toyield the title compound (95.6 mg, 47%) as a dark yellow solid. ¹H-NMR(400 MHz, DMSO₄) δ 0.81-1.50 (4H, m), 3.40-3.51 (2H, m), 3.55-3.66 (2H,m), 3.80-4.60 (4H, m), 6.32 (1H, brs), 6.40-6.50 (2H, m), 6.70 (1H, t,J=5.5 Hz), 9.97 (2H, brs), 7.30-7.40 (1H, m), 7.90-8.00 (1H, m), 15.14(1H, s). HRESIMS (+): 440.17315 (Calcd for C₂₂H₂₂FN₅O₄, 440.17340).

Example 479′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicAcid 47A) Preparation of ethyl (1-hydroxycyclobutyl)-acetate

Trimethylchlorosilane (1.14 mL, 8.92 mmol) was added by syringe to asuspension of zinc powder (7.97 g, 0.122 mol) in absolute Et₂O (200 mL).The mixture was stirred for 15 minutes at room temperature. The mixturewas then heated to reflux, the heat source was removed, and ethylbromoacetate (10.3 mL, 92.9 mmol) was added at such a rate that theether solution gently boiled. The mixture was refluxed one hour thenstirred for an additional hour at room temperature. A solution ofcyclopentanone (6.00 g, 75.9 mmol) in ether (30 mL) was added while thetemperature of the mixture was maintained at 19-20° C. by intermittentcooling. After being one hour of stirring at room temperature, themixture was poured into iced 25% ammonia (400 mL). The aqueous phase wasextracted with ether and the combined phases were dried over K₂CO₃.Filtration and evaporation of the solvent yielded the title compound asa colorless oil (6.50 g, 54%). ¹H-NMR (400 MHz, CDCl₃) δ 1.29 (3H, t,J=7.3 Hz), 1.47-1.64 (1H, m), 1.76-1.87 (1H, m), 1.93-2.06 (2H, m),2.12-2.22 (2H, m), 2.67 (2H, s), 3.70 (1H, s), 4.19 (2H, q, J=7.3 Hz).

47B) Preparation of Ethyl [1-(benzoylamino)cyclobutyl]acetate

H₂SO₄ (2.20 mL, 41.3 mmol) was slowly added to a mixture of ethyl1-hydroxycyclobutylacetate (6.45 g, 40.8 mmol) and benzonitrile (40 mL,0.392 mol) at room temperature. The mixture was stirred for 1 hour atroom temperature, then for an additional hour at 80° C. The mixture wascooled in an ice-water bath, and 2N NaOH solution was added until themixture reached pH=7. The mixture was extracted with ethyl acetate andthe combined organic extracts were dried over anhydrous Na₂SO₄, filteredand concentrated in vacuo. Flash chromatography (AcOEt:Hexane=5:1) ofthe residue gave the title compound as a colorless solid (5.40 g, 51%).¹H-NMR (400 MHz, CDCl₃) δ 1.22 (3H, t, J=7.3 Hz), 1.84-2.07 (2H, m),2.22-2.32 (2H, m), 2.44-2.55 (2H, m), 3.05 (2H, s), 4.11 (2H, q, J=7.3Hz), 6.73 (1H, s), 7.39-7.52 (3H, m), 7.72-7.79 (2H, m).

47C) Preparation of 2-[1-(benzylamino)cyclobutyl]ethanol

LiAlH₄ (3.88 g, 0.102 mol) was added to a solution of ethyl1-(benzoylamino)-cyclobutylacetate (5.30 g, 20.3 mmol) in THF (100 mL)at room temperature. The mixture was stirred for 1 hour, then refluxedfor one additional hour. The mixture was cooled in an ice-water bath, afew drops of water were added, and the mixture was allowed to standovernight. The mixture was diluted with ethyl acetate, dried overanhydrous Na₂SO₄, filtered, and concentrated in vacuo. Distillation ofthe residue gave the title compound as a colorless oil (2.53 g, 61%).¹H-NMR (400 MHz, CDCl₃) δ 1.69-1.86 (2H, m), 1.88 (2H, t, J=5.5 Hz),1.92-2.09 (4H, m), 3.73 (2H, s), 3.87 (2H, t, J=5.5 Hz), 7.22-7.35 (5H,m).

47D) Preparation of 2-[1-aminocyclobutyl]ethanol

10% Pd—C (500 mg) was added to a solution of2-[1-(benzylamino)cyclobutyl]ethanol (4.00 g, 19.5 mmol) in EtOH (100mL) and the mixture was stirred under H₂ gas 0.5 MPa at room temperaturefor 6 hours. The mixture was filtered, and the filtrate was concentratedin vacuo. Distillation of the residue gave the title compound as acolorless oil (1.65 g, 73%). ¹H-NMR (400 MHz, CDCl₃) δ 1.60-1.72 (2H,m), 1.75 (2H, t, J=5.5 Hz), 1.77-1.87 (2H, m), 2.03-2.13 (2H, m), 3.81(2H, q, J=5.5 Hz).

47E) Preparation of Ethyl3-[1-(2-hydroxyethyl)cyclobutylamino-]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate

A stirred solution of 3-oxo-3-(2,3,4,5-tetrafluorophenyl)propionate(3.67 g, 13.9 mmol), Ac₂O (7.89 mL, 83.5 mmol) and triethyl orthoformate(4.63 mL, 27.8 mmol) was heated at 120° C. for 3 hours. The mixture wasconcentrated in vacuo and dried under high vacuum.1-amino-1-(2-hydroxyethyl)cyclobutane (1.60 g, 13.9 mmol) in anhydroustoluene (20 mL) was added slowly at 0° C. to a solution of the mixturein anhydrous toluene (50 mL). The resulting mixture was stirred at roomtemperature for 2 hours, and the solvent was removed by evaporation.Flash chromatography (AcOEt:Hexane=1:1) of the residue gave the titlecompound as a pale yellow solid (3.30 g, 61%). ¹H-NMR (400 MHz, CDCl₃) δ0.96 (0.6H, t, J=7.3 Hz), 1.09 (2.4H, t, J=7.3 Hz), 1.85-2.03 (12H, m),2.06-2.13 (2H, m), 2.20-2.30 (2H, m), 2.32-2.43 (2H, m), 3.82-3.88 (2H,m), 4.02 (0.4H, q, J=7.3 Hz), 4.07 (1.6H, q, J=7.3 Hz), 6.94-7.03 (0.2H,m), 7.05-7.13 (0.8H, m), 8.23-8.30 (1H, m), 10.05-10.17 (0.2H, m),11.36-11.50 (0.8H, m).

47F) Preparation of Ethyl 10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

NaH was added (350 mg, 8.75 mmol) to a solution of ethyl3-[1-(2-hydroxyethyl)cyclobutylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate(2.80 g, 7.19 mmol) in DMF (30 mL) at 0° C. The mixture was stirred atroom temperature for 30 minutes, then heated at 80° C. for an additional30 minutes. Water was added to the mixture portionwise at 0° C. and theresulting precipitate was isolated by filtration, washed successivelywith water and dried to give the title compound (655 mg, 26%) as acolorless solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.27 (3H, t, J=7.3 Hz),1.67-1.79 (1H, m), 1.91-2.04 (1H, m), 2.42-2.53 (4H, m), 2.67 (2H, t,J=6.7 Hz), 4.24 (2H, q, J=7.3 Hz), 4.55 (2H, t, J=6.7 Hz), 7.72 (1H, dd,J=10.4 and 7.9 Hz), 8.41 (1H, s).

47G) Preparation of Ethyl10′,11′-difluoro-2′,3′-dihydro-9′-nitro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ej][1,4]benzoxazepine]-7′-carboxylate

A solution of ethyl10′,11′-difluoro-2′,3′-dihydro-8′-oxo-spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(925 mg, 2.65 mmol) in concentrated H₂SO₄ (11 mL) was treatedportionwise with solid KNO₃ (363 mg, 3.59 mmol) at 0° C. After stirringat 0° C. for 2 hours, the reaction mixture was poured into ice-water andthe resulting precipitate was combined by filtration and washed withwater. Flash chromatography (CH₂Cl₂-MeOH=10:1) of the residue give thetitle compound as a yellow solid (822 mg, 79%). ¹H-NMR (400 MHz,DMSO-d₆) δ 1.27 (3H, t, J=7.3 Hz), 1.68-1.78 (1H, m), 1.90-2.03 (1H, m),2.40-2.58 (4H, m), 2.69 (2H, t, J=6.7 Hz), 4.24 (2H, q, J=7.3 Hz), 4.63(2H, t, J=6.7 Hz), 8.44 (1H, s).

47H) Preparation of Ethyl9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

A solution of ethyl10′,11′-difluoro-2′,3′-dihydro-9′-nitro-8′-oxo-spiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(770 mg, 1.95 mmol) in DMF (70 mL) was treated with hydrogen underatmospheric pressure over 10% Pd/C (200 mg) at 50° C. for 1 hour. Thecatalyst was removed by filtration over Celite and the filtrate wasconcentrated in vacuo. Flash chromatography (CH₂Cl₂-MeOH=10:1) of theresidue gave the title compound as a colorless solid (559 mg, 79%).¹H-NMR (400 MHz, DMSO-d₆) δ 1.26 (3H, t, J=7.3 Hz), 1.65-1.77 (1H, m),1.87-2.01 (1H, m), 2.35-2.62 (6H, m), 4.21 (2H, q, J=7.3 Hz), 4.31-4.42(2H, brt), 7.40-7.60 (2H, brs), 8.23 (1H, s).

47I) Preparation of9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-d][1,4]benzoxazepine]-7′-carboxylicAcid

2N NaOH (7.0 mL, 14.0 mmol) was added to a mixture of ethyl9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(513 mg, 1.41 mmol) in EtOH (14 mL) at room temperature and the mixturewas heated at 50° C. for 3 hours. 2N HCl (7.0 mL) and water were addedto the reaction mixture. The resulting precipitate was collected byfiltration, washed successively with water and dried to give the titlecompound (427 mg, 90%) as a colorless solid. ¹H-NMR (400 MHz, DMSO-d₆) δ1.64-1.77 (1H, m), 1.89-2.02 (1H, m), 2.56-2.70 (2H, br), 4.30-4.50 (2H,br), 7.35-7.52 (2H, brs), 8.47 (1H, s), 14.60 (1H, s).

47J) Preparation of9′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicAcid

A solution of9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ej][1,4]benzoxazepine]-7′-carboxylicacid (186 mg, 0.553 mmol), N-(2-pyridinyl)-1,2-ethanediamine (115 mg,0.838 mmol) and triethylamine (117 μL) in DMSO (2.5 mL) was stirred at120° C. for 4 hours. The reaction mixture was added portionwise at 0° C.to ice-water and 2N HCl (3 drops) was added to the mixture. Theresulting precipitate was isolated by filtration, washed with EtOH anddried to give the title compound (165 mg, 66%) as a yellow solid. ¹H-NMR(400 MHz, DMSO-d₆) δ 1.61-1.74 (1H, m), 1.84-2.00 (1H, m), 2.30-2.65(6H, m), 3.40-3.50 (2H, m), 3.52-3.62 (2H, m), 4.10-4.33 (2H, br),6.20-6.30 (1H, m), 6.42-6.51 (2H, m), 6.69 (1H, t, J=5.5 Hz), 6.90-7.08(2H, br), 7.32-7.40 (1H, m), 7.97 (1H, dd, J=4.3 and 1.2 Hz), 8.26 (1H,s), 15.23 (1H, s). HRESIMS (+) 454.18677 (Calcd for C₂₃H₂₅FN₅O₄,454.18906).

Example 489′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclopentane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicAcid 48A) Preparation of ethyl3-[1-(2-hydroxyethyl)cyclopentylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate

A stirred solution of ethyl3-oxo-3-(2,3,4,5-tetrafluorophenyl)propionate (20.3 g, 76.8 mmol), Ac₂O(44.0 mL, 0.465 mol) and triethyl orthoformate (25.6 mL, 0.154 mol) washeated at 120° C. for 3 hours. The mixture was concentrated in vacuo anddried under high vacuum. 1-amino-1-(2-hydroxyethyl)cyclopentane (9.94 g,76.9 mmol) in anhydrous toluene (50 mL) was slowly added to a solutionof the mixture in anhydrous toluene (200 mL) at 0° C. The resultingmixture was stirred at room temperature for 2 hours. The solvent wasremoved by evaporation. Flash chromatography (AcOEt:Hexane=2:1) of theresidue gave the tilte compound as a colorless solid (23.2 g, 75%).¹H-NMR (400 MHz, CDCl₃) δ 0.96 (0.6H, t, J=7.3 Hz), 1.09 (2.4H, t, J=7.3Hz), 1.48-1.54 (1H, m), 1.74-1.90 (6H, m), 1.97-2.06 (4H, m), 3.78-3.85(2H, m), 3.98-4.10 (2H, m), 6.95-7.12 (1H, m), 8.17-8.24 (1H, m),9.81-9.94 (0.3H, m), 11.20-11.35 (0.7H, m).

48B) Preparation of Ethyl6,7,8-trifluoro-1,4-dihydro-1-[1-(2-hydroxyethyl)cyclopentyl]-4-oxo-3-quinolinecarboxylate

To an iced solution of ethyl3-[1-(2-hydroxyethyl)-cyclopentylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate(22.7 g, 56.3 mmol) in THF (200 mL) was added NaH (3.60 g, 90.0 mmol),and the mixture was stirred at room temperature for 1 hour. Water wasadded to the mixture portionwise at 0° C. The resulting mixture wasextracted with ethyl acetate, and the combined organic extracts wereconcentrated in vacuo. Flash chromatography (AcOEt:Hexane=2:1) of theresidue give the title compound as a colorless solid (14.1 g, 65%).¹H-NMR (400 MHz, DMSO-d₆) δ 1.27 (3H, t, J=7.3 Hz), 1.53-1.75 (4H, m),2.10-2.26 (4H, m), 2.31-2.44 (2H, m), 4.23 (2H, q, J=7.3 Hz), 4.55-4.60(1H, m), 7.99-8.07 (1H, m), 8.80 (1H, s).

48C) Preparation of Ethyl10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclopentane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

To a solution of ethyl6,7,8-trifluoro-1,4-dihydro-1-[1-(2-hydroxyethyl)cyclopentyl]-4-oxo-3-quinolinecarboxylate(3.84 g, 10.0 mmol) in DMF (40 mL) was added NaH (480 mg, 12.0 mmol),and the mixture was heated at 80° C. for 30 minutes. The mixture wastreated portionwise with water at 0° C. The resulting mixture wasextracted with ethyl acetate and the combined extracts were concentratedin vacuo. Flash chromatography (AcOEt:Hexane=2:1) of the residue givethe title compound as a colorless solid (1.12 g, 31%). ¹H-NMR (400 MHz,DMSO-d₆) δ 1.42 (3H, t, J=7.3 Hz), 1.52-1.64 (2H, m), 1.75-1.88 (2H, m),2.11-2.21 (2H, m), 2.27-2.37 (2H, m), 2.47 (2H, t, J=6.7 Hz), 4.39 (2H,q, J=7.3 Hz), 4.47 (2H, t, J=6.7 Hz), 7.98 (1H, dd, J=9.8 and 7.9 Hz),8.67 (1H, s).

48D) Preparation of Ethyl10′,11′-difluoro-2′,3′-dihydro-9′-nitro-8′-oxospiro[cyclopentane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

A solution of ethyl10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclopentane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(50.0 g, 0.138 mmol) in concentrated H₂SO₄ (1 mL) was treatedportionwise at 0° C. with solid KNO₃ (20.0 mg, 0.199 mmol). Afterstirring at 0° C. for 1 h, the reaction mixture was poured intoice-water and the resulting precipitate was combined by filtration,washed with water and dissolved in CH₂Cl₂-MeOH (5:1 v/v). The combinedextracts were concentrated in vacuo. Flash chromatography(CH₂Cl₂-MeOH=10:1) of the residue gave the title compound as a yellowsolid (26.0 mg, 46%). ¹H-NMR (400 MHz, DMSO-d₆) δ 1.37 (3H, t, J=7.3Hz), 1.52-1.66 (2H, m), 1.78-1.90 (2H, m), 2.15-2.30 (4H, m), 2.50 (2H,t, J=6.7 Hz), 4.36 (2H, q, J=7.3 Hz), 4.55 (2H, t, J=6.7 Hz), 8.69 (1H,s).

48E) Preparation of Ethyl9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclopentane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

A solution of ethyl10′,11′-difluoro-2′,3′-dihydro-9′-nitro-8′-oxospiro[cyclopentane-1,4′-[4H,8H]pyrido[1,2,3-ej][1,4]benzoxazepine]-7′-carboxylate(2.00 g, 4.90 mmol) in DMF (120 mL) was treated with hydrogen underatmospheric pressure over 10% Pd/C (400 mg) at 50° C. for 1.5 hours. Thecatalyst was removed by filtration over Celite and the filtrate wasconcentrated in vacuo. Flash chromatography (CH₂Cl₂-MeOH=10:1) of theresidue give the title compound as a yellow solid (527 mg, 28%). ¹H-NMR(400 MHz, DMSO-d₆) δ 1.26 (3H, t, J=7.3 Hz), 1.37-1.50 (2H, m),1.65-1.77 (2H, m), 2.06-2.25 (4H, m), 2.36 (2H, t, J=6.7 Hz), 4.20 (2H,q, J=7.3 Hz), 4.30 (2H, t, J=6.7 Hz), 7.53 (2H, brs), 8.47 (1H, s).

48F) Preparation of9′Amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclopentane-1,4′-[4H,8H]pyrido[1,2,3-4][1,4]benzoxazepine]-7′-carboxylicAcid

To a mixture of ethyl9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclopentane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(482 mg, 1.27 mmol) in EtOH (13 mL) was added 2N NaOH (6.5 mL, 13.0mmol) at room temperature and the mixture was heated at 50° C. for 3hours. 2N HCl (6.5 mL) and water were added to the reaction mixture. Theresulting precipitate was collected by filtration, washed successivelywith water and dried to give the title compound (425 mg, 96%) as acolorless solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.35-1.52 (2H, m),1.65-1.75 (2H, m), 2.10-2.30 (4H, m), 2.43 (2H, t, J=6.7 Hz), 4.34 (2H,t, J=6.7 Hz), 7.50 (2H, brs), 8.67 (1H, s), 14.5 (1H, brs).

48G) Preparation of9′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclopentane-1,4′-[4H,8H]pyrido[1,2,3-d][1,4]benzoxazepine]-7′-carboxylicAcid

A solution of9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclopentane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicacid (200 mg, 0.571 mmol) and N-(2-pyridinyl)-1,2-ethanediamine (118 mg,0.860 mmol) in DMSO (2.5 mL) was stirred at 100° C. for 4 hours. To thereaction mixture was added ice-water portionwise at 0° C., and theresulting precipitate was isolated by filtration and washed successivelywith water, iPr₂O and EtOH. The resulting precipitate was dried to givethe title compound (185 mg, 69%) as a pale yellow solid. ¹H-NMR (400MHz, DMSO-d₆) δ 1.34-1.49 (2H, m), 1.60-1.75 (2H, m), 2.03-2.23 (4H, m),2.34 (2H, t, J=6.7 Hz), 3.40-3.55 (2H, m), 3.55-3.64 (2H, m), 4.17 (2H,t, J=6.7 Hz), 6.25-6.33 (1H, br), 6.43-6.51 (2H, m), 6.69 (1H, t, J=5.5Hz), 7.06 (2H, br), 7.35 (1H, ddd, J=6.7, 6.7 and 1.8 Hz), 8.86 (1H, dd,J=4.9 and 1.2 Hz), 8.49 (1H, s), 15.1 (1H, brs). HRESIMS (+) 4678.20118(Calcd for C₂₄H₂₇FN₅O₄, 468.20471).

Example 499′-amino-10′-fluoro-2′,3′-dihydro-3′-methyl-8′-oxo11′-[2-(2-pyridylamino)ethylamino]-spiro[cyclobutane-1,4%[4H,8H]pyrido[1,2,3-ej][1,4]benzoxazepine]-7′-carboxyicAcid 49A) Preparation of Ethyl 2-(1-hydroxycyclobutyl)propionate

Trimethylchlorosilane (950 μL, 7.43 mmol) was added by syringe to asuspension of zinc powder (6.65 g, 0.102 mol) in absolute Et₂O (170 mL).The mixture was stirred for 15 minutes at room temperature, heated toreflux, the heat source removed, and ethyl 2-bromopropionate (10.1 mL,77.8 mmol) was added at such a rate that the ether gently boiled. Afterbeing heated to reflux for 1 hour, the mixture was stirred for 1 hour atroom temperature. A solution of cyclobutanone (5.00 g, 63.2 mmol) inEt₂O (10 mL) was added while the temperature of the mixture wasmaintained at 19-20° C. by intermittent cooling. After stirring for 1hour at room temperature, the mixture was poured into iced 25% ammonia(400 mL). The aqueous phase was extracted with ether, the combinedorganic phases were dried over K₂CO₃, and concentrated. the titlecompound was given as a colorless oil (12.9 g, 100%). ¹H-NMR (400 MHz,CDCl₃) δ 1.21 (3H, d, J=6.8 Hz), 1.29 (3H, t, J=7.3 Hz), 1.51-1.64 (1H,m), 1.80-1.90 (1H, m), 1.96-2.17 (4H, m), 2.70 (1H, q, J=7.3 Hz), 3.44(1H, s), 4.18 (2H, qd, J=7.3 and 1.2 Hz).

49B) Preparation of Ethyl 2-[1-(benzoylamino)cyclobutyl]-propionate

H₂SO₄ (3.90 mL, 73.2 mmol) was slowly added to a mixture of ethyl2-(1-hydroxycyclobutyl)propionate (12.5 g, 72.6 mmol) and benzonitrile(75 mL) at room temperature. The mixture was stirred for 1 hour at roomtemperature, then 80° C. for 1 hour. The mixture was cooled in anice-water bath and 2N NaOH solution was added until the mixture reachedpH=7. The mixture was extracted with ethyl acetate, the combined organicextracts were dried over anhydrous Na₂SO₄, filtered, and concentrated invacuo. Flash chromatography (AcOEt:Hexane=5:1) of the residue gave thetitle compound as a pale yellow solid (9.24 g, 46%). ¹H-NMR (400 MHz,CDCl₃) δ 1.25 (3H, t, J=7.3 Hz), 1.30 (3H, d, J=7.3 Hz), 1.73-1.87 (1H,m), 1.98-2.09 (2H, m), 2.21-2.32 (1H, m), 2.53-2.63 (1H, m), 2.84-2.94(1H, m), 3.11 (1H, q, J=7.3 Hz), 4.08-4.20 (2H, m), 6.88 (1H, brs),7.40-7.52 (3H, m), 7.75-7.80 (2H, m).

49C) Preparation of 2-[1-(benzylamino)cyclobutyl]pronanol

LiAlH₄ (6.30 g, 0.166 mol) was added to a solution of ethyl241-(benzoylamino)-cyclobutyl]propionate (9.07 g, 32.9 mmol) in THF (160mL) and the mixture was stirred at room temperature for 1 hour, thenrefluxed 1 hour. The mixture was cooled in an ice-water bath, and a fewdrops of water were added. The mixture was diluted with ethyl acetate,dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. Thedistillation of the residue gave the title compound as a pale yellow oil(6.92 g, 96%). ¹H-NMR (400 MHz, CDCl₃) δ 1.00 (3H, d, J=6.7 Hz),1.66-1.77 (1H, m), 1.81-1.97 (2H, m), 2.02-2.10 (1H, m), 2.10-2.24 (3J,m), 3.59 (1H, dd, J=11.0 and 7.9 Hz), 3.71 (1H, d, J=11.6 Hz), 3.74 (1H,dd, J=11.0 and 3.7 Hz), 3.89 (1H, d, J=11.6 Hz), 7.23-7.36 (5H, m).

49D) Preparation of 2-(1-aminocyclobutyl)propanol

10% Pd—C (700 mg) was added to a solution of2-[1-(benzylamino)cyclobutyl]propanol (6.81 g, 31.1 mmol) in EtOH (150mL) and the mixture was stirred under H₂ gas 5 kgf/cm² at roomtemperature for 6 hours. The mixture was filtered, and the filtrate wasconcentrated in vacuo. Distillation of the residue gave the titlecompound as a colorless oil (2.96 g, 74%). ¹H-NMR (400 MHz, CDCl₃) δ1.03 (3H, d, J=7.3 Hz), 1.63-1.74 (3H, m), 1.78-1.94 (2H, m), 2.10-2.28(2H, m), 3.50 (1H, dd, J=11.0 and 4.3 Hz), 3.91 (1H, dd, J=11.0 and 3.1Hz).

49E) Preparation of ethyl3-[1-(1-hydroxy-2-propyl)-cyclobutylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate

A solution of 3-oxo-3-(2,3,4,5-tetrafluorophenyl)propionate (6.13 g,23.2 mmol), Ac₂O (13.2 mL, 0.140 mol) and triethyl orthoformate (7.80mL, 46.8 mmol) was stirred at 120° C. for 3 hours. The mixture wasconcentrated in vacuo and dried under high vacuum. To the mixture of theresidue in anhydrous toluene (100 mL) was slowly added2-(1-aminocyclobutyl)propanol (3.00 g, 23.2 mmol) in anhydrous toluene(40 mL) at 0° C. The mixture was stirred at room temperature for 2 hoursand the solvent was removed by evaporation. Flash chromatography(AcOEt:Hexane=1:1) of the residue gave the title compound as a colorlesssolid (6.23 g, 67%). ¹H-NMR (400 MHz, CDCl₃) δ 0.95 (0.6H, t, J=7.3 Hz),0.97 (3H, d, J=7.3 Hz), 1.09 (2.4H, t, J=7.3 Hz), 1.54 (1H, t, J=4.9Hz), 1.85-2.15 (3H, m), 2.19-2.50 (4H, m), 3.62-3.75 (2H, m), 4.02(0.2H, q, J=7.3 Hz), 4.07 (0.8H, q, J=7.3 Hz), 6.97-7.13 (1H, m), 8.24(0.8H, d, J=15.3 Hz), 8.25 (0.2H, d, J=15.3 Hz), 10.03 (0.2H, d, J=14.1Hz), 11.40 (0.8H, d, J=14.1 Hz).

49F) Preparation of ethyl10′,11′-difluoro-2′,3′-dihydro-3′-methyl-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

NaH (40 mg) was added a solution of ethyl3-[1-(1-hydroxy-2-propyl)-cyclobutylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate(404 mg, 1.00 mmol) in DMF (4 mL) at 0° C. Additional NaH (40 mg) wasadded to the mixture after one hour of stirring at 0° C. The mixture wasstirred at 0° C. for an additional hour, at room temperature for 1 hour,and at 70° C. for 1 hour. Water was added portionwise to the mixture at0° C. and the resulting precipitate was isolated by filtration, washedsuccessively with water and ethyl acetate, and dried to give the titlecompound (289 mg, 80%) as a pale yellow solid. ¹H-NMR (400 MHz, DMSO-d₆)δ 0.93 (3H, d, J=6.1 Hz), 1.27 (3H, t, J=7.3 Hz), 1.66-1.77 (1H, m),1.85-2.00 (1H, m), 2.35 (1H, q, J=10.4 Hz), 2.53-2.69 (3H, m), 2.96-3.05(1H, m), 3.82 (1H, t, J=11.6 Hz), 4.24 (2H, qd, J=7.3 and 2.4 Hz), 4.77(1H, dd, J=12.9 and 8.9 Hz), 7.73 (1H, dd, J=10.4 and 8.6 Hz), 8.25 (1H,s).

49G) Preparation of Ethyl10′,11′-difluoro-2′,3′-dihydro-3′-methyl-9′-nitro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

A solution of ethyl10′,11′-difluoro-2′,3′-dihydro-3′-methyl-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ej][1,4]benzoxazepine]-7′-carboxylate(1.00 g, 2.75 mmol) in concentrated H₂SO₄ (12 mL) was treatedportionwise at 0° C. with solid KNO₃ (377 mg, 3.73 mmol). After stirringat 0° C. for 2 hours, the reaction mixture was poured into ice-water andthe resulting precipitate was combined by filtration and washed withwater. Recrystallization of the resulting solid from DMF (20 mL) gavethe title compound as a yellow solid (923 mg, 82%). ¹H-NMR (400 MHz,DMSO-d₆) δ 0.94 (3H, d, J=6.1 Hz), 1.26 (3H, t, J=7.3 Hz), 1.67-1.78(1H, m), 1.83-1.98 (1H, m), 2.40-2.64 (4H, m), 2.92-3.05 (1H, m), 3.98(1H, t, J=11.6 Hz), 4.24 (2H, t, J=7.3 Hz), 4.80 (1H, dd, J=11.6 and 7.9Hz), 8.25 (1H, s).

49H) Preparation of Ethyl9′-amino-10′,11′-difluoro-2′,3′-dihydro-3′-methyl-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

A solution of ethyl10′,11′-difluoro-2′,3′-dihydro-3′-methyl-9′-nitro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(900 mg, 2.20 mmol) in DMF (55 mL) was treated with hydrogen underatmospheric pressure over 10% Pd/C (180 mg) at 50° C. for 3 hours. Thecatalyst was removed by filtration over Celite and the filtrate wasconcentrated in vacuo. The residue was washed with EtOH, collected byfiltration and dried to give the title compound (756 mg, 91%) as a paleyellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 0.89 (3H, brs), 1.26 (3H, t,J=7.3 Hz), 1.65-1.77 (1H, m), 1.80-1.95 (1H, m), 2.30-2.67 (4H, m),2.82-2.94 (1H, m), 3.52-3.66 (1H, m), 4.15-4.28 (2H, m), 4.58-4.70 (1H,m), 7.40-7.65 (2H, br), 8.05 (1H, s).

49I) Preparation of9′-amino-10′,11′-difluoro-2′,3′-dihydro-3′-methyl-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicAcid

To a mixture of ethyl9′-amino-10′,11′-difluoro-2′,3′-dihydro-3′-methyl-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(720 mg, 1.90 mmol) in EtOH (20 mL) was added 2N NaOH (10.0 mL) at roomtemperature and the mixture was heated at 50° C. for 3 hours. 2N HCl(10.0 mL) and water were added to the reaction mixture. The resultingprecipitate was collected by filtration, washed with water and dried togive the title compound (654 mg, 98%) as a yellow solid. ¹H-NMR (400MHz, DMSO-d₆) δ 0.90 (3H, d, J=5.5 Hz), 1.64-1.76 (1H, m), 1.81-1.96(1H, m), 2.35-2.72 (4H, m), 2.88-3.02 (1H, m), 3.64 (1H, t, J=11.6 Hz),4.60-4.75 (1H, m), 7.46 (2H, brs), 8.26 (1H, s), 14.60 (1H, brs).

49J) Preparation of9′-amino-10′-fluoro-2′,3′-dihydro-3′-methyl-8′-oxo11′-[2-(2-pyridylamino)ethylamino]-spiro[cyclobutane-1,4%[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicAcid

A solution of9′-amino-10′,11′-difluoro-2′,3′-dihydro-3′-methyl-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicacid (300 mg, 0.856 mmol), N-2-(pyridinyl)-1,2-ethanediamine (177 mg,1.29 mmol) and triethylamine (180 μL) in DMSO (4 mL) was stirred at 120°C. for 5 hours. Ice-water was added portionwise to the reaction mixtureat 0° C. and the mixture was extracted with CH₂Cl₂. The combined organicextracts were dried over anhydrous Na₂SO₄, filtered, and concentrated invacuo. Flash chromatography (CH₂Cl₂:MeOH=10:1) of the residue gave thetitle compound as a yellow amorphous solid (177 mg, 44%). ¹H-NMR (400MHz, DMSO-d₆) δ 0.86 (3H, d, J=5.5 Hz), 1.62-1.73 (1H, m), 1.79-1.93(1H, m), 2.25-2.38 (1H, m), 2.38-2.64 (3H, m), 2.80-2.93 (1H, m),3.27-3.50 (3H, m), 3.52-3.14 (2H, m), 4.50-4.60 (1H, m), 6.28 (1H, brs),6.42-6.52 (2H, m), 6.69 (1H, t, J=5.5 Hz), 7.01 (2H, brs), 7.32-7.40(1H, m), 7.96 (1H, dd, J=4.9 and 1.2 Hz), 8.07 (1H, s), 15.24 (1H, s).HRESIMS (+) 468.20923 (Calcd for C₂₄H₂₇FN₅O₄, 468.20471).

Example 509′-amino-10′-fluoro-2′,3′-dihydro-2′-methyl-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicAcid 50A) Preparation of 1-[(benzoylamino)cyclobutyl]acetaldehyde

DIBAL (40.0 mL, 1M solution in toluene) was added dropwise at −78° C. toa stirred solution of ethyl [1-(benzoylamino)cyclobutyl]acetate (6.86 g,26.3 mmol) in THF (130 mL) over the course of 30 minutes. After stirringat −78° C. for 6 hours, MeOH (10 mL) was added dropwise to the mixtureat −78° C. over the course of 30 minutes. Saturated aqueous NH₄Cl (20mL) was then added to the mixture, and the mixture was stirred at roomtemperature for 1 hour. The mixture was extracted with Et₂O, dried overanhydrous Na₂SO₄, filtered, and concentrated in vacuo. Flashchromatography (hexane:AcOEt=2:1) of the residue gave the title compoundas a colorless solid (1.82 g, 32%). ¹H-NMR (400 MHz, CDCl₃) δ 1.87-2.07(2H, m), 2.25-2.34 (2H, m), 2.36-2.45 (2H, m), 3.28 (2H, s), 6.57 (1H,brs), 7.39-7.45 (2H, m), 7.46-7.53 (1H, m), 7.70-7.76 (2H, m), 9.79 (1H,s).

50B) Preparation of 1-[1-(benzoylamino)cyclobutyl]-2-propanol

Methyl magnesium chloride (14.0 mL, 3M solution in THF) was added to astirred solution of [1-(benzoylamino)cyclobutyl]acetaldehyde (2.82 g,13.0 mmol) in THF (30 mL) at −0° C., and the mixture was stirred at roomtemperature for 5 hours. Saturated aqueous NH₄Cl (10 mL) was added tothe mixture 0° C., and the resulting mixture was extracted with ethylacetate. The combined organic extracts were dried over anhydrous Na₂SO₄,filtered, and concentrated in vacuo. Flash chromatography(hexane:AcOEt=2:1) of the residue gave the title compound as a colorlessoil (2.65 g, 87%). ¹H-NMR (400 MHz, CDCl₃) δ 1.25 (3H, d, J=6.1 Hz),1.77-2.12 (5H, m), 2.28-2.40 (1H, m), 2.52 (1H, q, J=10.4 Hz), 2.75-2.85(1H, m), 3.26 (1H, d, J=3.7 Hz), 3.97-4.07 (1H, m), 6.91 (1H, brs),7.39-7.46 (2H, m), 7.46-7.53 (1H, m), 7.75-7.82 (2H, m).

50C) Preparation of 1-[1-(benzylamino)cyclobutyl]-2-propanol

LiAlH₄ (1.20 g, 31.6 mmol) was added to a solution of1-[1-(benzoylamino) cyclobutyl]propanol (2.64 g, 11.3 mmol) in THF (40mL) at room temperature. The mixture was stirred at room temperature for1 hour and refluxed for 30 minutes. The mixture was cooled in anice-water bath and a few drops of water were added. The mixture was thendiluted with ethyl acetate, dried over anhydrous Na₂SO₄, filtered, andconcentrated in vacuo. Flash chromatography (AcOEt) of the residue gavethe title compound as a colorless oil (2.25 g, 91%). ¹H-NMR (400 MHz,CDCl₃) δ 1.21 (3H, d, J=6.1 Hz), 1.63 (1H, dd, J=13.7 and 2.4 Hz),1.73-1.90 (5H, m), 2.04-2.13 (1H, m), 2.18-2.27 (1H, m), 3.59 (1H, d,J=11.6 Hz), 3.81 (1H, d, J=11.6 Hz), 4.07-4.16 (1H, m), 7.22-7.35 (5H,m).

50D) Preparation of 1-(1-aminocyclobutyl)-2-propanol

10% Pd—C (300 mg) was added to a solution of1-[1-(benzylamino)cyclobutyl]-2-propanol (2.24 g, 10.2 mmol) in EtOH (50mL) and the mixture was stirred under H₂ gas (5 kgf/cm²) at roomtemperature for 10 hours. The mixture was filtered and the filtrate wasconcentrated in vacuo. Distillation of the residue gave the titlecompound as a pale yellow oil (1.24 g, 94%).

¹H-NMR (400 MHz, CDCl₃) δ 1.17 (3H, d, J=6.1 Hz), 1.43 (1H, ddd, J=14.7,10.4 and 1.2 Hz), 1.61-1.69 (1H, m), 1.72 (1H, dd, J=14.7 and 1.8 Hz),1.75-1.90 (3H, m), 1.93-2.03 (1H, m), 2.12-2.20 (1H, m), 4.00-4.08 (1H,m).

50F) Preparation of ethyl3-[1-(2-hydroxypropyl)cyclobutylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate

A stirred solution of ethyl3-oxo-3-(2,3,4,5-tetrafluorophenyl)propionate (2.45 g, 9.27 mmol), Ac₂O(5.30 mL, 56.1 mmol) and triethyl orthoformate (3.10 mL, 18.6 mmol) washeated at 120° C. for 3 hours. The mixture was concentrated in vacuo anddried under high vacuum. To 1-[1-aminocyclobutyl]-2-propanol (1.20 g,9.29 mmol) in anhydrous toluene (10 mL) was slowly added to a mixture ofthe residue in anhydrous toluene (30 mL) at 0° C. and stirred at roomtemperature for 2 hours. The solvent was removed by evaporation. Flashchromatography (AcOEt:Hexane=1:1) of the residue gave the title compoundas a pale yellow solid (3.10 g, 83%). ¹H-NMR (400 MHz, CDCl₃) δ 0.95(0.6H, t, J=7.3 Hz), 1.09 (2.4H, t, J=7.3 Hz), 1.29 (3H, d, J=6.1 Hz),1.51 (1H, brs), 1.83-2.05 (4H, m), 2.18-2.35 (3H, m), 2.41-2.53 (1H, m),3.95-4.15 (3H, m), 6.96-7.13 (1H, m), 8.27 (0.8H, d, J=14.7 Hz), 8.31(0.2H, d, J=14.7 Hz), 10.30 (0.2H, d, J=13.4 Hz), 11.56 (0.8H, d, J=13.4Hz).

50G) Preparation of Ethyl10′,11′-difluoro-2′,3′-dihydro-2′-methyl-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

NaH (40 mg) was added to a solution of ethyl3-[1-(2-hydroxylpropyl)cyclobutylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate(404 mg, 1.00 mmol) in DMF (4 mL) at 0° C. NaH (40 mg) was added afterstirring at 0° C. for 1 hour. The mixture was stirred at 0° C. for anadditional hour, then at room temperature for 1 hour and at 80° C. forone additional hour. Water was added to the mixture portionwise at 0°C., and the resulting precipitate was isolated by filtration, washedsuccessively with water and iPr₂O, and dried to give the title compound(244 mg, 67%) as a colorless solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.27(3H, t, J=7.3 Hz), 1.43 (3H, d, J=6.1 Hz), 1.72 (1H, q, J=10.4 Hz),1.90-2.04 (1H, m), 2.24 (1H, q, J=10.4 Hz), 2.34-2.43 (1H, m), 2.53-2.74(4H, m), 4.24 (2H, q, J=7.3 Hz), 4.48-4.58 (1H, m), 7.72 (1H, qd, J=10.4and 7.9 Hz), 8.40 (1H, s).

50H) Preparation of Ethyl10′,11′-difluoro-2′,3′-dihydro-2′-methyl-9′-nitro-8′oxo-spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

A solution of ethyl10′,11′-difluoro-2′,3′-dihydro-2′-methyl-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(182 mg, 0.501 mmol) in concentrated H₂SO₄ (2 mL) was treatedportionwise at 0° C. with solid KNO₃ (72.0 mg, 0.712 mmol). Afterstirring at 0° C. for 2 hours, the reaction mixture was poured intoice-water and the resulting precipitate was isolated by filtration,washed with water and dried to give the title compound (190 mg, 93%) asa pale yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.27 (3H, t, J=7.3 Hz),1.45 (3H, d, J=6.1 Hz), 1.61-1.77 (1H, m), 1.90-2.03 (1H, m), 2.29-2.48(3H, m), 2.57-2.72 (3H, m), 4.24 (2H, q, J=7.3 Hz), 4.62-4.73 (1H, m),8.43 (1H, s).

50I) Preparation of Ethyl9′-amino-10′,11′-difluoro-2′,3′-dihydro-2′-methyl-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

A solution of ethyl10′,11′-difluoro-2′,3′-dihydro-2′-methyl-9′-nitro-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(1.13 g, 2.77 mmol) in DMF (70 mL) was treated with hydrogen underatmospheric pressure over 10% Pd/C (230 mg) at 50° C. for 2 hours. Thecatalyst was removed by filtration through Celite and the filtrate wasconcentrated in vacuo. The residue was washed with EtOH, collected byfiltration and dried to give the title compound (824 mg, 79%) as a paleyellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.26 (3H, t, J=7.3 Hz), 1.36(3H, d, J=6.1 Hz), 1.70 (1H, q, J=10.4 Hz), 1.86-2.00 (1H, m), 2.25 (1H,q, J=10.4 Hz), 2.30-2.39 (1H, m), 2.42-2.63 (4H, m), 4.14-4.27 (2H, m),4.27-4.37 (1H, m),7.49 (2H, brs), 8.22 (1H, s).

50.1) Preparation of9′-amino-10′,11′-difluoro-2′,3′-dihydro-2′-methyl-8′-oxospiro[cyclobutane-1,4%[4H,8H]pyrido[1,2,3-ej][1,4]benzoxazepine]-7′-carboxylicAcid

2N NaOH (10.0 mL) was added to a mixture of ethyl9′-amino-10′,11′-difluoro-2′,3′-dihydro-2′-methyl-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(768 mg, 2.03 mmol) in EtOH (20 mL) at room temperature and the mixturewas heated at 50° C. for 3 hours. 2N HCl (10.0 mL) and water were addedto the reaction mixture. The resulting precipitate was collected byfiltration, washed successively with water and dried to give the titlecompound (703 mg, 99%) as a yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ1.37 (3H, d, J=6.1 Hz), 1.70 (1H, q, J=11.0 Hz), 1.88-2.02 (1H, m), 2.31(1H, q, J=11.0 Hz), 2.37-2.69 (5H, m), 4.30-4.42 (1H, m), 7.43 (1H,brs), 8.47 (1H, s), 14.61 (1H, brs).

50K) Preparation of9′-amino-10′-fluoro-2′,3′-dihydro-2′-methyl-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicacid

A solution of9′-amino-10′,11′-difluoro-2′,3′-dihydro-2′-methyl-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicacid (351 mg, 1.00 mmol), N-2-pyridinyl-1,2-ethanediamine (210 mg, 1.53mmol) and triethylamine (0.22 mL) in DMSO (5 mL) was stirred at 120° C.for 5 hours. The reaction mixture was added portionwise to ice-water at0° C. and the mixture was extracted with CH₂Cl₂. The combined extractswere dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo.Flash chromatography (CH₂Cl₂:MeOH=10:1) of the residue gave the titlecompound as a yellow amorphous solid (278 mg, 59%). ¹H-NMR (400 MHz,DMSO-d₆) δ 1.29 (3H, d, J=6.1 Hz), 1.67 (1H, q, J=10.4 Hz), 1.84-1.99(1H, m), 2.21 (1H, q, J=10.4 Hz), 2.30-2.40 (1H, m), 2.40-2.62 (4H, m),3.40-3.50 (2H, m), 3.53-3.67 (2H, m), 4.08-4.20 (1H, m), 5.91 (1H, brs),6.42-6.50 (2H, m), 6.65 (1H, t, J=5.5 Hz), 7.00 (2H, brs), 7.32-7.38(1H, m), 7.94 (1H, dd, J=4.9 and 1.2 Hz), 8.25 (1H, s), 15.24 (1H, s).HRESIMS (+) 467.20453 (Calcd for C₂₄H₂₇FN₅O₄, 468.20471).

Example 519′-amino-10′-fluoro-8′-oxospiro[cyclobutane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicAcid 51A) Preparation of Ethyl5-[[1-(hydroxymethyl)cyclobutyl]-methylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate

A stirred solution of ethyl3-oxo-3-(2,3,4,5-tetrafluorophenyl)propionate (2.80 g, 10.6 mmol), Ac₂O(6.01 mL, 63.6 mmol) and triethyl orthoformate (3.53 mL, 21.2 mmol) washeated at 120° C. for 3 hours. The mixture was concentrated in vacuo anddried under high vacuum. The crude product was dissolved in toluene (30mL) and a suspension of [1-(aminomethyl)cyclobutyl]]methanolhydrochloride (1.60 g, 10.6 mmol) in toluene (20 mL) and triethylamine(1.48 mL, 10.6 mmol) were added under ice-cooling. The mixture wasstirred at room temperature for 6 hours and concentrated in vacuo toyield the crude product. The crude product was purified by columnchromatography (Hexane: EtOAc 10:1→2:1) to yield the title compound(1.88 g, 46%) as a white solid. ¹H-NMR (400 MHz, CDCl₃) δ 0.95-1.12 (3H,m), 1.66-1.69 (1H, m), 1.81-1.91 (4H, m), 1.94-2.03 (2H, m), 3.57 (2H,d, J=6.7 Hz), 3.72 (2H, d, J=4.3 Hz), 4.00-4.10 (2H, m), 6.96-7.12 (1H,m), 8.09-8.15 (1H, m), 9.65-11.15 (1H, m).

51B) Preparation of Ethyl10′,11′-difluoro-8′-oxospiro[cyclobutane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

A solution of ethyl5-[[1-(hydroxymethyl)cyclobutyl]methylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate(1.88 g, 4.83 mmol) in DMF (10 mL) was added to a suspension of 60% NaHin oil (424 mg, 10.6 mmol) in DMF (15 mL) under argon atmosphere andice-cooling. The reaction mixture was stirred at room temperature forone hour, then at 90° C. for an additional hour. The mixture was thenpoured into ice-water and the precipitate was collected by vacuumfiltration and washed with hexane and water to yield the title compound(1.41 g, 84%) as a pale yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.29(3H, t, J=7.3 Hz), 1.80-2.09 (6H, m), 4.24 (2H, q, J=7.3 Hz), 4.43 (2H,s), 4.61 (2H, s), 7.73 (1H, dd, J=10.4, 7.9 Hz), 8.74 (1H, s). EIMS (+):349 [M]⁺.

51C) Preparation of Ethyl10′,11′-difluoro-9′-nitro-8′-oxospiro-[cyclobutane-1,3′(4′H)-[2H,81-f]pyrido[1,2,3-ej][1,4]benzoxazepine]-7′-carboxylate

A solution of ethyl10,11-difluoro-8-oxospiro[cyclobutane-1,3′(4′H)-[2H,8H]-pyrido[1,2,3-ef][1,4]benzoxazepine]-7-carboxylate(1.29 g, 3.69 mmol) in concentrated H₂SO₄ (15 mL) was treatedportionwise with solid KNO₃ (523 mg, 5.17 mmol) at 0° C. After stirringat 0° C. for 3 hours, the reaction mixture was poured into ice-water andthe resulting precipitate was removed by filtration, washed with waterand suspended in hot EtOH. The reaction mixture was stirred at refluxfor 1 hour, cooled to room temperature and the precipitate was collectedby filtration to yield the title compound (1.20 g, 82%) as a pale yellowsolid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.27 (3H, t, J=7.3 Hz), 1.80-1.88(1H, m), 1.92-2.00 (2H, m), 2.02-2.09 (3H, m), 4.23 (2H, q, J=7.3 Hz),4.51 (2H, s), 4.61 (2H, s), 8.81 (1H, s). ESIMS (+): 395 [M+H]⁺.

51D) Preparation of Ethyl9′-amino-10′,11′-difluoro-8′-oxospiro-[cyclobutane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate

A solution of ethyl 10′,11′-difluoro-9′-nitro-8′-oxospiro[cyclobutane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(1.18 g, 2.99 mmol) in DMF (60 mL) was treated with hydrogen underpressure (0.35 MPa) over 10% Pd/C (120 mg) at 50° C. for 7 hours. Thecatalyst was removed by filtration through Celite and silica gel (50 g)was added to the filtrate. The mixture was stirred for 30 minutes, thesilica gel was removed by filtration and the solvent was removed invacuo. The precipitate was washed with EtOH and dried to yield the titlecompound (320 mg, 29%) as a pale yellow solid. ¹H-NMR (400 MHz, DMSO-d₆)δ 1.26 (3H, t, J=7.3 Hz), 1.76-2.04 (6H, m), 4.17-4.26 (4H, m), 4.51(2H, s), 7.57 (2H, brs), 8.52 (1H, s). ESIMS (+): 365 [M+H]⁺.

51E) Preparation of9′-amino-10′,11′-difluoro-8′-oxospiro-[cyclobutane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ej][1,4]benzoxazepine]-7′-carboxylicAcid

A solution of ethyl9′-amino-10′,11′-difluoro-8′-oxospiro[cyclobutane-1,3′-(4′H)-[2H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylate(300 mg, 0.823 mmol) in a mixture of AcOH—H₂O—H₂SO₄ (2:1:0.3 v/v, 6.6mL) was heated at 100° C. for 2 hours. The reaction mixture was pouredinto ice-water and the resulting precipitate was collected byfiltration, washed with water and dried to yield the title compound (242mg, 87%) as a brown solid ¹H-NMR (400 MHz, DMSO-d₆) δ 1.76-2.07 (6H, m),4.27 (2H, s), 4.69 (2H, s), 7.48 (2H, brs), 8.92 (1H, s), 14.63 (1H, s).ESIMS (+): 337 [M+H]⁺.

51F) Preparation of9′-amino-10′-fluoro-8′-oxo-11-[2-(pyridin-2-ylamino)ethylamino]spiro[cyclobutane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine-7′-carboxylicacid

A solution of9′-amino-10′,11′-difluoro-8′-oxospiro[cyclobutane-1,3′(4′H)-2H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicacid (220 mg, 0.654 mmol), N-2-pyridinyl-1,2-ethanediamine (135 mg,0.981 mmol) and triethylamine (0.137 mL, 0.981 mmol) in DMSO (5 mL) wasstirred at 100° C. for 5 hours. The precipitate was removed byfiltration through Celite, water was added to the filtrate and theresulting precipitate was collected by filtration, washed with EtOH anddried to yield the title compound (197 mg, 66%) as a pale brown solid.¹H-NMR (400 MHz, DMSO-d₆) δ 1.73-1.87 (3H, m), 1.91-2.06 (3H, m),3.43-3.47 (2H, m), 3.53-3.60 (2H, m), 4.02 (2H, s), 4.55 (2H, s),6.25-6.32 (1H, m), 6.45-6.49 (2H, m), 6.65-6.73 (1H, m), 7.02 (2H, brs),7.35 (1H, td, J=6.7, 1.8 Hz), 7.95 (1H, dd, J=5.5, 1.2 Hz), 8.65 (1H,s), 15.25 (1H, s). HRESIMS (+): 454.18998 (+0.93 mmu).

Example 529′-amino-10′-fluoro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclopropane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ef]benzoxazepine]-7′-carboxylicAcid 52A) Preparation of ethyl3-[[1-(hydroxymethyl)cyclopropyl]-methylamino]-2-(pentafluorobenzoyl)acrylate

A solution of ethyl 3-oxo-3-(pentafluorophenyl)propionate (7.01 g, 24.8mmol), Ac₂O (14.0 mL, 148 mmol) and triethyl orthoformate (8.25 mL, 49.6mmol) was heated at 120° C. for 2 h. The mixture was concentrated invacuo and dried under high vacuum. The crude product was dissolved inanhydrous toluene (120 mL) and [1-(aminomethyl)-cyclopropyl]]methanol(2.51 g, 24.8 mmol) was added very slowly at 0° C. The reaction mixturewas stirred at room temperature for 3 h, and the solvent was removed byevaporation. The crude product was purified by column chromatography(Hexane: EtOAc 2:1) to yield the title compound (7.30 g, 75%) as a paleyellow solid. Mp. 74.5-76.0° C. ¹H-NMR (400 MHz, CDCl₃) δ 0.57-0.63 (4H,m), 1.12 (3H, t, J=7.3 Hz), 1.62 (2H, t, J=5.5 Hz), 3.50 (2H, d, J=5.5Hz), 3.98-4.17 (2H, m), 8.17 (1H, d, J=5.5 Hz), 11.22 (1H, brs). EIMS(+) 393 [M]⁺. Anal. Calcd for C₁₇H₁₆F₅NO₄: C, 51.80; H, 3.90; N, 3.56.Found: C, 51.91; H, 4.10; N, 3.56.

52B) Preparation of Ethyl9′,10′,11′-trifluoro-8′-oxospiro-[cyclopropane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ef]benzoxazepine]-7′-carboxylate

A solution of NaH (920 mg, 23.0 mmol, 60% in oil) in DMF (50 mL) wascooled to 0° C. and treated dropwise with ethyl3-[[1-(hydroxymethyl)cyclopropyl]methylamino]-2-(pentafluorobenzoyl)acrylate(4.10 g, 10.4 mmol) in DMF (10 mL). The reaction mixture was stirred 4hours at room temperature and for an additional hour at 80° C. Thereaction mixture was then poured into ice water and the resultingprecipitate was removed by filtration and washed with water. Theresulting solid was dissolved in 100 mL of EtOH—CH₂Cl₂ (2:1) andfiltered. The filtrate was concentrated to 30 mL, and the resultingprecipitate was removed by filtration, washed with EtOH and dried toyield the title compound (2.45 g, 67%) as a pale yellow solid. M.p.209-211° C. ¹H-NMR (400 MHz, DMSO) δ0.56 (2H, t, J=6.1 Hz), 0.77 (2H, t,J=6.1 Hz), 1.26 (3H, t, J=7.3 Hz), 4.20 (2H, s), 4.21 (2H, q, J=7.3 Hz),4.49 (2H, s). EIMS (+) 353 [M]⁺.

52C) Preparation of Ethyl10′,11′-difluoro-9′-(2,4-dimethoxybenzylamino)-8′-oxospiro[cyclopropane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ef]benzoxazepine]-7′-carboxylate

A solution of ethyl9′,10′,11′-trifluoro-8′-oxospiro[cyclopropane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ef]benzoxazepine]-7′-carboxylate(1.51 g, 4.27 mmol) and triethylamine (0.890 mL, 6.34 mmol) and2,4-dimethoxybenzylamine (0.635 mL, 4.29 mmol) in toluene (30 mL) wasstirred at 90° C. for 6 hours. The reaction mixture was poured intowater, and extracted with EtOAc. The organic layer was washed with waterand brine, dried over anhydrous Na₂SO₄ and the solvent was removed. Thecrude product was purified by column chromatography (Hexane: EtOAc 2:3)to yield the title compound (1.48 g, 69%) as a yellow solid.

M.p. 131-132° C. ¹H-NMR (400 MHz, CDCl₃) δ 0.58 (2H, t, J=5.5 Hz), 0.75(2H, t, J=5.5 Hz), 1.36 (3H, t, J=7.3 Hz), 3.78 (3H, s), 3.82 (3H, s),4.03 (2H, s), 4.26 (2H, brs), 4.35 (2H, q, J=7.3 Hz), 4.59 (2H, dd,J=6.1, 3.0 Hz), 6.37-6.46 (2H, m), 7.23 (1H, d, J=7.9 Hz), 8.01 (1H, s),10.48 (1H, brs). EIMS (+) 500 [M]⁺.

52D) Preparation of Ethyl9′-amino-10′,11′-difluoro-8′-oxospiro-[cyclopropane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ej]benzoxazepine]-7′-carboxylate

A solution of ethyl10′,11′-difluoro-9′-(2,4-dimethoxybenzylamino)-8′-oxospiro-[cyclopropane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ef]benzoxazepine]-7′-carboxylate(1.42 g, 2.84 mmol) in trifluoroacetic acid (30 mL) was stirred at roomtemperature for 15 minutes. The reaction mixture was diluted with CH₂Cl₂and washed with saturated NaHCO₃, brine, and dried over anhydrousNa₂SO₄. The solvent was removed, and the resulting solid was dissolvedin DMF and filtered. The filtrate was poured into water and theresulting precipitate was removed by filtration, washed with water anddried to yield the title compound (835 mg, 84%) as a yellow solid. M.p.278-279° C. ¹H-NMR (400 MHz, DMSO) δ 0.50 (2H, dd, J=6.1, 4.8 Hz), 0.71(2H, dd, J=6.1, 4.8 Hz), 1.25 (3H, t, J=7.3 Hz), 4.03 (2H, s), 4.17 (2H,q, J=7.3 Hz), 4.44 (2H, s), 7.68 (2H, brs), 8.32 (1H, s). ESIMS (+): 351[M+H].

52E) Preparation of Ethyl9′-amino-10′,11′-difluoro-8′-oxospiro-[cyclopropane-1,3′(4′H)-(2H,8H]pyrido[1,2,3-ef]benzoxazepine]-7′-carboxylicAcid

A solution of ethyl9′-amino-10′,11′-difluoro-8′-oxospiro[cyclopropane-1,3′-(4′H)-2H,8H]pyrido[1,2,3-ej]benzoxazepine]7′-carboxylate(830 mg, 2.37 mmol) and 1M NaOH aq. in EtOH (20 mL) was stirred at room50° C. for 3 hours. The solvent was removed and the residue wasdissolved in water. The solution was acidified to pH 7 with 2M HCl andthe resulting precipitate was removed by filtration, washed with water,and dried to yield the title compound (757 mg, 99%) as a pale yellowsolid. ¹H-NMR 400 MHz, DMSO) δ 0.51 (2H, dd, J=6.1, 4.8 Hz), 0.73 (2H,dd, J=6.1, 4.8 Hz), 4.07 (2H, s), 4.62 (2H, s), 7.58 (2H, brs), 8.67(1H, s), 14.66 (1H, s). ESIMS (+): 323[M+11].

52F) Preparation of9′-amino-10′-fluoro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclopropane-1,3′(4′H)-[2H,8H]pyrido[1,2,3-ef]benzoxazepine]-7′-carboxylicAcid

A solution of ethyl9′-amino-10′,11′-difluoro-8′-oxospiro[cyclopropane-1,3′-(4′H)-2H,8H]pyrido[1,2,3-ef]benzoxazepine]-7′-carboxylicacid (505 mg, 1.57 mmol), triethylamine (0.320 mL, 2.30 mmol) andN-2-pyridinyl-1,2-ethanediamine (322 mg, 2.35 mmol) in DMSO (8 mL) wasstirred at 100° C. for 3 hours. The reaction mixture was poured into icewater and the resulting precipitate was removed by filtration, washedwith ethanol, and dried to yield the title compound (595 mg, 86%) as ayellow solid.

¹H-NMR (400 MHz, DMSO) δ 0.39 (2H, t, J=6.1 Hz), 0.68 (2H, t, J=6.1 Hz),3.40-3.50 (2H, m), 3.52-3.64 (2H, m), 3.86 (2H, s), 4.48 (2H, brs), 6.28(1H, brs), 6.40-6.50 (2H, m), 6.66 (1H, t, J=5.5 Hz), 7.09 (2H, brs),7.34 (1H, td, J=6.7, 1.8 Hz), 7.90-7.98 (1H, m), 7.90-8.00 (1H, m), 8.43(1H, s), 15.26 (1H, s). ESIMS (+): 440[M+H]⁺.

Example 539′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzodiazepine]-7′-carboxylicAcid 53A) Preparation of ethyl (1-hydroxycyclobutyl)acetate

Trimethylchlorosilane (1.14 mL, 8.92 mmol) was added by syringe to asuspension of zinc powder (7.97 g, 0.122 mol) in absolute Et₂O (200 mL).The mixture was stirred for 15 minutes at room temperature, heated toreflux, the heat source was removed, and ethyl bromoacetate (10.3 mL,92.9 mmol) was added at such a rate that the ether solution gentlyboiled. After being heating for one hour at reflux, the mixture wasstirred for one additional hour at room temperature. A solution ofcyclopentanone (6.00 g, 75.9 mmol) in ether (30 mL) was added while thetemperature of the mixture was maintained at 19-20° C. by intermittentcooling. The mixture was stirred for 1 hour at room temperature andpoured into iced 25% ammonia (400 mL). The aqueous phase was extractedwith ether, the combined organic phases were dried over K₂CO₃ and thesolvent was evaporated to yield the title compound as a colorless oil(6.50 g, 54%). ¹H-NMR (400 MHz, CDCl₃) δ 1.29 (3H, t, J=7.3 Hz),1.47-1.64 (1H, m), 1.76-1.87 (1H, m), 1.93-2.06 (2H, m), 2.12-2.22 (2H,m), 2.67 (2H, s), 3.70 (1H, s), 4.19 (2H, q, J=7.3 Hz).

53B) Preparation of Ethyl [1-(benzoylamino)cyclobutyl]acetate

H₂SO₄ (2.20 mL, 41.3 mmol) was slowly added to a mixture of ethyl(1-hydroxycyclobutyl)acetate (6.45 g, 40.8 mmol) and benzonitrile (40mL, 0.392 mol) at room temperature. The mixture was stirred for 1 hourat room temperature, then for an additional hour at 80° C. The mixturewas cooled in an ice-water bath, and 2N NaOH solution was added untilthe solution reached pH=7. The mixture was extracted with ethyl acetateand the combined organic extracts were dried over anhydrous Na₂SO₄,filtered, and concentrated in vacuo. Flash chromatography(AcOEt:Hexane=5:1) of the residue gave the title compound as a colorlesssolid (5.40 g, 51%). ¹H-NMR (400 MHz, CDCl₃) δ 1.22 (3H, t, J=7.3 Hz),1.84-2.07 (2H, m), 2.22-2.32 (2H, m), 2.44-2.55 (2H, m), 3.05 (2H, s),4.11 (2H, q, J=7.3 Hz), 6.73 (1H, s), 7.39-7.52 (3H, m), 7.72-7.79 (2H,m).

53C) Preparation of [1-(benzoylamino)cyclobutyl]acetic Acid

3N KOH (10 mL, 30 mmol) was added to a solution of ethyl1-(benzoylamino)-cyclobutylacetate (3.87 g, 14.8 mmol) in EtOH (30 mL)at room temperature and the mixture was stirred for 1 hour. The reactionmixture was concentrated in vacuo and 6N HCl (5.0 mL) was added. Theresulting precipitate was collected by filtration, washed successivelywith water and diisopropylether and dried to give the title compound(3.15 g, 91%) as a colorless solid. ¹H-NMR (400 MHz, DMSO-d₆) δ1.76-1.89 (2H, m), 2.16-2.26 (2H, m), 2.28-2.40 (2H, m), 2.90 (2H, s),7.43 (2H, t, J=6.7 Hz), 7.50 (1H, t, J=6.7 Hz), 7.83 (2H, d, J=6.7 Hz),8.45 (1H, s), 12.00 (1H, brs).

53D) Preparation of 11-(benzoylamino)cyclobutyl]acetamide

A mixture of [1-(benzoylamino)cyclobutyl]acetic acid (1.00 g, 4.29 mmol)and thionyl chloride (3.20 mL, 43.9 mmol) was stirred at roomtemperature for 1 hour. The mixture was concentrated in vacuo. 25%aqueous ammonia (30 mL) was added to a mixture of the residue in THF (30mL) cooled in an ice-water bath. The mixture was stirred at roomtemperature for 1 hour. The mixture was then diluted with AcOEt-MeOH(3:1 v/v) and washed with water. The organic layer was dried overanhydrous Na₂SO₄, filtered, and concentrated in vacuo to give the titlecompound (925 mg, 93%) as a colorless solid. ¹H-NMR (400 MHz, DMSO-d₆) δ1.75-1.87 (2H, m), 2.14-2.23 (2H, m), 2.37-2.47 (2H, m), 2.70 (2H, s),6.80 (1H, s), 7.29 (1H, s), 7.43 (2H, t, J=6.7 Hz), 7.50 (1H, t, J=6.7Hz), 7.82 (2H, d, J=6.7 Hz), 8.39 (1H, s).

53E) Preparation of 2-[1-(benzylamino)cyclobutyl]ethylamine

LiAlH₄ (570 mg, 15.0 mmol) was added portionwise to a solution of[1-(benzoylamino) cyclobutyl]acetamide (687 mg, 3.00 mmol) in THF (30mL) at room temperature over the course of 30 minutes, and the mixturewas heated to reflux for 5 hours. The mixture was cooled in an ice-waterbath, aqueous THF and few drops of water were added, and the mixture wasallowed to stand overnight. The mixture was filtered through celite andthe solution was dried over anhydrous Na₂SO₄. The solution wasconcentrated in vacuo to give the title compound as a pale yellow oil(609 mg, 99%). ¹H-NMR (400 MHz, CDCl₃) δ 1.65-1.80 (2H, m), 1.82 (2H, t,J=7.3 Hz), 1.86-2.02 (4H, m), 2.82 (2H, t, J=7.3 Hz), 3.65 (2H, s),7.20-7.38 (5H, m).

53F) Preparation of2-[1-(benzylamino)cyclobutyl]-N-(tert-butoxycarbonyl)ethylamine

Boc₂O (230 mg, 1.05 mmol) was added to a solution of2-[1-(benzylamino)cyclobutyl]ethylamine (205 mg, 1.00 mmol) in THF (1mL) in an ice-water bath. The mixture was stirred for 30 minutes in anice-water bath. The mixture was concentrated in vacuo, and flashchromatography (AcOEt:Hexane=2:1) of the residue gave the title compoundas a colorless solid (164 mg, 54%). ¹H-NMR (400 MHz, DMSO-d₆) δ 1.36(9H, s), 1.60-1.84 (6H, m), 1.84-1.94 (2H, m), 2.92-3.04 (2H, m), 3.53(2H, s), 6.83 (1H, t, J=5.5 Hz), 7.21 (1H, t, J=7.3 Hz), 7.29 (2H, t, J₇7.3 Hz), 7.35 (2H, d J=7.3 Hz).

53G) Preparation of2-(1-aminocyclobutyl)-N-(tert-butoxycarbonyl)ethylamine

To a solution of2-[1-(benzylamino)cyclobutyl]-N-(tert-butoxycarbonyl)ethylamine (117 mg,0.384 mmol) in EtOH (5 mL) was added 10% Pd—C (35 mg) and the mixturewas stirred under H₂ gas 5 kgf/cm² at room temperature for 5 h. Themixture was filtered, and the filtrate was concentrated in vacuo. Thedistillation of the residue gave the title compound as a colorless solid(76.0 mg, 92%). ¹H-NMR (400 MHz, DMSO-d₆) δ 1.37 (9H, s), 1.49-1.58 (2H,m), 1.62-1.77 (4H, m), 1.82-1.91 (2H, m), 2.92-3.01 (2H, m), 6.78 (1H,t, J=5.5 Hz).

53H) Preparation of Ethyl3-[1-[2-(tert-butoxycarbonylamino)ethyl]cyclobutylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate

A stirred solution of ethyl3-oxo-3-(2,3,4,5-tetrafluorophenyl)propionate (5.28 g, 20.0

mmol), Ac₂O (11.4 mL, 0.121 mol) and triethyl orthoformate (6.66 mL,40.0 mmol) was heated at 120° C. for 3 hours. The mixture wasconcentrated in vacuo and dried under high vacuum.2-[1-(benzylamino)cyclobutyl]-N-(tert-butoxycarbonyl)ethylamine (4.29 g,20.0 mmol) in anhydrous toluene (30 mL) was slowly added to a mixture ofthe residue in anhydrous toluene (70 mL) at 0° C. and stirred at roomtemperature for 1 hour. The solvent was removed by evaporation, andflash chromatography (AcOEt:Hexane=2:1) of the residue gave the titlecompound as a pale yellow oil (9.10 g, 93%). ¹H-NMR (400 MHz, CDCl₃) δ0.98 (0.7H, t, J=7.3 Hz), 1.10 (2.3H, t, J=7.3 Hz), 1.43 (9H, s),1.90-2.07 (4H, m), 2.17-2.38 (4H, m), 3.12-3.23 (2H, m), 4.00-4.15 (2H,m), 4.53-4.65 (1H, br), 6.95-7.03 (0.7H, m), 7.05-7.13 (0.3H, m), 8.13(1H, d, J=14.1 Hz), 9.88 (0.3H, d, J=13.5 Hz), 11.29 (0.7H, d, J=13.5Hz). HRMS (ESI⁺) for C₁₈H₁₉F₄NO₄ [M+H]⁺: calcd, 489.20126; found,489.20200.

53I) Preparation of Ethyl1′-(tert-butoxycarbonyl)-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-d][1,4]benzodiazepine]-7′-carboxylate

A solution of ethyl3-[1-[2-(tert-butoxycarbonylamino)ethyl]cyclobutylamino]-2-(2,3,4,5-tetrafluorobenzoyl)acrylate(500 mg, 1.02 mmol) in DMF (5 mL) was cooled in an ice-water bath. NaH(82.0 mg, 2.05 mmol) was added and the mixture was stirred for 30minutes, then at room temperature for 2 hours. The mixture was cooled 0°C. and water was added portionwise to the mixture. The resultingprecipitate was combined by filtration, washed successively with waterand diisopropylether and dried to give the title compound (312 mg, 68%)as a pale yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.28 (3H, t, J=7.3Hz), 1.42 (5H, s), 1.54 (4H, s), 1.67-1.80 (1H, m), 1.80-1.95 (1H, m),2.10-2.22 (1H, m), 2.22-2.37 (2H, m), 2.40-2.56 (1H, m), 2.65-2.80 (2H,m), 4.17-4.37 (3H, m), 7.93-8.01 (1H, m), 8.47 (0.44H, s), 8.51 (0.56H,s).

53J) Preparation of Ethyl10′,11′-difluoro-2′,3′-dihydro-9′-nitro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzodiazepine]-7′-carboxylate

A solution of ethyl1′-(tert-butoxycarbonyl)-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]-pyrido[1,2,3-ef][1,4]benzodiazepine]-7′-carboxylate(5.50 g, 12.3 mmol) in concentrated H₂SO₄ (60 mL) was treatedportionwise at 0° C. with solid KNO₃ (1.37 g, 13.6 mmol). After stirringat 0° C. for 1 hour, the reaction mixture was poured into ice-water andthe resulting precipitate was combined by filtration and washed withwater. Flash chromatography (CH₂Cl₂—AcOEt=1:1) of the residue gave thetitle compound as a yellow solid (3.28 g, 68%). ¹H-NMR (400 MHz,DMSO-d₆) δ 1.26 (3H, t, J=7.3 Hz), 1.63-1.75 (1H, m), 1.85-1.98 (1H, m),2.35-2.57 (6H, m), 3.47-3.55 (2H, m), 4.22 (2H, q, J=7.3 Hz), 6.96-7.02(1H, m), 8.32 (1H, s).

53K) Preparation of Ethyl9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-14H,81-f]pyrido[1,2,3-ef][1,4]benzodiazepine]-7′-carboxylate

A solution of ethyl10′,11′-difluoro-2′,3′-dihydro-9′-nitro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ej][1,4]benzodiazepine]-7′-carboxylate(1.23 g, 3.13 mmol) in DMF (77 mL) was treated with hydrogen underatmospheric pressure over 10% Pd/C (250 mg) at 50° C. for 1 hour. Thecatalyst was removed by filtration over Celite and the filtrate wasconcentrated in vacuo. Flash chromatography (CH₂Cl₂-MeOH=2:1) of theresidue give the title compound as a yellow solid (1.00 g, 88%). ¹H-NMR(400 MHz, DMSO-d₆) δ 1.25 (3H, t, J=7.3 Hz), 1.62-1.73 (1H, m),1.82-1.96 (1H, m), 2.24-2.41 (4H, m), 2.45-2.60 (2H, m), 3.27-3.38 (2H,m), 4.19 (2H, q, J=7.3 Hz), 5.28-5.34 (1H, m), 7.10 (2H, brs), 8.12 (1H,s).

53L) Preparation of9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzodiazepine]-7′-carboxylicAcid

2N NaOH (7.0 mL, 14.0 mmol) was added to a mixture of ethyl9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]-benzodiazepine]-7′-carboxylate(515 mg, 1.41 mmol) in EtOH (15 mL) at room temperature and the mixturewas heated for 3 hours at 50° C. 2N HCl (7.0 mL) and water were added tothe reaction mixture. The resulting precipitate was collected byfiltration, washed successively with water and dried to give the titlecompound (397 mg, 83%) as a yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ1.61-1.73 (1H, m), 1.82-1.97 (1H, m), 2.30-2.44 (4H, m), 2.55-2.69 (2H,m), 3.25-3.50 (2H, m), 5.53-5.59 (1H, br), 7.03 (2H, brs), 8.35 (1H, s),14.75 (1H, s).

53M) Preparation of9′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzodiazepine]-7′-carboxylicAcid

A solution of9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′oxo-spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzodiazepine]-7′-carboxylicacid (300 mg, 0.895 mmol), N-(2-pyridinyl)-1,2-ethanediamine (185 mg,1.35 mmol) and triethylamine (0.23 mL) in DMSO (4 mL) was stirred at120° C. for 5 hours. The reaction mixture was added portionwise toice-water and the mixture was extracted with CH₂CH₂. The organic layerwas dried over anhydrous Na₂SO₄, and concentrated in vacuo. Flashchromatography (CH₂Cl₂-MeOH=10:1) of the residue gave the title compoundas a yellow solid (259 mg, 64%). ¹H-NMR (400 MHz, DMSO-d₆) δ 1.58-1.70(1H, m), 1.78-1.92 (1H, m), 2.21-2.38 (4H, m), 2.43-2.60 (2H, m),3.19-3.37 (2H, m), 3.37-3.51 (4H, m), 4.50 (1H, t, J=5.5 Hz), 5.50-5.58(1H, br), 6.42-6.51 (2H, m), 6.65 (1H, t, J=5.5 Hz), 6.82 (2H, brs),7.36 (1H, td, J=6.7 and 1.8 Hz), 7.95 (1H, dd, J=4.9 and 1.2 Hz), 8.18(1H, s), 15.28 (1H, s). HRESIMS (+) 453.20466 (Calcd for C₂₃H₂₆FN₆O,453.20504).

Example 548′-amino-9′-fluoro-7′-oxo-10′-[2-(2-pyridylamino)ethylamino]spiro[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicAcid 54A) Preparation of[3-(tert-butoxycarbonylamino)oxolan-3-yl]methanol

To a solution of 1-(tert-butoxycarbonylamino)cyclopentanecarboxylic acid(6.57 g, 28.4 mmol) in THF (60 mL) was added LiAlH4 (2.89 g, 61.0 mol)at room temperature. After stirred for 5 h, the reaction mixture waspoured into ice-water and stirred for 30 min. To the mixture was addedAcOEt and stirred for 30 min. The mixture was filtered and the filtratewas extracted with AcOEt. The extraction mixture was washed with waterand brine, dried over MgSO4, and concentrated in vacuo. The residue waspurified by column chromatography (Hexane:AcOEt 1:1) to give[3-(tert-butoxycarbonylamino)oxolan-3-yl]methanol (2.82 g, 46%) as acolorless solid. ¹H-NMR (400 MHz, DMSO-d₆) δ1.36 (9H, s), 1.84-1.91 (1H,m), 1.93-2.02 (1H, m), 3.46 (2H, d, J=5.5 Hz), 3.59-3.62 (1H, d, J=8.6Hz), 3.66-3.70 (3H, m), 4.83 (1H, t, J=5.5 Hz), 6.78 (1H, brs).

54B) Preparation of (3-aminooxolan-3-yl)methanol hydrochloride

A solution of [3-(tert-butoxycarbonylamino)oxolan-3-yl]methanol (2.50 g,11.5 mmol) in 4M HCl-dioxane (30 mL) was stirred at room temperature for2 h. The mixture was concentrated in vacuo and dried to give(3-aminooxolan-3-yl)methanol hydrochloride as a pale brown oil (2.17 g,quant.). ¹H-NMR (400 MHz, DMSO-d₆) δ 1.89-2.01 (2H, m), 3.51-3.58 (2H,m), 3.66 (2H, s), 3.71-3.76 (1H, m), 3.86-3.92 (1H, m), 8.33 (3H, brs).

54C) Preparation of Ethyl3-[3-[1-(hydroxymethyl)]oxolanylamino]-(2,3,4,5-tetrafluorobenzoyl)acrylate

A stirred solution of ethyl 2,3,4,5-tetrafluorobenzoyl acetate (3.04 g,11.5 mmol), Ac₂O (6.52 mL, 69.0 mmol) and triethyl orthoformate (3.83mL, 23.0 mmol) was heated at 130° C. for 3 h. The mixture wasconcentrated in vacuo and dried under high vacuum. The crude product wasdissolved in EtOH (50 mL) and (3-aminooxolan-3-yl)methanol hydrochloride(2.17 g, 11.5 mmol), triethylamine (1.92 mL, 13.8 mmol) were added.After stirred at room temperature for 17 h, the mixture was concentratedin vacuo to yield crude product. The crude product was purified bycolumn chromatography (Hexane: EtOAc 4:1→1:2) to yield3-∂3-[1-(hydroxymethyl)oxolanylamino]-(2,3,4,5-tetrafluorobenzoyl)acrylate(4.18 g, 93%) as a yellow oil. ¹H-NMR (400 MHz, DMSO) δ 0.87 (3H×¼, t,J=7.3 Hz), 0.99 (3H×¾, t, J=7.3 Hz), 2.09-2.14 (2H, m), 3.56-3.74 (3H,m), 3.78-3.97 (5H, m), 5.50 (1H×¼, t, J=5.5 Hz), 5.54 (1H×¾, t, J=5.5Hz), 7.33-7.46 (1H, m), 8.20-8.27 (1H, m), 9.88 (1H×¼, d, J=14.7 Hz),11.27 (1H×¾, d, J=14.7 Hz).

54D) Preparation of Ethyl-9′,10′-difluoro-7′-oxospiro[oxolane-3,3%2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate

To a solution of3-[3-[1-(hydroxymethyl)oxolanylamino]-2-(2,3,4,5-tetrafluorobenzoyl)-acrylate(3.94 g, 10.6 mmol) in DMF (50 mL), 60% NaH in oil (892 mg, 22.3 mmol)was added under argon atmosphere and ice-cooling. After stirred at 60°C. for 5 h, the reaction mixture was poured into ice-water and theresulting precipitate was collected by filtration, washed with water andEtOH, and dried to yield ethyl9′,10′-difluoro-7′-oxospiro-[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate(2.93 g, 79%) as a colorless solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.27(3H, t, J=7.3 Hz), 2.38-2.42 (2H, m), 3.78 (1H, d, J=10.4 Hz), 3.92-3.98(1H, m), 4.09-4.14 (1H, m), 4.20-4.25 (3H, m), 4.57 (1H, d, J=11.6 Hz),4.65 (1H, d, J=11.6 Hz), 7.67 (1H, dd, J=10.4, 8.6 Hz), 8.50 (1H, s).

54E) Preparation ofEthyl-9′,10′-difluoro-8′-nitro-7′-oxospiro-[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate

A solution of ethyl9′,10′-difluoro-7′-oxospiro[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate(2.90 g, 8.26 mmol) in concentrated H₂SO₄ (40 mL) was treated portionwise at 0° C. with solid KNO₃ (1.17 g, 11.6 mmol). After stirring at 0°C. for 2 h, the reaction mixture was poured into ice-water and theresulting precipitate was collected by filtration, washed with water anddried to yield ethyl9′,10′-difluoro-8′-nitro-7′-oxospiro[oxolane-3,3′(2′H)-[7H]pyrido-[1,2,3-de][1,4]benzoxazine]-6′-carboxylate(3.20 g, 98%) as a colorless solid. ¹H-NMR (400 MHz, DMSO-d₆) δ1.26 (3H,t, J=7.3 Hz), 2.41-2.46 (2H, m), 3.78 (1H, d, J=10.4 Hz), 3.92-3.98 (1H,m), 4.09-4.14 (1H, m), 4.21-4.29 (3H, m), 4.62 (1H, d, J=11.6 Hz), 4.72(1H, d, J=11.6 Hz), 8.53 (1H, s).

54F) Preparation ofEthyl-8′-amino-9′,10′-difluoro-7′-oxospiro-[oxolane-3,3′(2′)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate

A mixture of ethyl9′,10′-difluoro-8′-nitro-7′-oxospiro[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate(3.15 g, 7.95 mmol) and iron (2.66 mg, 47.7 mmol) in AcOH (40 mL) wasstirred at 90° C. for 5 h. After the reaction mixture was concentratedin vacuo, DMF was added and the mixture was filtrated through Celite.The filtrate was poured into water and the resulting precipitate wascollected by filtration and dried to yield ethyl8′-amino-9′,10′-difluoro-7′-oxospiro[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate(1.54 g, 53%) as a colorless solid. ¹H-NMR (400 MHz, DMSO-d₆)

1.25 (3H, t, J=7.3 Hz), 2.29-2.38 (2H, m), 3.72 (1H, d, J=11.0 Hz),3.90-3.96 (1H, m), 4.06-4.11 (1H, m), 4.15 (1H, d, J=11.0 Hz), 4.19 (2H,q, J=7.3 Hz), 4.32 (1H, d, J=11.0 Hz), 4.41 (1H, d, J=11.0 Hz), 7.42(2H, brs), 8.34 (1H, s).

54G) Preparation of8′-amino-9′,10′-difluoro-7′-oxospiro[oxolane-3,3′(2′H)[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicAcid

A solution of ethyl8′-amino-9′,10′-difluoro-7′-oxospiro[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylate(1.51 g, 4.12 mmol) in a mixture of AcOH—H₂O—H₂SO₄ (2:1:0.3 v/v, 26.4mL) was heated at 100° C. for 2 h. The reaction mixture was poured intoice-water and stirred. After 30 min, the resulting precipitate wascollected by filtration, washed with water and dried to yield8′-amino-9′,10′-difluoro-7′-oxospiro[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylic acid (1.32 g,95%) as a pale yellow solid ¹H-NMR (400 MHz, DMSO-d₆)

2.38-2.44 (2H, m), 3.76 (1H, d, J=11.0 Hz), 3.91-3.97 (1H, m), 4.09-4.14(1H, m), 4.25 (1H, d, J=11.0 Hz), 4.38 (1H, d, J=11.0 Hz), 4.50 (1H, d,J=11.0 Hz), 7.36 (2H, brs), 8.59 (1H, s), 14.62 (1H, s).

54H) Preparation of 8′-amino-9′-fluoro-7′-oxo-10′-[3-(2-pyridyl)propylamino]spiro[oxolane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicAcid

A solution of8′-amino-9′,10′-difluoro-7′-oxospiro[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicacid (300 mg, 0.887 mmol), 3-(2-pyridyl)propylamine (181 mg, 1.33 mmol)and triethylamine (0.185 mL, 1.33 mmol) in DMSO (4 mL) was stirred at100° C. for 6 h. To the reaction mixture, water and saturated NH₄Clsolution were added to pH<4 and stirred for 30 min. The resultingprecipitate was collected by filtration, washed with water and EtOH, anddried to yield8′-amino-9′-fluoro-7′-oxo-10′-[3-(2-pyridyl)propylamino]spiro[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylic acid (373 mg, 93%) as apale yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.90-1.98 (2H, m),2.26-2.39 (2H, m), 2.77 (2H, t, J=7.3 Hz), 3.42-3.51 (2H, m), 3.73 (1H,d, J=10.4 Hz), 3.91-3.97 (1H, m), 4.07-4.13 (1H, m), 4.16 (1H, d, J=10.4Hz), 4.24 (1H, d, J=11.0 Hz), 4.35 (1H, d, J=11.0 Hz), 6.01-6.10 (1H,m), 6.92 (2H, brs), 7.18 (1H, dd, J=6.7, 5.5 Hz), 7.24 (1H, d, J=7.9Hz), 7.67 (1H, td, J=7.3, 1.8 Hz), 8.42 (1H, s), 8.45 (1H, d, J=4.3 Hz),15.27 (1H, s). HRESIMS (+) 455.17350 (Calcd for C₂₃H₂₃FN₄O₅, 455.17307).

Examples 55-81

By using the procedures set out above, the compounds of example 55 to 81were prepared:

Example No. R^(b)—X³— Data 55

¹H-NMR (400 MHz, DMSO-d₆) δ 1.62-1.73 (1H, m), 1.85-1.99 (1H, m),2.35-2.47 (4H, m), 2.52-2.62 (2H, m), 3.68 (3H, s), 4.22-4.32 (2H, m),4.49 (2H, d, J = 5.5 Hz), 6.39-6.42 (2H, m), 6.83 (1H, d, J = 8.6 Hz),6.95 (2H, brs), 7.16 (1H, d, J = 8.6 Hz), 8.26 (1H, s), 15.17 (1H, s).HRESIMS (+): 454.18220 (calcd for C₂₄H₂₅FN₃O₅, 454.17782). 56

¹H-NMR (400 MHz, DMSO-d₆) δ 1.61-1.74 (1H, m), 1.85-1.97 (3H, m),2.38-2.56 (6H, m), 2.74 (2H, t, J = 7.3 Hz), 3.37-3.45 (2H, m),4.18-4.36 (2H, m), 5.92 (1H, t, J = 5.5 Hz), 6.99 (2H, brs), 7.18 (1H,dd, J = 6.7, 4.9 Hz), 7.23 (1H, d, J = 7.9 Hz), 7.67 (1H, td, J = 7.9,1.8 Hz), 8.26 (1H, s), 8.45 (1H, dd, J = 4.9, 1.8 Hz), 15.21 (1H, brs).HRESIMS (+): 453.19699 (Calcd for C₂₄H₂₆FN₄O₄, 453.19381) 57

¹H-NMR (400 MHz, DMSO-d₆) δ 1.02 (3H, t, J = 7.3 Hz), 1.60-1.81 (3H, m),1.83-1.98 (1H, m), 2.35-2.64 (6H, m), 3.23-3.37 (4H, m), 3.80-3.50 (2H,m), 4.20-4.32 (2H, m), 5.90-6.00 (1H, m), 6.50 (1H, t, J = 7.3 Hz), 6.56(2H, d, J = 8.6 Hz), 7.00 (2H, brs), 7.05 (2H, t, J = 8.6 Hz), 8.27(1H,s), 15.22 (1H, s). HRESIMS (+): 495.24079 (Calcd for C₂₇H₃₂FN₄O₅,495.24076). 58

¹H-NMR (400 MHz, DMSO-d₆) δ 1.57-1.71 (1H, m), 1.80-1.94 (1H, m),2.28-2.61 (6H, m), 3.47-3.55 (2H, m), 3.55-3.62 (2H, m), 4.12-4.30 (2H,m), 5.94 (1H, t, J = 6.1 Hz), 6.97 (2H, brs), 7.55-7.60 (1H, m),7.92-8.02 (2H, m), 8.25 (1H, s), 8.59-8.64 (1H, m), 8.90 (1H, t, J = 6.1Hz), 15.20 (1H, s). HRESIMS (+): 482.18452 (Calcd for C₂₄H₂₅FN₅O₅,482.18397). 59

¹H-NMR (400 MHz, DMSO-d₆) δ 1.60-1.72 (1H, m), 1.73-1.87 (2H, m),1.90-2.00 (1H, m), 2.33-2.69 (8H, m), 3.35-3.41 (2H, m), 4.15-4.35 (2H,m), 5.84 (1H, brs), 6.98 (2H, brs), 7.07 (2H, t, J = 8.6 Hz), 7.20 (2H,dd, J = 8.6, 6.1 Hz), 8.26 (1H, s), 15.22 (1H, s). HRESIMS (+):470.18822 (Calcd for C₂₅H₂₆F₂N₃O₄, 470.18822). 60

¹H-NMR (400 MHz, DMSO-d₆) δ 1.61-1.74 (1H, m), 1.86-2.01 (3H, m),2.38-2.46 (4H, m), 2.51-2.58 (2H, m), 3.27-3.37 (2H, m), 4.00 (2H, t, J= 7.3 Hz), 4.17-4.35 (2H, m), 5.86-5.94 (1H, m), 6.87 (1H, s), 6.99 (2H,brs). 7.16 (1H, s), 7.61 (1H, s), 8.27 (1H, s), 15.20 (1H, s). HRESIMS(+): 442.19136 (Calcd for C₂₂H₂₅FN₅O₄, 442.18906). 61

¹H-NMR (400 MHz, DMSO-d₆) δ 1.58-1.71 (1H, m), 1.78-1.93 (3H, m),2.31-2.42 (4H, m), 3.31-3.63 (4H, m), 4.13-4.30 (2H, m), 5.88-6.02 (2H,m), 7.00 (2H, brs). 7.59-7.74 (1H, m), 7.93 (1H, d, J = 9.2 Hz),8.01-8.09 (1H, m), 8.25 (1H, s), 15.19 (1H, s). HRESIMS (+): 514.18612(Calcd for C₂₃H₂₅FN₇O₆, 514.18503). 62

¹H-NMR (400 MHz, DMSO-d₆) δ 1.59-1.73 (1H, m), 1.82-1.98 (1H, m),2.01-2.14 (1H, m), 2.16-2.28 (1H, m), 2.42-2.56 (6H, m), 3.37-3.54 (3H,m), 3.65 (1H, dd J = 10.4, 6.1 Hz), 4.17-4.35 (2H, m), 4.51-4.63 (1H,m), 5.50 (1H, d, J = 7.3 Hz), 6.43 (1H, d, J = 8.6 Hz), 6.53 (1H, dd, J= 7.3, 4.9 Hz), 7.06 (2H, brs), 7.43-7.49 (1H, m), 8.03 (1H, dd, J =4.9, 1.2 Hz), 8.28 (1H,s), 15.15 (1H,s). HRESIMS (+): 480.20444 (Calcdfor C₂₅H₂₇FN₅O₄, 480.20471).

Example No. R^(b)—X³— Data 63

¹H-NMR (400 MHz, CDCl₃) δ 0.58-0.62 (1H, m), 1.08-1.14 (1H, m),1.35-1.44 (1H, m), 1.81-1.92 (2H, m), 1.95-2.10 (6H, m), 2.89 (1H, dd, J= 14.7, 9.2 Hz), 3.00-3.10 (2H, m), 4.03 (2H, s), 6.26 (2H, brs), 6.44(1H, brs), 7.15 (1H, dd, J = 7.3, 4.9 Hz), 7.21 (1H, d, J = 7.3 Hz),7.62 (1H, td, J = 7.3, 1.8 Hz), 8.51 (1H, s), 8.54 (1H, d, J = 4.3 Hz),15.36 (1H, s). HRESIMS (+): 465.19382 (calcd for C₂₅H₂₅FN₄O₄,465.19381). 64

¹H-NMR (400 MHz, CDCl₃) δ 0.81-0.90 (2H, m), 1.41-1.50 (1H, m),1.80-1.92 (2H, m), 1.95-2.09 (6H, m), 2.62 (1H, dd, J = 14.7, 8.6 Hz),2.87-2.95 (1H, m), 3.10 (1H, dd, J = 14.7, 5.5 Hz), 3.99 (2H, s),4.65-4.71 (1H, m), 6.27 (2H, brs), 7.15 (1H, dd, J = 6.7, 5.5 Hz), 7.22(1H, d, J = 7.9 Hz), 8.51 (1H, s), 8.55 (1H, d, J = 4.3 Hz), 15.24 (1H,s). HRESIMS (+): 465.19312 (calcd for C₂₅H₂₅FN₄O₄, 465.19381). 65

MS (EP) m/z: 452.0 (M⁺ + 1). (Calcd. For C₂₅H₂₆FN₃O₄, 451.19). 66

MS (EP) m/z: 454.0 (M⁺ + 1). (Calcd. For C₂₄H₂₄FN₃O₅, 453.17). 67

MS (EP) m/z: 496.0 (M⁺ + 1). (Calcd. For C₂₇H₃₀FN₃O₅, 495.22). 68

¹H-NMR (400 MHz, DMSO-d₆) δ 1.76-1.84 (4H, m), 1.89-1.99 (4H, m),3.48-3.56 (2H, m), 3.60-3.68 (2H, m), 4.10 (2H, s), 5.92-5.99 (1H, m),6.88 (2H, brs), 7.54-7.59 (1H, m), 7.92-8.01 (2H, m), 8.34 (1H, s), 8.61(1H, dd, J = 4.9, 1.2 Hz), 8.90 (1H, t, J = 5.5 Hz), 1.525 (1H, s).HRESIMS (+): 482.18487 (Calcd for C₂₄H₂₅FN₅O₅, 482.18397). 69

MS (EP) m/z: 482 (M⁺ + 1). (Calcd. For C₂₆H₂₈FN₃O₅, 481.20) 70

MS (EP) m/z: 492.0 (M⁺ + 1). (Calcd. For C₂₆H₂₆FN₅O₄, 491.20). 71

MS (EP) m/z: 507.1 (M⁺ + 1). (Calcd. For C₂₈H₃₁FN₄O₄, 506.23). 72

MS (EP) m/z: 572.0 (M⁺ + 1). (Calcd. For C₃₂H₃₀ClFN₃O₆, 571.21). 73

¹H-NMR (400 MHz, DMSO-d₆) δ 1.75-1.86 (4H, m), 1.90-2.03 (4H, m),2.07-2.19 (1H, m), 2.20-2.31 (1H, m), 3.38-3.48 (2H, m), 3.49-3.58 (1H,m), 3.64-3.72 (1H, m), 4.14 (2H, s), 4.59-4.65 (1H, m), 5.61 (1H, d, J =7.9 Hz), 6.44 (1H, d, J = 8.6 Hz), 6.53 (1H, dd, J = 6.1, 4.9 Hz), 6.92(2H, brs), 7.43-7.49 (1H, m), 8.04 (1H, dd, J = 4.9, 1.2 Hz), 8.37 (1H,s). HRESIMS (+): 480.30794 (Calcd for C₂₅H₂₇FN₅O₄, 480.20471). 74

MS (ESP) m/z: 502.0 (M⁺ + 1). (Calcd. For C₂₅H₂₅ClFN₃O₅, 501.15). 75

MS (EP) m/z: 530.0 (M⁺ + 1). (Calcd. For C₃₀H₂₈FN₃O₅, 529.20). 76

MS (EP) m/z: 510.0 (M⁺ + 1). (Calcd. For C₂₅H₂₄FN₅O₄S, 509.15). 77

¹H-NMR (400 MHz, DMSO-d₆) δ 1.60-1.90 (6H, m), 1.93-2.05 (4H, m),2.10-2.35 (4H, m), 4.19 (2H, s), 4.50-4.60 (1H, m), 4.76 (1H, qui, J =7.3 Hz), 5.61 (1H, d, J = 6.1 Hz), 6.89 (1H, s), 6.94 (2H, brs), 7.24(1H, s), 7.69 (1H, s), 15.23 (1H, s). HRESIMS (+): 468.20413 (Calcd forC₂₄H₂₇FN₅O₄, 468.20471). 78

¹H-NMR (400 MHz, DMSO-d₆) δ 1.60-1.90 (6H, m), 1.96-2.23 (8H, m), 3.44(1H, qui, J = 7.9 Hz), 4.16 (2H, s), 4.52-4.60 (1H, m), 5.43 (1H, d, J =6.7 Hz), 6.94 (2H, brs), 7.17 (1H, dd, J = 6.7, 4.9 Hz), 7.26 (1H, d, J= 7.3 Hz), 7.67 (1H, td, J = 7.3, 1.2 Hz), 8.36 (1H, s), 8.49 (1H, d, J= 3.7 Hz), 15.26 (1H, s). HRESIMS (+): 479.21004 (Calcd for C₂₆H₂₈FN₄O₄,479.20940). 79

¹H-NMR (400 MHz, DMSO-d₆) δ 1.65-1.70 (1H, m), 1.73-2.05 (11H, m),2.06-2.18 (1H, m), 2.30-2.40 (1H, m), 3.36-3.50 (1H, m), 4.17 (1H, d, J= 11.6 Hz), 4.22 (1H, d, J = 11.6 Hz), 4.52-4.55 (1H, m), 6.84-7.05 (3H,m), 7.23 (1H, dd, J = 7.3, 5.5 Hz), 7.31 (1H, d, J = 7.3 Hz), 7.71 (1H,t, J = 7.3 Hz), 8.35 (1H, s), 8.59 (1H, d, J = 4.3 Hz), 15.30 (1H, s).HRESIMS (+): 479.20996 (Calcd for C₂₆H₂₈FN₄O₄, 479.20940). 80

¹H-NMR (400 MHz, DMSO-d₆) δ 1.75-2.05 (10H, m), 2.64 (2H, t, J = 7.6Hz), 3.39-3.49 (2H, m), 4.11 (2H, s), 5.91-6.01 (1H, m), 6.90 (1H, brs),7.22 (2H, d, J = 5.5 Hz), 8.35 (1H, s), 8.43 (1H, d, J = 5.5 Hz), 15.3(1H, s). HRESIMS (+): 453.19373 (calcd for C₂₄H₂₆FN₄O₄, 453.19381). 81

¹H-NMR (400 MHz, DMSO-d₆) δ 1.74-2.06 (10H, m), 2.87 (2H, t, J = 7.6Hz), 3.48-3.51 (2H, m), 4.12 (2H, s), 5.97 (1H, brs), 6.90 (1H, brs),8.19 (1H, dd, J = 7.9, 1.8 Hz), 8.35 (1H, s), 8.90 (1H, d, J = 1.2 Hz),15.3 (1H, s). HRESIMS (+): 478.18896 (calcd for C₂₅H₂₅FN₅O₄, 478.18906).

Example 829′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ej][1,5]benzoxazepine]

A mixture of9′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)-ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylicacid (300 mg, 0.662 mmol) and sodium cyanide (325 mg, 6.63 mmol) inanhydrous DMSO (6 mL) was stirred at 120° C. for 3 hours. After cooling,the reaction mixture was poured into water (100 mL) and extracted withEtOAc. The extraction mixture was washed with water and brine, driedover Na₂SO₄, and concentrated in vacuo. The residue was purified bycolumn chromatography (Chromatorex NH-DM2035 (Fuji Sylysia Chemical Co.,Ltd.) EtOAc) to give the title compound (197 mg, 72%) as a yellow solid.¹H-NMR (400 MHz, DMSO-d₆) δ 1.60-1.72 (1H, m), 1.80-1.93 (1H, m),2.28-2.44 (6H, m), 3.39 (2H, q, J=5.5 Hz), 3.45-3.53 (2H, m), 4.10-4.19(2H, m), 5.55 (1H, td, J=6.1, 2.4 Hz), 5.64 (1H, d, J=7.9 Hz), 6.42-6.47(2H, m), 6.61 (1H, t, J=5.5 Hz), 7.01 (2H, brs), 7.31-7.36 (1H, m), 7.44(1H, d, J=7.9 Hz), 7.94 (1H, dd, J=4.9, 1.2 Hz). HRESIMS (+): 410.19901(calcd for C₂₂H₂₅FN₅O₂, 410.19923).

Examples 83-85

The following compounds were prepared in the same manner that9′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]was prepared above. The compounds were prepared according to theprocedure of example 82:

Example No. R^(b)—X³— m n Data 83

1 2 ¹H-NMR (400 MHz, DMSO-d₆) δ 1.59-1.73 (1H, m), 1.81-1.93 (3H, m),2.28-2.45 (6H, m), 2.73 (2H, t, J = 7.3 Hz), 4.16-4.25 (2H, m), 5.27(1H, td, J = 6.7, 2.4 Hz), 5.64 (1H, d, J = 7.3 Hz), 7.00 (2H, brs),7.17 (1H, dd, J = 4.9, 4.9 Hz), 7.21 (1H, d, J = 7.3 Hz), 7.44 (1H, d, J= 7.3 Hz), 7.66 (1H, td, J = 7.3, 1.8 Hz), 8.45 (1H, dd, J = 4.9, 1.8Hz). HRESIMS (+): 409.20524 (Cacld for C₂₃H₂₆FN₄O₂, 409.203988). 84

1 2 ¹H-NMR (400 MHz, DMSO-d₆) δ 1.63-1.74 (1H, m), 1.83-1.97 (3H, m),2.29-2.45 (6H, m), 3.24-3.35 (2H, m), 3.99 (2H, t, J = 6.7 Hz),4.16-4.26 (2H, m), 5.23-5.30 (1H, m), 5.65 (1H, d, J = 7.9 Hz), 6.86(1H, d, J = 1.2 Hz), 7.01 (2H, brs), 7.14 (1H, t, J = 1.2 Hz), 7.45 (1H,d, J = 7.9 Hz), 7.50 (1H, s). HRESIMS (+): 398.20165 (Calcd forC₂₁H₂₅FN₅O₂, 398.19923). 85

2 1 ¹H-NMR (400 MHz, CDCl₃) δ 1.78-2.00 (8H, m), 2.02-2.09 (2H, m), 2.89(2H, t, J = 7.3 Hz), 3.42-3.60 (2H, m), 3.94 (2H, s), 4.38 (1H, brs),5.93 (1H, d, J = 7.3 Hz), 6.39 (2H, brs), 7.12 (1H, dd, J = 7.3, 4.9Hz), 7.15-7.19 (1H, m), 7.31(1H, d, J = 7.3 Hz), 7.59 (1H, td, J = 7.9,1.2 Hz), 8.53 (1H, d, J = 4.3 Hz). HRESIMS (+): 409.20371 (calcd forC₂₃H25FN₄O₂, 409.20398).

Example 869′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridyl-amino)-ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxamide

Triethylamine (0.14 mL, 1.00 mmol) and ethyl chloroformate (0.076 mL,0.795 mmol) were added to a solution of9′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)-ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylicacid (300 mg, 0.662 mmol) in DMF (5 mL) at 0° C. After stirring at 0° C.for 1.5 hours, 25% aqueous NH₃ (5 mL) was added. The mixture was stirredat room temperature for 6 hours. The reaction mixture was poured intowater (200 mL) and extracted with EtOAc. The mixture was washed withwater and brine, dried over Na₂SO₄, and concentrated in vacuo. Theresidue was purified by column chromatography (CH₂Cl₂:MeOH 50:1) to givethe title compound (270 mg, 90%) as a yellow solid. ¹H-NMR (400 MHz,DMSO-d₆) δ 1.62-1.73 (1H, m), 1.90 (1H, q, J=9.2 Hz), 2.28-2.47 (6H, m),3.42 (2H, q, J=5.5 Hz), 3.49-3.57 (2H, m), 4.11-4.25 (2H, m), 5.85-5.89(1H, m), 6.42-6.49 (2H, m), 6.64 (1H, t, J=5.5 Hz), 7.08 (2H, brs), 7.26(1H, d, J=4.9 Hz), 7.31-7.37 (1H, m), 7.95 (1H, dd, J=4.9, 1.2 Hz), 8.26(1H, s), 9.13 (1H, d, J=4.9 Hz). HRESIMS (+): 453.20594 (calcd forC₂₃H₂₆FN₆O₃, 453.20504).

Example 87 8′-amino-9′-fluoro-7′-oxo-10′-[3-(2-pyridyl)propylamino]spiro[oxolane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxamide

The title compound was prepared from the compound of example 54according to the procedure of example 86. ¹H-NMR (400 MHz, DMSO-d₆)δ1.88-1.96 (2H, m), 2.18-2.25 (1H, m), 2.30-2.37 (1H, m), 2.76 (2H, t,J=7.3 Hz), 3.37-3.47 (2H, m), 3.72 (1H, d, J=10.4 Hz), 3.91-3.96 (1H,m), 4.05-4.12 (2H, m), 4.21 (1H, d, J=11.6 Hz), 4.29 (1H, d, J=11.6 Hz),5.62-5.69 (1H, m), 7.01 (2H, brs), 7.17 (1H, dd, J=6.7, 5.5 Hz), 7.23(1H, d, J=7.9 Hz), 7.33 (1H, d, J=4.3 Hz), 7.67 (1H, td, J=7.3, 1.8 Hz),8.45 (1H, d, J=4.3 Hz), 8.48 (1H, s), 9.18 (1H, d, J=4.9 Hz).

Example 889′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carbohydrazide

Triethylamine (0.185 mL, 1.33 mmol) and ethyl chloroformate (0.100 mL,1.04 mmol) were added to a solution of9′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridyl-amino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylicacid (400 mg, 0.882 mmol) in DMF (6 mL) at 0° C. After stirring at 0° C.for 1.5 hours, hydrazine monohydrate (4 mL) was added. The mixture wasstirred at room temperature for 6 hours. The reaction mixture was pouredinto water (100 mL) and the solid was collected by filtration and driedto give the title compound (369 mg, 89%) as a yellow solid. ¹H-NMR (400MHz, DMSO-d₆) δ 1.63-1.73 (1H, m), 1.83-1.97 (1H, m), 2.26-2.55 (6H, m),3.42 (2H, q, J=6.1 Hz), 3.49-3.57 (2H, m), 4.12-4.25 (2H, m), 4.47 (2H,d, J=4.3 Hz), 5.87 (1H, td, J=6.1, 1.8 Hz), 6.42-6.48 (2H, m), 6.64 (1H,t, J=5.5 Hz), 7.07 (2H, brs), 7.31-7.37 (1H, m), 7.95 (1H, dd, J=5.5,1.2 Hz), 8.23 (1H, s), 10.47 (1H, s). HRESIMS (+): 468.2143 (calcd forC₂₃H₂₇FN₇O₃, 468.2159).

Example 899′-amino-10′-fluoro-2′,3′-dihydro-8′oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4%[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carbohydroxamicAcid

Triethylamine (0.185 mL, 1.33 mmol) and ethyl chloroformate (0.100 mL,1.04 mmol) were added to a solution of9′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylicacid (400 mg, 0.882 mmol) in DMF (6 mL) at 0° C. After stirring at 0° C.for 1.5 hours, 50% aqueous NH₂OH (3 mL) was added. The mixture wasstirred at room temperature for 6 hours and poured into water (60 mL).The resulting solid was collected by filtration and dried.Recrystallization of the residue from MeOH gave the title compound (135mg, 33%) as a yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.62-1.73 (1H,m), 1.84-1.97 (1H, m), 2.28-2.56 (6H, m), 3.42 (2H, q, J=6.1 Hz),3.50-3.57 (2H, m), 4.12-4.26 (2H, m), 5.87-5.93 (1H, m), 6.42-6.48 (2H,m), 6.64 (1H, t, J=5.5 Hz), 7.05 (2H, brs), 7.32-7.36 (1H, m), 7.95 (1H,dd, J=4.9, 1.2 Hz), 8.22 (1H, s), 9.02 (1H, d, J=1.8 Hz), 11.54 (1H, d,J=1.8 Hz). HRESIMS (+): 469.2036 (calcd for C₂₃H₂₆FN₆O₄, 469.2000).

Example 909′-amino-10′-fluoro-2′,3′-dihydro-N-methyl-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4%[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxamide

Triethylamine (0.185 mL, 1.33 mmol) and ethyl chloroformate (0.100 mL,1.04 mmol) were added to a solution of9′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-d][1,5]benzoxazepine]-7′-carboxylicacid (400 mg, 0.882 mmol) in DMF (6 mL) at 0° C. After stirring at 0° C.for 1.5 hours, 2 M methylamine in THF (4 mL) was added. The mixture wasstirred at room temperature for 6 hours. The reaction mixture was pouredinto water (60 mL) and extracted with EtOAc. The extraction mixture waswashed with water and brine, dried over Na₂SO₄, and concentrated invacuo. The residue was purified by column chromatography (CH₂Cl₂:MeOH20:1) to give the title compound (370 mg, 90%) as a yellow solid. ¹H-NMR(400 MHz, DMSO-d₆) δ 1.62-1.73 (1H, m), 1.84-1.97 (1H, m), 2.28-2.48(6H, m), 3.41 (3H, d, J=4.9 Hz), 2.79 (2H, q, J=5.5 Hz), 3.49-3.56 (2H,m), 4.12-4.24 (2H, m), 5.85 (1H, td, J=5.5, 2.4 Hz), 6.42-6.48 (2H, m),6.61-6.66 (1H, m), 7.07 (2H, brs), 7.31-7.36 (1H, m), 7.94 (1H, dd,J=4.9, 1.8 Hz), 8.25 (1H, s), 9.64 (1H, q, J=4.9 Hz). HRESIMS (+):467.2182 (calcd for C₂₃H₂₈FN₆O₃, 467.2207).

Example 919′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-d][1,5]benzoxazepine]-7′-carbonitrile91A) Preparation of9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxamide

Triethylamine (2.50 mL, 17.9 mmol) and ethyl chloroformate (1.36 mL,14.2 mmol) were added to a suspension of9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylicacid (4.00 g, 11.9 mmol) in DMF (200 mL). After stirring at 0° C. for 2hours, 25% aqueous NH₃ (7 mL) was added and the mixture was stirred atroom temperature for 3 hours. The reaction mixture was poured into water(1.5 L) and the resulting precipitate was collected by filtration,washed with water and dried to give the title compound (3.23 g, 81%) asa brown solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.64-1.76 (1H, m), 1.87-2.00(1H, m), 2.35-2.48 (4H, m), 2.53-2.64 (2H, m), 4.30-4.42 (2H, m),7.33-7.68 (3H, m), 8.44 (1H, s), 8.94 (1H, d, J=4.3 Hz). ESIMS (+): 336[M+H]⁺.

91B) Preparation of9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carbonitrile

Triethylamine (4.38 mL, 31.4 mmol) and a solution of trifluoroaceticanhydride (2.68 mL, 19.3 mmol) in CH₂Cl₂ (30 mL) were added to asuspension of9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-d][1,5]benzoxazepine]-7′-carboxamide (1.70 g, 5.06 mmol) in CH₂Cl₂ (120 mL)at 0° C. After stirring at 0° C. for 1 hour, the reaction mixture waswashed with water, saturated aqueous NaHCO₃ and brine, dried overNa₂SO₄, and concentrated in vacuo. The residue was purified by columnchromatography (Chromatorex NH-DM2035 (Fuji Sylysia Chemical Co., Ltd.)Hexane:CH₂Cl₂ 1:1) to give the title compound (1.12 g, 70%) as acolorless solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.62-1.73 (1H, m),1.83-1.96 (1H, m), 2.35-2.57 (6H, m), 4.32-4.42 (2H, m), 7.48 (2H, brs),8.41 (1H, s). ESIMS (+): 318 [M+H]⁺.

91C) Preparation of9′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carbonitrile

A mixture of9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carbonitrile(830 mg, 2.62 mmol), N-(2-pyridyl)-1,2-ethanediamine (718 mg, 5.23 mmol)and triethylamine (0.730 mL, 0.330 mmol) in anhydrous DMSO (16 mL) wasstirred at 60° C. for 10 hours. After cooling, the reaction mixture waspoured into ice-water (150 mL). The resulting precipitate was collectedby filtration, washed with water and dried. The obtained solid waspurified by column chromatography (Chromatorex NH-DM2035 (Fuji SylysiaChemical Co., Ltd.) Hexane:CH₂Cl₂ 1:2→CH₂Cl₂→CH₂Cl₂:MeOH 100:1) to givethe title compound (860 mg) as a brown solid. The solid was purifiedagain by column chromatography (CH₂Cl₂:MeOH 30:1) to give the titlecompound (500 mg, 44%) as a yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ1.58-1.72 (1H, m), 1.80-1.92 (1H, m), 2.30-2.47 (6H, m), 3.41 (2H, q,J=6.1 Hz), 3.48-3.56 (2H, m), 4.13-4.24 (2H, m), 5.93-6.01 (1H, m),6.42-6.48 (2H, m), 6.65 (1H, t, J=6.1 Hz), 7.05 (2H, brs), 7.31-7.37(1H, m), 7.94 (1H, dd, J=4.9, 1.2 Hz), 8.16 (1H, s). HRESIMS (+):435.19403 (calcd for C₂₃H₂₄FN₆O₂, 435.19443).

Example 92 8′-amino-9′-fluoro-7′-oxo-10′-[3-(2-pyridyl)propylamino]spiro[oxolane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carbonitrile

A mixture of8′-amino-9′-difluoro-7′-oxo-10′-[3-(2-pyridyl)propylamino]-spiro[oxolane-1,3′(2′H)-[4H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxamide(165 mg, 0.364 mmol), POCl₃ (167 mg, 1.09 mmol) and triethylamine (0.254mL, 1.82 mmol) in CH₂Cl₂ (2 mL) was stirred at room temperature for 10h. To the reaction mixture, saturated aqueaous NaHCO₃ was added to pH>7and extracted with AcOEt. The organic layer was wash with brine anddried over MgSO4, and the solvent was removed in vacuo. The crudeproduct was purified by column chromatography (Hexane:EtOAc1:1→EtOAc→EtOAc:MeOH 10:1) to yield8′-amino-9′-fluoro-7′-oxo-10′-[3-(2-pyridyl)-propylamino]spiro[oxolane-1,3′(2′G)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carbonitrile(42.4 mg, 27%) as a pale yellow solid. ¹H-NMR (400 MHz, DMSO-d₆)81.88-1.95 (2H, m), 2.17-2.25 (1H, m), 2.35-2.42 (1H, m), 2.75 (2H, t,J=7.3 Hz), 3.38-3.46 (2H, m), 3.70 (1H, d, J=10.4 Hz), 3.89 (1H, td,J=8.6, 5.5 Hz), 3.97 (1H, d, J=10.4 Hz), 4.13-4.19 (1H, m), 4.22 (1H, d,J=11.6 Hz), 4.24 (1H, d, J=11.6 Hz), 5.73-5.80 (1H, m), 6.99 (2H, brs),7.18 (1H, dd, J=6.7, 5.5 Hz), 7.23 (1H, d, J=7.9 Hz), 7.67 (1H, td,J=7.3, 1.8 Hz), 8.23 (1H, s), 8.45 (1H, d, J=4.3 Hz). HRESIMS (+)436.17877 (Calcd for C₂₃H₂₂FN₅O₃, 436.17849).

Example 939′-amino-10′-fluoro-2′,3′-dihydro-8′-oxo-11′-[3-(1-imidazolyl)propylamino]spiro-[cyclobutane-1,4%[4H,8H]pyrido-[1,2,3-ef][1,5]benzoxazepine]-7′-carbonitrile

The title compound was prepared from9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carbonitrileusing synthetic procedures similar to those described in the examplesabove. ¹H-NMR (400 MHz, CDCl₃) δ 1.80-2.04 (2H, m), 2.06-2.13 (1H, m),2.38-2.55 (6H, m), 3.44 (2H, dq, J=2.4, 6.7 Hz), 4.06 (2H, t, J=6.7 Hz),4.31-4.40 (2H, m), 4.46 (1H, td, J=6.7, 1.8 Hz), 6.50 (2H, brs), 6.93(1H, t, J=1.2 Hz), 7.09 (1H, t, J=1.2 Hz), 7.49 (1H, s), 7.65 (1H, s).HRESIMS (+): 423.19445 (calcd for C₂₃H₂₃FN₆O₂, 423.19448).

Example 949′-amino-10′-fluoro-2′,3′-dihydro-6′-methyl-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4%[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylicAcid 94A) Preparation of Ethyl10′,11′-difluoro-2′,3′,6′,7-tetrahydro-6′-methyl-9′-nitro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxaepine]-7′-carboxylate

3 M Methylmagnesium chloride in THF (10.8 mL, 32.4 mmol) was added underargon atmosphere to a stirred mixture of ethyl10′,11′-difluoro-2′,3′-dihydro-9′-nitro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylate(3.88 g, 9.84 mmol) and cuprous iodide (562 mg, 2.95 mmol) in THF (200mL) at −78° C. The reaction mixture was stirred at room temperature for24 hours, poured into water (1 L). Concentrated HCl (50 mL) was added topH<1 and the mixture stirred for 30 minutes. The crude product wasextracted with AcOEt, washed with saturated aqueous NaHCO₃ and brine,dried over MgSO₄ and the solvent was removed in vacuo. The crude productwas purified by column chromatography (Hexane:EtOAc 20:1→5:1) to yieldthe title compound (1.71 g, 42%) as a yellow solid. ¹H-NMR (400 MHz,DMSO-d₆) δ 1.09 (3H, d, J=6.1 Hz), 1.27 (3H, t, J=7.3 Hz), 1.60-1.69(1H, m), 1.72-1.83 (1H, m), 1.94-2.15 (4H, m), 2.24-2.35 (1H, m),2.51-2.57 (1H, m), 4.28 (2H, q, J=7.3 Hz), 4.39-4.50 (2H, m), 4.58-4.63(1H, m), 11.64 (1H, s).

94B) Preparation of Ethyl10′,11′-difluoro-2′,3′-dihydro-6′-methyl-9′-nitro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-d][1,5]benzoxazepine]-7′-carboxylate

A mixture of ethyl10′,11′-difluoro-2′,3′,6′,7′-tetrahydro-6′-methyl-9′-nitro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylate(1.50 g, 3.66 mmol) and manganese dioxide (32.0 g, 366 mmol) in CH₂Cl₂(40 mL) was stirred at room temperature for 40 hours. The mixture wasfiltered through Celite and the filtrate concentrated in vacuo. Thecrude product was purified by column chromatography (Hexane:EtOAc2:1→1:2) to yield the title compound (168 mg, 11%) as a pale yellowsolid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.25 (3H, t, J=7.3 Hz), 1.59-1.67(1H, m), 1.81-1.88 (1H, m), 2.08-2.18 (1H, m), 2.27 (3H, s), 2.34-2.54(4H, m), 2.80-2.92 (1H, m), 4.20-4.27 (2H, m), 4.63-4.83 (2H, m).

94C) Preparation of Ethyl9′-amino-10′,11′-difluoro-2′,3′-dihydro-6′-methyl-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylate

A mixture of ethyl10′,11′-difluoro-2′,3′-dihydro-6′-methyl-9′-nitro-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylate(160 mg, 0.392 mmol) and iron (146 mg, 2.35 mmol) in AcOH (4 mL) wasstirred at 90° C. for 3 hours. The reaction mixture was concentrated invacuo and 1 M aqueous HCl was added. The crude product was extractedwith AcOEt, washed successively with saturated aqueous NaHCO₃ and brine,dried over MgSO₄ and the solvent was removed in vacuo. The residue wasdried to yield the title compound (146 mg, 98%) as a yellow amorphoussolid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.24 (3H, t, J=7.3 Hz), 1.58-1.65(1H, m), 1.75-1.87 (1H, m), 1.93-2.05 (1H, m), 2.16 (3H, s), 2.22-2.34(2H, m), 2.37-2.46 (1H, m), 2.51-2.60 (1H, m), 2.68-2.80 (1H, m),4.18-4.24 (2H, m), 4.26-4.36 (1H, m), 4.53-4.64 (1H, m), 7.23 (2H, brs).

94D) Preparation of9′-amino-10′,11′-difluoro-2′,3′-dihydro-6′-methyl-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylicAcid

A mixture of ethyl9′-amino-10′,11′-difluoro-2′,3′-dihydro-6′-methyl-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylate(136 mg, 0.359 mmol) and 1M aq. NaOH (1.4 mL) in EtOH (1.4 mL) wasstirred at reflux for 5 hours. The reaction mixture was concentrated invacuo, the residue dissolved in water, and 2M aq. HCl was added to pH<3.The resulting precipitate was collected by filtration in vacuo, washedwith water and dried to yield the title compound (110 mg, 87%) as ayellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.53-1.61 (1H, m), 1.77-1.85(1H, m), 1.97-2.05 (1H, m), 2.28-2.40 (3H, m), 2.52-2.58 (1H, m), 2.60(3H, s), 2.76-2.84 (1H, m), 4.38 (1H, td, J=12.2, 4.3 Hz), 4.62 (1H, dd,J=12.2, 6.7 Hz), 7.27 (2H, brs), 15.18 (1H, brs).

94E) Preparation of 9′-amino-10′-fluoro-2′,3′-dihydro-6′-methyl-8%oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4%[4H,8H]pyrido[1,2,3-ej][1,5]benzoxazepine]-7′-carboxylic Acid

A solution of9′-amino-10′,11′-difluoro-2′,3′-dihydro-6′-methyl-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylicacid (100 mg, 0.285 mmol), N-(2-pyridyl)-1,2-ethanediamine (58.7 mg,0.428 mmol) and triethylamine (0.0597 mL, 0.428 mmol) in DMSO (3 mL) wasstirred at 100° C. for 5 h. After the reaction mixture was poured intosaturated aq. NH₄Cl, the crude product was extracted with CH₂Cl₂, washedwith brine, dried over MgSO₄ and the solvent was removed in vacuo. Thecrude product was purified by preparative thin layer chromatography(EtOAc: MeOH 20:1) to yield the title compound (70.3 mg, 53%) as ayellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.49-1.59 (1H, m), 1.72-1.79(1H, m), 1.85-1.92 (1H, m), 2.23-2.32 (2H, m), 2.37-2.45 (2H, m), 2.57(3H, s), 2.66-2.75 (1H, m), 3.40-3.47 (2H, m), 3.51-3.62 (2H, m), 4.19(1H, td, J=12.2, 3.7 Hz), 4.49 (1H, dd, J=12.2, 6.7 Hz), 6.10-6.16 (1H,m), 6.43-6.49 (2H, m), 6.64-6.70 (1H, m), 6.88 (2H, brs), 7.34 (1H, t,J=6.7 Hz), 7.95-7.96 (1H, m), 16.08 (1H, brs). HRESIMS (+): 468.20454(Calcd for C₂₄H₂₆FN₅O₄, 468.2047).

Example 959′-amino-10′-chloro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylicacid 95A) Preparation of Ethyl10′-amino-11′-fluoro-2′,3′-dihydro-9′-nitro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7%carboxylate

A mixture of ethyl10′,11′-difluoro-2′,3′-dihydro-9′-nitro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylate(5.00 g, 12.7 mmol) and (NH₄)₂CO₃ (11.0 g, 114 mmol) in DMF (50 mL) wasstirred at 90° C. for 21 hours. The reaction mixture was poured intowater, the resulting precipitate was collected by filtration in vacuo,washed successively with hot AcOEt and hot EtOH and dried to yield thetitle compound (2.51 g, 50%) as a yellow solid. ¹H-NMR (400 MHz,DMSO-d₆) δ 1.24 (3H, t, J=7.3 Hz), 1.65-1.76 (1H, m), 1.88-2.00 (1H, m),2.41-2.46 (4H, m), 2.60-2.63 (2H, m), 4.19 (2H, q, J=7.3 Hz), 4.47-4.50(2H, m), 6.07 (2H, brs), 8.26 (1H, s).

95B) Preparation of Ethyl10′-chloro-11′-fluoro-2′3,-dihydro-9′-nitro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylate

Ethyl10′-amino-11′-fluoro-2′,3′-dihydro-9′-nitro-8′-oxospiro[cyclobutane-1,4′-[4H,81-1]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylate(2.51 g, 6.41 mmol) was added to a mixture of tert-butyl nitrite (1.14mL, 9.62 mmol) and copper (II) chloride (1.81 g, 12.8 mmol) in CH₃CN (64mL), and the mixture was stirred at room temperature for 20 hours. Thereaction mixture was poured into water (300 mL), concentrated HCl (50mL) was added to pH<1, and resulting precipitate was collected byfiltration, washed with hot EtOH and dried to yield the title compound(2.17 g, 82%) as a pale yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.25(3H, t, J=7.3 Hz), 1.67-1.75 (1H, m), 1.92-1.99 (1H, m), 2.41-2.53 (4H,m), 2.66-2.69 (2H, m), 4.22 (2H, q, J=7.3 Hz), 4.60-4.63 (2H, m), 8.42(1H, s).

95C) Preparation of Ethyl9′-amino-10′-chloro-11′-fluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]7′-carboxylate

A mixture of ethyl10′-chloro-11′-fluoro-2′,3′-dihydro-9′-nitro-8′-oxospiro-[cyclobutane-1,4′-[4H,8]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylate(2.17 g, 5.28 mmol) and iron (1.97 g, 31.7 mmol) in AcOH (50 mL) wasstirred at 90° C. for 5 hours. The reaction mixture was concentrated invacuo, the residue was dissolved in AcOEt and stirred for 30 minutes.The resulting precipitate was removed by filtration through Celite. Thefiltrate was washed successively with water, saturated aqueous NaHCO₃and brine, dried over MgSO₄, and the solvent was removed in vacuo. Thecrude product was washed with hot EtOH to yield the title compound (1.03g, 51%) as a pale yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.25 (3H, t,J=7.3 Hz), 1.65-1.75 (1H, m), 1.89-1.96 (1H, m), 2.38-2.47 (4H, m),2.52-2.59 (2H, m), 4.20 (2H, q, J=7.3 Hz), 4.30-4.41 (2H, m), 7.33-7.55(2H, m), 8.23 (1H, s).

95D) Preparation of9′-amino-10′-chloro-11′-fluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylicacid

A solution of ethyl9′-amino-10′-chloro-11′-fluoro-2′,3′-dihydro-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-d][1,5]benzoxazepine]-7′-carboxylate(1.03 g, 2.70 mmol) in a mixture of AcOH—H₂O—H₂SO₄ (2:1:0.3 v/v, 6.6 mL)was heated at 100° C. for 2 hours. Ice-water was added and the mixturestirred for 30 minutes. The resulting precipitate was collected byfiltration in vacuo, washed with water and dried to yield the titlecompound (908 mg, 95%) as a colorless solid. ¹H-NMR (400 MHz, DMSO-d₆)δ1.65-1.74 (2H, m), 1.88-1.99 (2H, m), 2.40-2.69 (4H, m), 4.25-4.51 (2H,m), 7.73 (2H, brs), 8.49 (1H, s), 14.56 (1H, s).

95E) Preparation of9′-amino-10′-chloro-2′,3′-dihydro-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylicAcid

A solution of 9′-amino-10′-chloro-11′-fluoro-2′,3′-dihydro-8′-oxospiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,5]benzoxazepine]-7′-carboxylicacid (900 mg, 2.55 mmol), N-2-pyridinyl-1,2-ethanediamine (525 mg, 3.83mmol) and triethylamine (0.534 mL, 3.83 mmol) in DMSO (10 mL) wasstirred at 100° C. for 7 hours. Saturated aqueous NH₄Cl was added to thereaction mixture until pH<3, and the resulting precipitate was collectedby vacuum filtration and washed with water. The crude product waspurified by preparative thin layer chromatography (CH₂Cl₂: MeOH 50:1) toyield the title compound (565 mg, 47%) as a yellow solid. ¹H-NMR (400MHz, DMSO-d₆) δ 1.64-1.72 (1H, m), 1.86-1.98 (1H, m), 2.32-2.66 (6H, m),3.40-3.44 (2H, m), 3.62-3.66 (2H, m), 3.94-4.53 (2H, m), 6.00 (1H, t,J=5.5 Hz), 6.44-6.47 (2H, m), 6.66 (1H, t, J=5.5 Hz), 7.07-7.63 (3H, m),7.94 (1H, dd, J=5.5, 1.2 Hz), 8.29 (1H, s), 15.15 (1H, s). HRESIMS (+):470.15831 (Calcd for C₂₃H₂₄ClN₅O₄, 470.1595).

Examples 96-98

Compounds 96-98 may be prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]-quinoline-3,1′-cyclopentane]-6-carboxylicacid or9′-amino-10′,11′-difluoro-2′,3′-dihydro-8′-oxospiro-[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-ef][1,4]benzoxazepine]-7′-carboxylicacid using synthetic procedures similar to those described in theexamples above.

Example 9610-(3-(1H-imidazol-1-yl)propylamino)-8-amino-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carboxylicAcid

MS (EP) m/z: 442.0 (M+1). (Calcd. For C₂₂H₂₄FN₅O₄, 441.18).

Example 979-amino-10-fluoro-8-oxo-11-(3-(pyridin-2-ylamino)-pyrrolidin-1-yl)-3,8-dihydro-2H-spiro[[1,4]oxazepino[2,3,4-ij]quinoline-4,1′-cyclobutane]-7-carboxylicAcid

¹H-NMR (400 MHz, DMSO-d₆) δ 1.59-1.73 (1H, m), 1.81-1.97 (2H, m),2.05-2.19 (1H, m), 2.47-2.51 (6H, m), 3.42-3.53 (1H, m), 3.85-3.97 (3H,m), 4.11-4.29 (3H, m), 6.44-6.51 (2H, m), 6.75 (1H, d, J=6.1 Hz), 6.94(2H, brs), 7.32-7.39 (1H, m), 7.96 (1H, dd, J=6.1, 1.2 Hz), 8.26 (1H,s), 15.13 (1H, brs). HRESIMS (+): 480.20547 (Calcd for C₂₅H₂₇FN₅O₄,480.20471).

Example 988′-amino-9′-fluoro-7′-oxo-10′-(3-(pyridin-2-ylamino)pyrrolidin-1-yl)-2′,7′-dihydro-1′H-spiro[cyclopentane-1,3′-pyrido[3,2,1-ij]quinoline]-6′-carboxylicAcid

¹H-NMR (400 MHz, DMSO-d₆) δ 1.72-2.04 (9H, m), 2.08-2.19 (1H, m),3.50-3.58 (1H, m), 3.71-3.80 (1H, m), 3.81-3.90 (1H, m), 3.95-4.02 (1H,m), 4.08 (2H, s), 4.33-4.42 (1H, m), 6.44-6.51 (2H, m), 6.76 (1H, d,J=6.1 Hz), 6.88 (2H, brs), 7.32-7.38 (1H, m), 7.97 (2H, dd, J=4.9, 1.2Hz), 8.38 (1H, s), 15.19 (1H, s). HRESIMS (+):480.20378 (Calcd forC₂₅H₂₇FN₅O₄, 480.20471).

Example 999-amino-10-fluoro-6-methyl-11-(2-(pyridin-2-ylamino)-ethylamino)-2H-spiro[[1,4]oxazepino[2,3,4-ij]quinoline-4,1′-cyclobutan]-8(3H)-one

A mixture of9′-amino-10′-fluoro-2′,3′-dihydro-6′-methyl-8′-oxo-11′-[2-(2-pyridylamino)ethylamino]spiro[cyclobutane-1,4′-[4H,8H]pyrido[1,2,3-d][1,5]benzoxazepine]-7′-carboxylicacid (42.7 mg, 0.0913 mmol) and sodium cyanide (46.1 mg, 0.913 mmol) inanhydrous DMSO (2 mL) was stirred at 150° C. for 8 hours. After cooling,the reaction mixture was poured into saturated aqueous NaHCO₃ andextracted with EtOAc. The extraction mixture was washed with brine,dried over MgSO₄, and concentrated in vacuo. The residue was purified bypreparative TLC (Silica gel 60 (Merck Co., Ltd.) EtOAc: MeOH 10:1) togive the title compound (20.8 mg, 54%) as a yellow solid. ¹H-NMR (400MHz, DMSO-d₆) δ 1.52-1.60 (1H, m), 1.73-1.79 (1H, m), 2.10 (3H, s),3.27-3.33 (6H, m), 3.37-3.41 (2H, m), 3.43-3.51 (2H, m), 3.96-4.53 (2H,m), 5.41-5.47 (1H, m), 5.57 (1H, s), 6.42-6.47 (2H, m), 6.60 (1H, t,J=5.5 Hz), 6.84 (2H, brs), 7.33 (1H, dd, J=6.7, 1.8 Hz), 7.93-7.95 (1H,m). HRESIMS (+): 424.21446 (calcd for C₂₃H₂₆FN₅O₂, 424.21488).

Example: 1008′-amino-9′-fluoro-7′-oxo-10′-[3-(4,6-bistrifluoropyridin-2-yl)propylamino]spiro[oxolane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carbonitrile100A) Preparation of tert-butyl 3-(4,6-bistrifluoromethylpyridin-2-yl)propylcarbamate

To a stirred solution of tert-butyl allylcarbamate (1.95 g, 12.4 mmol)in THF (12 mL), 0.5 mol/L 9-borabicyclo[3.3.1]nonane (29.8 mL, 14.9mmol) was added under argon atmosphere at room temperature. Afterstirred at room temperature for 4 h, a solution of2-bromo-4,6-bistrifluoromethylpyridine (3.65 g, 12.4 mmol) in DMF (12mL), Pd(OAc)₂ (278 mg, 1.24 mmol), DPPF (859 mg, 1.55 mmol) and K₂CO₃(2.92 g, 21.1 mmol) were added to the reaction mixture and stirred atroom temperature for 7 h. To the reaction mixture, water was added andthe crude product was extracted with EtOAc, washed with brine, driedover NaSO₄ and the solvent was removed in vacuo. The crude product waspurified by column chromatography (Hexane:EtOAc 10:1→2:1) to yieldtert-butyl 3-(4,6-bistrifluoromethylpyridin-2-yl)propylcarbamate (3.41g, 74%) as a colorless solid. ¹H NMR (CDCl₃, 400 MHz) δ 1.44 (9H, s),1.96-2.03 (2H, m), 2.98-3.02 (2H, m), 3.20-3.25 (2H, m), 4.71 (1H, brs),7.59 (1H, s), 7.72 (1H, s). CIMS (+) 373 [M+H]⁺.

100B) Preparation of 3-(4,6-bistrifluoropyridin-2-yl)propylamine

A solution of tert-butyl3-(4,6-bistrifluoromethylpyridin-2-yl)propylcarbamate (3.10 g, 8.33mmol) in 4 mol/L hydrogen chloride in EtOAc (20 mL) was stirred at roomtemperature for 30 min. The solvent was removed in vacuo and to theprecipitate, 1 mol/L aq. NaOH was added to alkalify and the crudeproduct was extracted with EtOAc, washed with brine, dried over NaSO₄and the solvent was removed in vacuo. The precipitate was dried to yield3-(4,6-bistrifluoropyridin-2-yl)propylamine (2.26 g, quant.) as a yellowoil. ¹H NMR (DMSO-d₆, 400 MHz) δ 1.54 (2H, brs), 1.73-1.80 (2H, m), 2.56(2H, t, J=6.7 Hz), 2.96 (2H, t, J=7.9 Hz), 8.06 (1H, s), 8.09 (1H, s).CIMS (+) 273 [M+H]⁺.

100C) Preparation of8′-amino-9′,10-difluoro-7′-oxospiro[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxamide

A solution of8′-amino-9′-fluoro-7′-oxo-10′-[3-(pyridin-2-yl)propylamino]spiro[oxolane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxylicacid (1.00 g, 2.96 mmol), ethyl chloroformate (0.312 mL, 3.26 mmol) andtriethylamine (0.495 mL, 3.55 mmol) in DMF (15 mL) was stirred underargon atmosphere and ice-cooling for 2 h. To the reaction mixture, 25%aqueous NH₃ (1 mL) was added and stirred at room temperature for 2 h. Tothe reaction mixture, water was added and the crude product wasextracted with EtOAc, washed with brine, dried over NaSO₄ and thesolvent was removed in vacuo. The precipitate was dried to yield8′-amino-9′,10-difluoro-7′-oxospiro[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxamide(186 mg, 81%) as a pale yellow solid.

¹H NMR (DMSO-d₆, 400 MHz) δ 2.25-2.32 (1H, m), 2.35-2.42 (1H, m), 3.74(1H, d, J=11.0 Hz), 3.91-3.97 (1H, m), 4.06-4.12 (1H, m), 4.16 (1H, d,J=11.0 Hz), 4.34 (1H, d, J=11.6 Hz), 4.45 (1H, d, J=11.6 Hz), 7.41 (2H,brs), 7.54 (1H, d, J=4.3 Hz), 8.63 (1H, s), 8.98 (1H, d, J=4.3 Hz).

100D) Preparation of 8′-amino-9′,10-difluoro-7′-oxospiro[oxolane-3,3′(2′11)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carbonitrile

To a stirred solution of 8′-amino-9′,10-difluoro-7′-oxospiro[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carboxamide(860 mg, 2.55 mmol) and triethylamine (1.78 mL, 12.8 mmol) in CH₂Cl₂ (26mL), phosphoryl chloride (1.17 g, 7.65 mmol) was added under ice-coolingand stirred at room temperature for 5 h. The solvent was removed invacuo and to the crude product, MeOH—H₂O (1:2, 50 mL) was added. Afterstirred for 30 min, the resulting precipitate was collected byfiltration, washed with water and dried to yield8′-amino-9′,10-difluoro-7′-oxospiro[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carbonitrile(683 mg, 84%) as a pale yellow solid.

¹H NMR (DMSO-d₆, 400 MHz) δ 2.22-2.29 (1H, m), 2.42-2.46 (1H, m), 3.72(1H, d, J=10.4 Hz), 3.88 (1H, td, J=8.6, 6.1 Hz), 4.05 (1H, d, J=10.4Hz), 4.16-4.22 (1H, m), 4.37 (1H, d, J=11.6 Hz), 4.38 (1H, d, J=11.6Hz), 7.40 (2H, brs), 8.46 (1H, s).

100E) Preparation of8′-amino-9′-fluoro-7′-oxo-10′-[3-(4,6-bistrifluoropyridin-2-yl)propylamino]spiro[oxolane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carbonitrile

A solution of 8′-amino-9′,10-difluoro-7′-oxospiro[oxolane-3,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carbonitrile(320 mg, 1.00 mmol), 3-(4,6-bistrifluoromethylpyridine-2-yl)propylamine(408 mg, 1.50 mmol) and triethylamine (0.210 mL, 1.50 mmol) in DMSO (5mL) was stirred at 100° C. for 6 h then at 120° C. for 2 h. To thereaction mixture, saturated aqueous NH₄Cl was added to neutralize andthe crude product was extracted with EtOAc, washed with brine, driedover NaSO₄ and the solvent was removed in vacuo. The crude product waspurified by column chromatography (Hexane: EtOAc 5:1→1:1) to yield8′-amino-9′-fluoro-7′-oxo-10′-[3-(4,6-bistrifluoropyridin-2-yl)propylamino]spiro[oxolane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carbonitrile(387 mg, 68%) as a pale yellow solid.

¹H NMR (DMSO-d₆, 400 MHz) δ 1.95-2.02 (2H, m), 2.17-2.24 (1H, m),2.35-2.42 (1H, m), 2.99 (2H, t, J=7.6 Hz), 3.40-3.49 (2H, m), 3.69 (1H,d, J=10.4 Hz), 3.88 (1H, td, J=9.2, 5.5 Hz), 3.96 (1H, d, J=10.4 Hz),4.14-4.20 (1H, m), 4.21 (1H, d, J=11.0 Hz), 4.24 (1H, d, J=11.0 Hz),5.71-5.81 (1H, m), 6.97 (2H, brs), 8.07 (1H, s), 8.10 (1H, s), 8.24 (1H,s).

HRESIMS (+) 572.15292 (calcd for C₂₅H₂₁F₇N₅O₃).

Examples 101-108

By using the procedures set out above, the compounds of example 101 to108 were prepared:

Example No. R^(b)—X³— n R³ Data 101

3 COOH ¹H-NMR (DMSO-d₆, 400 MHz) δ 1.21 (3H, d, J = 6.1 Hz), 1.77-1.89(5H, m), 1.90-2.04 (5H, m), 2.80 (2H, t, J = 7.3 Hz), 3.95-4.06 (1H, m),4.12 (2H, s), 5.31 (1H, d, J = 9.2 Hz), 6.91 (2H, brs), 7.14-7.22 (2H,m), 7.65 (1H, td, J = 7.9, 1.8 Hz), 8.36 (1H, s) ,8.45 (1H, d, J = 4.3Hz), 15.26 (1H, s). HREIMS (+): 467.20949 (Calcd. for C₂₅H₂₇FN₄O₄,467.20946). 102

3 COOH ¹H-NMR (DMSO-d₆, 400 MHz) δ 1.75-2.05 (10H, m), 2.63 (2H, t, J =7.3 Hz), 3.39-3.49 (2H, m), 4.11 (2H, s), 5.91-6.01 (1H, m), 6.90 (2H,brs), 7.22 (2H, d, J = 5.5 Hz), 8.35 (1H, s), 8.43 (1H, d, J = 5.5 Hz),15.27 (1H, s). HRESIMS(+): 453.19373. (Calcd. for C₂₄H₂₅FN₄O₄,453.10381). 103

3 COOH ¹H-NMR (DMSO-d₆, 400 MHz) δ 1.74-2.06 (10H, m), 2.87 (2H, t, J =7.3 Hz), 3.48-3.51 (2H, m), 4.12(2H, s), 5.97 (1H, s), 6.90 (2H, s),7.50 (2H, d, J = 7.9 Hz), 8.35 (1H, dd, J = 7.9, 1.8 Hz), 8.35 (1H, s),8.90 (1H, d, J = 1.2 Hz), 15.28 (1H, s). HREIMS (+): 478.18896. (Calcd.for C₂₅H₂₅FN₅O₄, 478.18905). 104

3 COOH ¹H-NMR (400 MHz, DMSO-d₆) δ 1.55 (2H, quint, J = 7.3 Hz), 1.68(2H, quint, J = 7.3 Hz), 1.76-1.88 (4H, m), 1.90-2.06 (4H, m), 2.7 (2H,t, J = 7.3 Hz), 3.37-3.48 (2H, m), 4.12 (2H, s), 5.87-5.98 (1H, m), 6.90(2H, s), 7.15 (1H, dd, J = 7.0, 5.2 Hz), 7.21 (1H, d, J = 7.9 Hz), 7.65(1H, td, J = 7.5, 1.4 Hz), 8.34 (1H, s), 8.43 (1H, d, J = 4.3 Hz), 15.3(1H, s). HREIMS (+): 467.20952 (Calcd. for C₂₅H₂₇FN₄O₄, 467.20946). 105

1 COOH ¹H NMR (DMSO-d₆, 400 MHz) δ 1.14 (2H, t, J = 6.7 Hz), 1.61 (2H,t, J = 6.7 Hz), 1.91-1.98 (2H, m), 2.77 (2H, t, J = 7.9 Hz),3.43-3.51(2H, m), 4.19 (2H, s), 5.96-6.03 (1H, m), 6.89 (2H, brs), 7.17(1H, dd, J = 7.3, 4.9 Hz), 7.24 (1H, d, J = 7.3 Hz), 7.67 (1H, td, J =7.3, 1.8 Hz), 8.12 (1H, s), 8.45 (1H, d, J = 4.3 Hz), 15.27 (1H, s).

106

1 CONH₂ ¹H NMR (DMSO-d₆, 400 MHz) δ 1.12 (2H, t, J = 6.7 Hz), 1.47 (2H,t, J = 6.7 Hz), 1.89-1.96 (2H, m), 2.76 (2H, t, J = 7.9 Hz), 3.38-3.47(2H, m), 4.15 (2H, s), 5.59-5.62 (1H, m), 6.98 (2H, brs), 7.17 (1H, dd,J = 7.3, 4.9 Hz), 7.24 (1H, d, J = 7.3 Hz), 7.28 (1H, d, J = 4.3 Hz),7.67 (1H, td, J = 7.9, 1.8 Hz), 8.10 (1H, s), 8.45 (1H, d, J = 3.7 Hz),9.15 (1H, d, J = 4.3 Hz). 107

1 COOH ¹H NMR (DMSO-d₆, 400 MHz) δ 1.14 (2H, t, J = 6.7 Hz), 1.62 (2H,t, J = 6.7 Hz), 1.70-1.82 (2H, m), 2.00-2.26 (4H, m), 3.40-3.49 (1H, m),4.22 (2H, s), 4.53 (1H, brs), 5.41 (1H, d, J = 6.7 Hz), 6.93 (2H, brs),7.17 (1H, dd, J = 7.3, 4.9 Hz), 7.26 (1H, d, J = 7.9 Hz), 7.67 (1H, td,J = 7.3, 1.8 Hz), 8.13 (1H, s), 8.49 (1H, d, J = 4.3 Hz), 1.524 (1H, s).108

1 CN ¹H NMR (DMSO-d₆, 400 MHz) δ 1.05 (2H, t, J = 6.1 Hz), 1.64 (2H, t,J = 6.1 Hz), 1.68-1.81 (2H, m), 1.98-2.04 (1H, m), 2.07-2.21 (3H, m),3.39-3.47 (1H, m), 4.16 (2H, s), 4.42-4.52 (1H, m), 5.15 (1H, dd, J =7.9, 1.8 Hz), 6.99 (2H, brs), 7.17 (1H, dd, J = 7.3, 4.9 Hz), 7.26 (1H,d, J = 7.3 Hz), 7.67 (1H, td, J = 7.3, 1.8 Hz), 8.21 (1H, s), 8.48 (1H,d, J = 37 Hz).

Example 109 and 110(+)-8′-amino-9′-fluoro-7′-oxo-10′-[3-(pyridin-2-yl)propylamino]spiro[oxolane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carbonitrileand(−)-8′-amino-9′-fluoro-7′-oxo-10′-[3-(pyridin-2-yl)propylamino]spiro[oxolane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carbonitrile

Racemic8′-amino-9′-fluoro-7′-oxo-10′-[3-(pyridin-2-yl)propylamino]spiro[oxolane-1,3′(2′H)-[7H]pyrido[1,2,3-de][1,4]benzoxazine]-6′-carbonitrile(250 mg) was separated by preparative HPLC using a Chiralpak IA column(φ20×250 mm) and MeCN as the eluent at a flow rate 9 mL/min for 1 h. TheUV detector was set at 254 nm, the injection loop volume was 5 mL, andthe injection load was 34-36 mg in a MeCN solution.

Example 109; 102 mg, >99% purify with >99% e.e. (Chiralpak IA column(φ4.6×250 mm), MeCN, 1 mL/min, Rt=13.6 min), [α]_(D) ²⁵+10.2 (c 1.00,CHCl₃) Example 110; 107 mg, >99% purify with >99% e.e. (Chiralpak IAcolumn (φ4.6×250 mm), MeCN, 1 mL/min, Rt=34.35 min), [α]_(D) ²⁵−7.9 (c1.00, CHCl₃)

Examples 111-114 a) Ethyl3-(1-(hydroxymethyl)cyclopropylamino)-2-(2,3,4,5-tetrafluorobenzoyl)-acrylate

A stirred solution of ethyl3-oxo-3-(2,3,4,5-tetrafluorophenyl)propionate (10.0 g, 37.8 mmol),acetic anhydride (50 mL) and triethyl orthoformate (10.0 mL, 56.7 mmol)was heated at 130° C. for 3 h. The mixture was concentrated and driedunder high vacuum for 5 hours. The crude product was dissolved in DCM(50 mL) and then 1-amino-1-cyclopropylmethanol (3.9 g, 45.3 mmol) wasadded dropwise at room temperature. After 1.5 h, the solvent was removedby evaporation to yield the title compound as a yellow solid (9 g) thatwas used in the next step without further purification. MS (EP) m/z: 362(M⁺+1). (Calcd. For C₁₆H₁₅F₄NO₄, 361.29)

b) Ethyl9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carboxylate

A mixture of ethyl3-(1-(hydroxymethyl)cyclopropylamino)-2-(2,3,4,5-tetrafluoro-benzoyl)acrylate(300 mg, 0.83 mmol), K₂CO₃ powder (344 mg, 2.49 mmol), and 3 ml ofanhydrous DMF were heated in a CEM Discover microwave for 10 min at 200°C. After that the sample was rapidly cooled to room temperature yieldinga dark brown liquid. The DMF was removed by evaporation to give a darksolid. The solid was dissolved in 50 ml of ethylacetate and washed twotimes with 10 ml of water. The organic layer was dried over Na₂SO₄ toafford a light yellow solid as the title compound which was used withoutfurther purification in the next step (133 mg, 0.415 mmol). MS (EP) m/z:322 (M⁺+1). (Calcd. for C₁₆H₁₃F₂NO₄, 321.28)

c)9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carboxylicAcid

To a solution of ethyl9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carboxylate(1.3 g, 4 mmol) in EtOH/water (50:50 v/v, 55 mL) was added K₂CO₃ powder(1.65 g, 12 mmol) and the mixture was heated under reflux for 2 h. Thesolvent was removed to dryness. The remaining solid was acidified to pH6by using 2N acetic acid. A precipitate formed and was collected byfiltration, washed with water and then dried to give the title compound(0.656 g, 2.24 mmol as a light yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) δ1.29 (2H, t), 1.8 (2H, t), 4.56 (2H, s), 7.84 (1H, m), 8.51 (1H, s),14.3 (1H, b). MS (EP) m/z: 294 (M⁺+1). (Calcd for C₁₄H₉F₂NO₄, 293.22)

d)9,10-difluoro-8-nitro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carboxylicAcid

The title compound was prepared from9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carboxylicacid using synthetic procedures similar to those as described in theexamples above. MS (EP) m/z: 339 (M⁺+1). (Calcd for C₁₄H₈F₂N₂O₆, 338.22)

e)9,10-difluoro-8-nitro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carboxamide

The title compound was prepared from9,10-difluoro-8-nitro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carboxylic acid using synthetic procedures similar to thosedescribed in the examples above. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.32 (2H,t), 1.7 (2H, t), 4.58 (2H, s), 7.66 (1H, b), 8.46 (1H, s), 8.59 (1H, b).MS (EP) m/z: 338 (M⁺+1). (Calcd for C₁₄H₉F₂N₃O₅, 337.24).

f)8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carboxamide

The title compound was prepared from9,10-difluoro-8-nitro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carboxamide using synthetic procedures similar to thosedescribed in the examples above. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.17 (2H,t), 1.55 (2H, t), 4.26 (2H, s), 7.30 (2H, b), 8.26 (1H, s). MS (EP) m/z:308 (M⁺+1). (Calcd for C₁₄H₁₁F₂N₃O₃, 307.25).

g)8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carbonitrile

The title compound was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carboxamideusing synthetic procedures similar to those described in the examplesabove. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.18 (2H, t), 1.77 (2H, t), 4.31 (2H,s), 7.41 (2H, b), 8.51 (1H, s). MS (EP) m/z: 290 (M⁺+1). (Calcd forC₁₄H₉F₂N₃O₂, 289.24).

Example 11110-(3-(1H-pyrazol-1-yl)propylamino)-8-amino-9-fluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carbonitrile

The title compound was prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carbonitrileand pyrazolepropylamine using synthetic procedures similar to thosedescribed in the examples above. ¹H-NMR (400 MHz, DMSO-d₆) δ 1.16 (2H,t), 1.58 (2H, t), 1.99 (2H, m), 3.65 (2H, m), 4.16 (2H, s), 4.26 (2H,m), 6.29 (1H, s), 7.49 (1H, s), 7.63 (1H, s), 8.04 (1H, s). MS (EP) m/z:395 (M⁺+1). (Calcd for C₂₀H₁₉FN₆O₂, 394.40).

Example 1128-amino-9-fluoro-7-oxo-10-(3-(pyridin-3-yl)propylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carbonitrile

A solution of8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino-[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carbonitrile(150 mg, 0.52 mmol), 3-(pyridine-3-yl)propan-1-amine (176 mg, 1.3 mmol),and triethylamine (108 μL, 1.3 mmol) in DMSO (3 mL) was stirred at 120°C. for 15 hr. The reaction mixture was cooled and concentrated. Thecrude product was taken up in acetonitrile and purified by preparativeHPLC to yield the title compound as a yellow solid (52.9 mg). MS (EP)m/z: 406.2 (M⁺+1). (Calcd for C₂₂H₂₀FN₅O₂, 405.42). ¹H NMR (400 MHz,D₂O) δ 1.20 (2H, t), 1.50 (2H, t), 2.00 (2H, m,), 2.94 (2H, m,), 3.51(2H, m), 4.14 (2H, s), 7.86 (1H, m), 8.03 (1H, m), 8.41 (1H, m), 8.52(1H, m), 8.58 (1H, s)

Example 1138-amino-9-fluoro-7-oxo-10-(3-(pyridin-2-yl)propylamino)-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carbonitrile

A solution of8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopropane]-6-carbonitrile(320 mg, 1.1 mmol) and 3-(pyridine-2-yl)propan-1-amine (270 mg, 2 mmol)and triethylamine (221 μL, 2.7 mmol) in DMSO (8 mL) was stirred at 120°C. for 15 hr. The reaction mixture was added portion wise to water andwas extracted with ethyl acetate. The organic layer was dried oversodium sulfate and concentrated under vacuum. The dry residue waspurified by column chromatograph (ethylacetate, to ethylacetate-MeOH10:1) to yield the title compound (76.9 mg) as a yellow solid. MS (EP)m/z: 406.2 (M⁺+1). (Calcd for C₂₂H₂₀FN₅O₂, 405.42). ¹H NMR (400 MHz,CD₃OD) δ 1.15 (2H, t), 1.59 (2H, t), 2.03 (2H, t), 2.88 (2H, t), 3.54(2H, m), 4.15 (2H, s), 7.23 (1H, m), 7.33 (1H, m), 7.74 (1H, m), 8.04(1H, s), 8.42 (1H, m)

Example 1148-amino-9-fluoro-7-oxo-10-(3-(pyridin-4-yl)propylamino)-2,7-dihydrospiro[[1,4′-oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carbonitrile

The title compound may be prepared from8-amino-9,10-difluoro-7-oxo-2,7-dihydrospiro[1,4]oxazino[2,3,4-ij]quinoline-3,1′-cyclopentane]-6-carbonitrileusing synthetic procedures similar to those described in the examplesabove.

MS (EP) m/z: 434.2 (M+1). (Calcd. for C₂₄H₂₄FN₅O₂, 433.49). ¹H NMR (400MHz, DMSO) δ 8.69 (d, J=6.5 Hz, 2H), 8.35 (s, 1H), 7.74 (d, J=6.2 Hz,2H), 5.74 (s, 1H), 4.03 (s, 2H), 3.42-3.37 (m, 2H), 2.86-2.82 (m, 2H),1.92-1.90 (m, 2H), 1.88-1.82 (m, 4H), 1.71-1.65 (m, 4H)

Glycogen Synthesis Activity in Hep G2 Cells

Hep G2 cells were obtained from the Japanese Collection of ResearchBioresources and were grown in standard culture medium; a low-glucoseDulbecco's modified Eagle's medium (DMEM) containing 10% fetal calfserum supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin,in a humidified and 5% CO₂ atmosphere kept at 37° C. The Hep G2 cellswere harvested with 0.25% trypsin solution containing 1 mM EDTA and wereseeded on 12 well plates at 1×10⁵ cells per well. Following a culturefor 3 days, the cells were washed once with phosphate buffered saline(PBS), and were incubated with serum-free low-glucose DMEM supplementedwith 100 U/mL penicillin and 100 μg/mL streptomycin. Following a culturefor 3 hours, compounds provided herein at various concentrations and 2.5μCi/mL D-[2-³H]glucose (PerkinElmer, Boston, Mass., USA) were added tothe serum-free low-glucose DMEM. A vehicle control of DMSO (0.3%, finalconcentration) was also used. The total volume per well of the reactionmedium was 1.0 mL of serum-free low-glucose DMEM. After incubation at37° C. for 3 hours, the medium was aspirated and cells were washed twicewith PBS, and 0.25 mL of 1 N KOH containing 0.4 mg/mL carrier glycogenwas added. After incubation at 37° C. for 30 minutes, 0.25 mL of 48.8%(w/v) KOH was added to each well for cell lysis. After incubation at 95°C. for 30 min, 1.5 mL of 95% (v/v) ethanol was added to the cell lysate.Total glycogen was precipitated overnight at −20° C. Glycogenprecipitates were recovered by centrifugation at 19,000×g for 30 minutesat 4° C. Precipitates were washed once with 1 mL of 70% (v/v) ethanol,and were re-suspended in 0.5 mL water. [³H]Glucose incorporation intoglycogen was assessed using a liquid scintillation counter (PackardInstrument Co., Meriden, Conn., USA).

Animal Study: Oral Glucose Tolerance Test

Male Crlj: CD1 (ICR) mice were obtained from Charles River LaboratoriesJapan (Yokohama, Japan). All mice were given a standard diet (CleaJapan, Tokyo, Japan) and tap water ad libitum. All institutionalguidelines for animal care and use were applied in this study. Testcompounds were suspended in 0.3% carboxymethyl-cellulose sodium salt(CMC-Na; Sigma, St. Louis, Mo.). After fasting for 15-17 hours, the testcompound (3, 10, 30, 100 or 300 mg/kg) or vehicle (0.3% CMC-Na) wasorally administered to 7-week-old ICR mice. Glucose solution (5 g/kg)was orally administered at 30 minutes after test compound treatment.Blood samples were collected from tail vein using capillary tubescontaining EDTA.2K before test compound treatment, and at 0, 0.5, 1, and2 hours after glucose load. The blood samples were centrifuged at2,500×g for 5 minutes and separated plasma was kept on ice and analyzedin the same day. Plasma glucose levels were determined using the glucoseC II-test (Wako Pure Chemical Industries, Osaka, Japan). The sum ofplasma glucose levels at 0.5 and 1 hr after glucose load was compared tothat of vehicle treatment, and results were presented as percentdecrease.

In Tables 1 and 2, the IC₅₀ (nM) for GSK313 are represented as follows:A≦15; B=16-60; C=61-150; D≧150 and ND=no data.

TABLE 1 Exemplary Compounds and Their Activity. GSK3β Compound StructureIC₅₀ 1

A 2

C 3

C 4

A 5

B 6

B 7

B 8

B 9

B 10

B 11

A 12

C 13

C 14

A 15

A 16

A 17

D 18

A 19

C 20

A 21

A 22

C 23

A 24

C 25

B 26

A 27

A 28

A 29

B 30

A 31

B 32

A 33

A 34

C 35

B 36

A 37

A 38

A 39

A 40

D 41

B 42

A 43

C 44

B 45

C 46

B 47

B 48

D 49

A 50

D 51

C 52

D 53

B 54

B 55

C 56

A 57

B 58

B 59

A 60

A 61

C 62

D 63

D 64

B 65

A 66

D 67

D 68

B 69

A 70

A 71

D 72

D 73

D 74

D 75

D 76

D 77

A 78

A 79

D 80

A 81

A 82

B 83

C 84

A 85

B 86

A 87

ND 88

A 89

A 90

D 91

B 93

B 94

B 95

C 96

A 97

B 98

D 99

D

TABLE 2 Exemplary Compounds and Their Activity. GSK3β Structure IC₅₀

A

A

A

A

Dog Emesis Study

Male beagle dogs were obtained from Japan Laboratory Animals Inc.(Tokyo, Japan). The dogs were fed on a standard diet (Oriental Yeast,Tokyo, Japan). Water was available ad libitum. Test compounds weredissolved in dimethyl sulfoxide (100 mg/mL) followed by a dilution with50% polyethylene glycol 400 to give a concentration of 1, 3 and 10mg/mL. The dogs were dosed intravenously via cephalic vein with thecompounds (0.1, 0.3 and 1 mg/kg, 0.1 mL/kg). Blood samples werecollected from opposite cephalic vein into evacuated tube containingEDTA-2K (VENOJECT II, Terumo, Tokyo, Japan) at 0.17, 0.5, 1, 2, and 4 hpostdose and kept on ice. Plasma samples were separated bycentrifugation (2200×g, 10 min, 4° C.) and stored at −20° C. The plasmasamples were mixed with 2 volume of the mixture of methanol andacetonitrile (1:1, v/v) containing internal standard and centrifuged at13400×g for 3 min. The supernatant was diluted 20 times with 15%acetonitrile and a 10-1 μL aliquot was subjected into LC/MS/MS system.Separation by HPLC was conducted with a Waters Alliance 2795 SeparationsModule (Waters Corp., MA). Mass spectra were determined using aMicromass Quattro Ultima Pt (Waters Corp.) with an electrosprayionization interface in the MRM mode using positive ion pairs.

The following compounds were tested in this study:

In certain embodiments, the test compounds showed T_(1/2) in the rangeof 0.5 to 1 h. In certain embodiments, the test compounds showedC_(10min) in the range 3-7 μm. In certain embodiments, emesis wasexamined in dogs treated with test compounds.

The embodiments described above are intended to be merely exemplary, andthose skilled in the art will recognize, or will be able to ascertainusing no more than routine experimentation, numerous equivalents ofspecific compounds, materials, and procedures. All such equivalents areconsidered to be within the scope of the claimed subject matter and areencompassed by the appended claims.

What is claimed is:
 1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein R² is hydrogen orlower alkyl; R³ is hydrogen, CN, C(O)R^(3a), C(NH)NHOH or 5-tetrazolyl;R^(3a) is OH, alkoxy or NHR^(3b); R^(3b) is hydrogen, NH₂, OH or loweralkyl; R^(5a) and R^(5b) are each independently hydrogen, lower alkyl oraralkyl which is optionally substituted with one to three substituents,each independently selected from Q⁰ groups; where Q⁰ is halo, cyano,nitro, NH₂, alkyl or alkoxy; R⁶ is halo; in each instance,independently, R^(a) and X³ are selected from (i) or (ii) as follows:(i) R^(a) is hydrogen or lower alkyl; and X³ is substituted orunsubstituted C₁-C₃ alkylene, substituted or unsubstituted 3-6 memberedcycloalkylene or substituted or unsubstituted 3-6 memberedheterocyclylene, wherein the substituents when present are selected fromone to four Q² groups; or (ii) R^(a) and X³ together with the nitrogenatom to which they are bonded, may form a 5 to 7 membered saturated orunsaturated ring optionally containing one or more O or S atoms, or oneor more additional N atoms, in the ring; R^(b) is —(CHR^(7a))_(n)R⁷,—NR^(7b)R⁷, —OR⁷, —S(O)_(r)R⁷, —NR^(7b)COY¹R⁷ or —Y²CONR^(7b)R⁷; Y¹ isbond, O or NR^(7b); Y² is bond or O; n is 0 or 1; r is an integer of 0to 2; R⁷ is alkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, fusedheterocyclylaryl, or fused arylheterocyclyl, where R⁷ is optionallysubstituted with one to five substituents, each independently selectedfrom Q¹ groups; R^(7a) is hydrogen, alkyl, aryl, cycloalkyl,heterocyclyl, heteroaryl, fused heterocyclylaryl, or fusedarylheterocyclyl, where R^(7a) is optionally substituted with one tofive substituents, each independently selected from Q¹ groups; R^(7b) ishydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or fusedheterocyclylaryl, where R^(7b) is optionally substituted with one tofive substituents, each independently selected from Q¹ groups; whereinQ¹ is halo, hydroxy, oxo, thioxo, cyano, nitro, azido, mercapto, formyl,hydroxycarbonyl, hydroxycarbonylalkyl, alkyl, haloalkyl, alkenyl,alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl,heteroaralkyl, alkoxy, haloalkoxy, cycloalkoxy, heterocyclyloxy,aryloxy, heteroaryloxy, aralkyloxy, heretoaralkyloxy, alkylcarbonyl,arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl,aralkyloxycarbonyl, unsubstituted or substituted aminocarbonyl,alkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy,alkoxycarbonyloxy, aryloxycarbonyloxy, aralkyloxycarbonyloxy,unsubstituted or substituted aminocarbonyloxy, unsubstituted orsubstituted amino, alkylthio, cycloalkylthio, arylthio, heteroarylthio,aralkylthio, heteroaralkylthio, alkylsulfinyl, cycloalkylsulfinyl,arylsulfinyl, heteroarylsulfinyl, aralkylsulfinyl,heteroaralkylsulfinyl, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl,heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl,alkoxysulfonyl, aryloxysulfonyl, unsubstituted or substitutedaminosulfonyl or hydroxysulfonyl; X¹ is O; X² is CH₂, O, NR¹ or S; R¹ ishydrogen or lower alkyl; A is substituted or unsubstituted C₁ alkylene,wherein the substituents when present are selected from one to four Q²groups; where Q² is alkyl or haloalkyl; p is 0; and q is an integer of 0to
 2. 2. The compound of claim 1, wherein R^(5a) and R^(5b) arehydrogen.
 3. The compound of claim 1, wherein R² is hydrogen.
 4. Thecompound of claim 1, wherein Y¹ is bond.
 5. The compound of claim 1,wherein R³ is CN.
 6. The compound of claim 1, wherein R³ is C(O)R^(3a).7. The compound of claim 1, wherein R³ is C(NH)NHOH.
 8. The compound ofclaim 1, wherein R³ is 5-tetrazolyl.
 9. The compound of claim 6, whereinR^(3a) is OH.
 10. The compound of claim 1, wherein R^(a) is hydrogen.11. The compound of claim 1, wherein X³ is substituted or unsubstitutedC₁-C₃ alkylene, wherein the substituents when present are selected fromone to four Q² groups, where Q² is alkyl or haloalkyl.
 12. The compoundof claim 1, wherein A is substituted with from one to four Q² groups,wherein Q² is alkyl or haloalkyl.
 13. The compound of claim 1, whereinX² is CH₂.
 14. The compound of claim 1, wherein X² is O.
 15. Thecompound of claim 13, wherein A is CH₂; and q is
 2. 16. The compound ofclaim 1, wherein R⁶ is F.
 17. A compound of claim 1, having Formula(Ia):

or a pharmaceutically acceptable salt thereof, wherein R³ is hydrogen,CN, C(O)R^(3a), C(NH)NHOH or 5-tetrazolyl; R^(3a) is OH, alkoxy orNHR^(3b); R^(3b) is hydrogen, NH₂, OH or lower alkyl; R^(5a) and R^(5b)are each independently hydrogen or lower alkyl; R⁶ is halo; in eachinstance, independently, R^(a) and X³ are selected from (i) or (ii) asfollows: (i) R^(a) is hydrogen or lower alkyl; and X³ is substituted orunsubstituted C₁-C₃ alkylene, substituted or unsubstituted 3-6 memberedcycloalkylene or substituted or unsubstituted 3-6 memberedheterocyclylene, wherein the substituents when present are selected fromone to four Q² groups; or (ii) R^(a) and X³ together with the nitrogenatom to which they are bonded, may form a 5 to 7 membered saturated orunsaturated ring optionally containing one or more O or S atoms, or oneor more additional N atoms, in the ring; R^(b) is —(CHR^(7a))_(n)R⁷,—NR^(7b)R⁷, —OR⁷, —S(O)_(l)R⁷, —NR^(7b)COY¹R⁷ or —Y²CONR^(7b)R⁷; Y¹ isbond, O or NR^(7b); Y² is bond or O; n is 0 or 1; l is an integer of 0to 2; R⁷ is alkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, fusedheterocyclylaryl, or fused arylheterocyclyl, where R⁷ is optionallysubstituted with one to five substituents, each independently selectedfrom Q¹ groups; R^(7a) is hydrogen, alkyl, aryl, cycloalkyl,heterocyclyl, heteroaryl, fused heterocyclylaryl, or fusedarylheterocyclyl, where R^(7a) is optionally substituted with one tofive substituents, each independently selected from Q¹ groups; R^(7b) ishydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or fusedheterocyclylaryl, where R^(7b) is optionally substituted with one tofive substituents, each independently selected from Q¹ groups; whereinQ¹ is halo, hydroxy, oxo, thioxo, cyano, nitro, azido, mercapto, formyl,hydroxycarbonyl, hydroxycarbonylalkyl, alkyl, haloalkyl, alkenyl,alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl,heteroaralkyl, alkoxy, haloalkoxy, cycloalkoxy, heterocyclyloxy,aryloxy, heteroaryloxy, aralkyloxy, heretoaralkyloxy, alkylcarbonyl,arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl,aralkyloxycarbonyl, unsubstituted or substituted aminocarbonyl,alkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy,alkoxycarbonyloxy, aryloxycarbonyloxy, aralkyloxycarbonyloxy,unsubstituted or substituted aminocarbonyloxy, unsubstituted orsubstituted amino, alkylthio, cycloalkylthio, arylthio, heteroarylthio,aralkylthio, heteroaralkylthio, alkylsulfinyl, cycloalkylsulfinyl,arylsulfinyl, heteroarylsulfinyl, aralkylsulfinyl,heteroaralkylsulfinyl, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl,heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl,alkoxysulfonyl, aryloxysulfonyl, unsubstituted or substitutedaminosulfonyl or hydroxysulfonyl; and Q² is alkyl or haloalkyl.
 18. Thecompound of claim 17, wherein R^(5a) and R^(5b) are hydrogen.
 19. Thecompound of claim 17, wherein R³ is CN.
 20. The compound of claim 17,wherein R³ is C(O)R^(3a).
 21. The compound of claim 17, wherein R³ isC(NH)NHOH.
 22. The compound of claim 17, wherein R³ is 5-tetrazolyl. 23.The compound of claim 20, wherein R^(3a) is OH.
 24. The compound ofclaim 17, wherein R^(a) is hydrogen.
 25. A compound selected from


26. A compound selected from


27. A pharmaceutical composition comprising a compound of claim 1 and apharmaceutically acceptable carrier.